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BACKGROUND AND MOTIVATION
In the last decade, the field of developmental stuttering is gradually evolving into an 
evidence based practice (EBP) discipline. EBP is a derivative of the concept of evidence 
based medicine (EBM) and is defined as “the integration of the best research evidence with 
clinical expertise and patient values, aiming to provide optimal clinical care” [1]. In order 
to practice EBP, clinicians have to identify and apply high-quality scientific evidence in the 
process of clinical decision making. Despite an increasing research effort within paramedical 
disciplines, about a decade ago the evidence base underlying speech and language 
pathology was still scarce [2]. Most studies included small sample sizes and only applied 
condition-specific outcome measures. Decision making by speech-language pathologists 
(SLPs) was primarily opinion- and experience-based. The growing emphasis on empirically 
supported treatments affected directions of research in the field developmental stuttering, 
as evidenced by a special edition of the Journal of Fluency Disorders addressing EBP in 
2003 [3-5] and publication of the results of the first phase III randomized trial into stuttering 
treatment in children in 2005 [6].
 
The need for rigorous outcome evaluations in the field of developmental stuttering 
is embedded in a changing health care environment. In particular, rising medical costs 
have placed an increasing emphasis on value for money in reimbursement decisions and, 
consequently, on the empirical validation of treatments. Although speech and language 
pathology in the Netherlands had not yet been affected by health care budget restraints at 
the time this thesis was initiated, a future demand for more evidence on effectiveness and 
cost-effectiveness was anticipated. 
Thus, there is an increased demand for more studies in the field of developmental stuttering 
in order to enhance clinical care and strengthen the position of SLPs in reimbursement 
decision-making. It is against this background that this thesis found its origin. Before 
describing the topics of this thesis, the context in which this work was conducted will be 
discussed. Specifically, I will focus on the current state of knowledge on the disorder and 
treatment of developmental stuttering, and the need for incorporating broad based health 
outcome measures as well as costs in the evaluation of stuttering. 
DEVELOPMENTAL STUTTERING
Stuttering is a developmental disorder characterized by an abnormally high frequency of 
disruptions in the flow of speech. These disfluencies can take the form of repetitions of 
sounds and syllables (“W-W-W-Where are you go-go-going?”), prolongations (“SSSSave 
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me a seat.”), or blockages (no sound) [7,8]. People who stutter may use excessive physical 
and/or mental effort in order to speak fluently. Speech may therefore be associated with 
unusual facial and body movements. To the speaker, stuttering can involve far more than 
just the observable behavior [9]. People who stutter may for instance experience feelings of 
shame, embarrassment, and anxiety due to their stuttering. Stuttering is most likely to start 
in the preschool years. The peak onset is around the age of 2.6-3.6 years [10,11]. About 5 
to 11% of children in the age of 3 to 6 years start to stutter [11,12]. Since about 175.000 
children are born in the Netherlands every year, this implies that each year 8750 to 19000 
Dutch children are affected.
The precise cause of stuttering is yet not fully understood, although research from the last 
two decades has resulted in a great leap forward into the knowledge about the etiology of 
stuttering. Whereas sixty years ago stuttering was perceived to be caused by parents labelling 
normal disfluencies in the child’s speech as stuttering (Wendell Johnson’s “diagnosogenic 
theory”), nowadays stuttering is commonly viewed as a multifactorial disorder. It is most 
probably the result of a complex interaction between genetic susceptibility to the disorder, 
neurological development, environmental factors and child developmental factors [8,13], 
although it is not clear how each of these factors precisely contribute to the onset of 
stuttering. Family studies [14,15], twin studies [16,17], adoption studies [18] and, more 
recently, genetic linkage studies [19-22] have shown evidence for a strong genetic basis 
underlying the stuttering disorder. Evidence for a neurological component includes studies 
showing neuroanatomical differences [23,24] and differences in in auditory processing of 
speech and language by children who stutter (CWS) compared to children who do not 
stutter (CWNS) [25,26], as well as differences in neural pathways involved in speech fluency 
[27]. Examples of environmental factors that may precipitate stuttering in children prone 
for the disorder are high parental expectations and a hectic, fast-talking home. Lastly, 
research findings suggest that the speech language system of CWS is more fragile and 
susceptible to disruption than that of CWNS. Studies have pointed to difficulties in lexical 
encoding [28], the influence of sentence length and syntactic complexity on stuttering 
[29,30], and discrepancies among language skills in stuttering children [31,32]. Studies into 
the relation between phonology and stuttering have provided mixed results [33]. Reilly et 
al. [11] showed that stuttering children had better language skills than their non-stuttering 
peers, suggesting that stuttering might be a “by-product” of rapid language development 
in the preschool years. 
Most children outgrow the disorder of stuttering before the age of 10 years [12,34,35], 
resulting in a prevalence rate of about 1% in the adult population [7]. The natural recovery 
rate (thus, without formal intervention) about 5 years after onset is estimated to be 70 to 
85% [12,34,36,37]. Girls, children who start to stutter before the age of 3 years and children 
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with a family history of recovery from stuttering have a higher chance to recover naturally 
[38]. Recovery may be initiated close to the onset of the disorder, however, in most cases 
full recovery takes several years. Although several predictive factors for recovery are 
known, it remains unpredictable whether an individual child will recover spontaneously 
or not. For those who do not recover, the risk of negative effects hampering psychosocial 
development lies ahead. For instance, school aged children who stutter have shown to 
be more vulnerable to bullying [39]. Furthermore, stuttering has been linked to higher 
levels of social anxiety in adults [40]. Persistent stuttering can impact on several domains of 
functioning and quality of life, like social and emotional functioning [41] and employment 
opportunities [42,43]. The risk of these negative long-term effects warrant treatment close 
to the onset of stuttering. Moreover, treatment in the preschool years is associated with a 
higher chance on successful outcome, presumably so because neural plasticity decreases 
with age. Delaying treatment beyond 15 months post onset is known to reduce the chance 
of full recovery by about 25% [44]. Hence, early intervention is generally recommended for 
children who stutter. 
TREATMENT OF DEVELOPMENTAL STUTTERING IN PRESCHOOL 
CHILDREN
In the Netherlands, parents of children suspected of stuttering will usually consult a general 
practitioner or an SLP. Treatment is, however, not necessary for every child. Many children 
go through a period of speech disfluencies while developing their speech and language 
skills. The SLP’s assessment will include evaluation of the frequency, type, duration and 
severity of disfluencies, and observation of excessive physical effort, signs of frustration or 
other emotional reactions by the child. These signs, together with the presence or absence 
of risk factors for persistency and parental concerns, help the clinician in the process of 
identifying children in need for treatment. 
Two basic approaches to treatment for preschool children who stutter can be discriminated. 
Indirect approaches focus on manipulating child related and environmental factors 
assumed to influence the child’s speech fluency, while direct approaches directly target 
the child’s speech fluency [44-46]. An example of the first approach is treatment based on 
the Demands and Capacities Model (DCM) [47], which has been the standard treatment 
for preschool stuttering children in the Netherlands since the late eighties. An example of 
the latter approach is behavioral treatment according to the Lidcombe Program for early 
intervention (LP) [48]. The LP was introduced in the Netherlands in the year 2000, based on 
promising initial results in Australia [49-51]. In the next section indirect and direct treatment 
for preschool stuttering children will be discussed. DCM based treatment and the LP will 
receive particular attention.
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Indirect treatment: Treatment based on the Demands and Capacities Model
Indirect approaches to stuttering in children are based on the theoretical notion that 
stuttering is a multifactorial disorder [52-54] with physical, linguistic, psychological, and/
or environmental factors influencing the onset and development of stuttering. Specifically, 
most indirect treatments find their origin in the Demands and Capacities model, which will 
be discussed next. 
Demands and Capacities Model (DCM) based treatment is premised on the assumption 
that stuttering develops when a child lacks the capacities to speak as fluently as the 
environment demands. Therefore, treatment aims to achieve a favorable balance between 
environmental demands and demands by the child him- or herself, and the child’s capacities 
for speaking fluently [47,55]. Demands and capacities can be motoric, linguistic, emotional 
or cognitive of nature. For instance, parents are trained to slow down their habitual speech 
rate (motoric demand), reduce their number of questions (linguistic demand), respond 
to the child’s specific temperament (emotional demand), or ask questions of conceptual 
complexity that is age-appropriate (cognitive demand). Examples of the child’s capacities 
that are addressed are improving the child’s speech motor movements (motoric capacity), 
training word finding capacity (linguistic capacity), promoting his self-esteem (emotional 
capacity) or teaching the child the concept of turn-taking and rules for conversation 
(cognitive capacity). 
Prior to therapy, demands and capacities are assessed by way of speech- and language 
assessments and a videotape of parent-child interaction. In a first parent session, parents 
are informed on stuttering and their concerns are explored. Parents are also introduced 
to the concept of “parent-child special time”. That is, they are required to spend 15 
minutes a day (for minimal 5 days a week) giving the child their undivided attention and 
practicing homework assignments. Treatment generally starts with lowering demands 
through counseling and training of the parents, the child himself and significant others 
in the child’s environment. Subsequently, explicit training of the capacities of the child 
may be introduced. If lowering the demands and promoting the capacities should fail to 
resolve the stuttering problem to a satisfactory extent, speech fluency may be worked on 
by modelling slower, more relaxed, smoother speech. The parents and the child initially 
attend the clinic once a week for a one-hour session. After four sessions with parent and 
child, as a rule a parent session will take place at which the child is not present. The intensity 
of therapy is gradually reduced when the child shows acceptable speech, parents master 
implementing a fluency enhancing environment and know what to do if a relapse occurs. 
The mean number of sessions is estimated to be 12, however with a high variability [47]. In 
a preliminary study by Franken, Kielstra, and Boelens [56], the mean number of treatment 
sessions of DCM based treatment of one hour each in the first three months was 11, and 
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three-fourths of children were still on treatment at the end of the three months. In the rest 
of this introduction I will refer to DCM based treatment as RESTART-DCM treatment; the 
DCM based approach that was evaluated in the RESTART-trial of which the results are 
presented in this thesis.
Examples of other published indirect treatment approaches are Parent Child Interaction 
Therapy (PCIT) [57,58] and Family Focused Treatment [59]. They share several components 
with RESTART-DCM treatment. All treatments begin with a comprehensive assessment, 
based on the multifactorial model of stuttering. This assessment helps the therapist and 
parents to identify the factors that are supporting or impacting the child’s fluency, forming 
the basis for setting up treatment goals. Furthermore, parents play an important role 
throughout the whole course of therapy. Environmental or parental aspects are typically 
addressed first, before the child-focused aspects of treatment (i.e., the child’s capacities). 
Lastly, the treatments are generally designed to be flexible in order to adapt to the specific 
strengths and needs of the child and family. There are also differences between these 
indirect treatments. For instance, PCIT and Family-focused treatment place more emphasis 
on the “demand” side. Within PCIT, this mainly consists of improving the quality of the 
parent-child relationship and changing parent-child interaction patterns. The central part 
of Family-focused treatment is educating parents on stuttering and teaching them to 
implement facilitating communication modifications in their interactions with their child 
skills. PCIT and Family-focused treatment also deploy a more restricted structure than 
RESTART-DCM treatment. PCIT is delivered as six once weekly clinic sessions, followed by 
a 6-week home consolidation period [60,61]. Family-Focused treatment usually consists of 
six to eight 45-minute appointments and is divided into three sections: (a) education and 
counselling of parents, (b) communication modification training of parents, and (c) review 
and reassessment [59]. 
Direct treatment: the Lidcombe Program for early intervention
Direct stuttering treatment approaches are not explicitly based on a theory of the onset 
and development of stuttering, but hold the notion that manipulating the child’s speech 
production will increase fluent speech and decrease stuttered speech. Direct treatment for 
preschool children who stutter mainly include response-contingent therapies. The best-
developed and most extensively researched form of response-contingent treatment for 
children is the Lidcombe Program, which will be discussed next. 
The Lidcombe Program (LP) [48] is a behavioral treatment for preschool children who 
stutter, based on operant methods. In the LP, parents are taught by the SLP to deliver 
verbal contingencies during conversations with their child when the child is speaking 
mostly stutter-free. Contingencies for stutter-free speech are acknowledgment or praise 
Introduction | 13
1
of fluency (e.g., “That was smooth,” “Good talking!”) or requesting self-evaluation 
(e.g., “Were there any bumpy words?”). Contingencies for stuttered speech include 
acknowledgment of stuttering (e.g., “That was a bit bumpy.”) or requesting self-correction 
(e.g., “Can you say that again?”). There should be far more contingencies for stutter-
free speech than for stuttered speech. Initially, contingencies are given in daily, so-called 
structured conversations of about 15 minutes. When the parent has become proficient in 
delivering contingencies and the stuttering of the child during the day is mild, the parent 
starts delivering contingencies during daily conversations. The treatment consists of two 
stages. During stage 1, the parent conducts the treatment every day and the parent and 
child attend the speech clinic once a week. This continues until stuttering either disappears 
or reaches an extremely low level. During stage 2, the use of parental feedback as well as 
the number of clinic visits is gradually reduced, provided that fluency is maintained. The LP 
is individualized for every child and family (e.g., according to the child’s age or stuttering 
severity).
Examples of other direct treatment programs for preschoolers who stutter, although 
less frequently applied, are the Fluency Development System for Young Children [62], 
Extented Length of Utterance (ELU) [63], and Gradual Increase in Length and Complexity 
of Utterance (GILCU) [64]. Although the Fluency Development System for Young Children 
is mainly a direct approach (i.e., teaching children to use smooth and relaxed speech 
instead of bumpy speech), it also comprises indirect elements, like parent training. The 
ELU and GILCU are fluency shaping programs for older children. In an adapted form, they 
can be applied in preschool children. They are, as the LP, based on operant conditioning, 
but explicitly structures treatment by gradually increasing the length and complexity of 
utterances. 
All Dutch SLPs are trained in DCM based treatment in their regular education program. 
Therefore, in Dutch primary care most children who stutter are treated according to a 
DCM approach. However, the methods used in the various education programs differ, 
presumably causing non-uniformity in clinical practice. A smaller number of SLPs has also 
followed Lidcombe Program training. Thus, the choice for treatment according to a DCM 
approach or the LP depends for a great part on the clinician a child presents to. It was only 
recently that the first Dutch guideline on stuttering was published [65]. This guideline can 
help in clinical decision making; however, most of the recommendations in this guideline 
are based on limited evidence. 
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PLUGGING GAPS IN THE EVIDENCE BASE UNDERLYING TREATMENT 
FOR PRESCHOOL CHILDREN WHO STUTTER
Current evidence on the effectiveness of treatments
Randomized Clinical Trials (RCTs) are considered the gold standard for proving clinical 
research evidence. A recent review by Nye and colleagues [66] identified seven studies 
into stuttering treatment outcome in preschool children that applied an RCT design. The 
mean quality of these studies was judged to be moderate. Moreover, six of these studies 
dealt with the efficacy of the LP [6,56,67-70]. Except for the study by Jones et al. [6], these 
studies had a short follow-up (4 to 16 weeks) and small sample sizes (12 to 45 stuttering 
children). The follow-up in Jones et al. [6] lasted nine months and was adequately powered 
(n=110), however, only 54 children (49%) were included [6]. The results of the studies by 
Jones et al. [6], Harris et al. [67], and Lattermann et al. [69] showed that the LP leads to a 
larger and faster reduction in stuttering frequency than natural recovery. However, there 
is a lack of replications by independent researchers as well as prospective studies with a 
follow-up that lasts long enough for children to complete treatment. Moreover, the long-
term results obtained with the LP have not been compared to that of clinically relevant 
alternative interventions. Franken et al. [56] compared the outcomes of the LP and DCM 
based treatment in 23 children in a 12-week period. Stuttering frequency decreased for both 
treatments after 12 weeks and there was no between-group difference. This study was the 
pilot-study of the RESTART-trial, for which the results are presented in this thesis. Compared 
to the evidence base for the LP, the scientific evidence underlying indirect treatment is 
marginal. Besides the preliminary study by Franken et al. [56], no studies employing an 
RCT design have been performed. Two single subject studies exploring the efficacy of PCIT 
provide some empirical support for the PCIT [60,61]. A preliminary study examining the 
outcomes of Family-Focused Treatment in 17 preschool children demonstrated reduced 
frequency of stuttering-like disfluencies at the end of treatment and at long-term follow-up 
[59]. Thus, with the limited data available at present, the LP offers the best evidence-based 
intervention for preschool CWS [66]. Based on the evidence presented above, the Dutch 
guideline for stuttering (Richtlijn stotteren) [65] recommends that both the LP and DCM 
based treatment can be considered in selecting a treatment approach. 
The need for incorporating broad outcome measures
Since the speech disruptions and concomitant stuttering behaviors are the central feature 
of the stuttering disorder, it is not surprising that treatment evaluation has traditionally 
focused on these observable characteristics. Moreover, the selection of treatment 
outcomes generally is closely related to the goal of treatment. For children who stutter, 
the primary goal of treatment approaches is to reduce or eliminate the stuttering behavior. 
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Therefore, it is understandable that measures such as percentage of syllables stuttered 
(%SS) or a severity judgment by the clinician or parent have been conventionally used in the 
evaluation of therapy for preschool stuttering children. On the contrary, the goal of most 
treatments for older children and adults who stutter is not only to reduce the observable 
stuttering behavior, but also to diminish any negative psychosocial impact. There are several 
instruments to evaluate non-speech related aspects, like the Speech Situation Checklist [71] 
to evaluate speech anxiety, the Erickson S24 [72,73] to evaluate communication attitude, 
and the Subjective Screening of Stuttering [74] to evaluate the speakers’ social, emotional, 
cognitive, or other reactions to their stuttering. These instruments have, however, all been 
criticized for their weak psychometric properties [75]. Moreover, their scope is limited to 
one or a few aspects of the broader impact of the stuttering disorder. 
 
Since the year 2000, the potential of broad-based outcome parameters like quality of life 
and well-being have been acknowledged in the field of stuttering research [41,75-78]. This 
aligns with a general shift in health care outcome research in the last decade from symptoms 
as the primary outcomes toward direct measurement of the impact of the disorder on the 
patient’s daily life. This shift is motivated by acknowledgment of the complex relationship 
between biological aspects, symptoms and the impact on daily living [79,80] and studies 
showing that changes in physical endpoints are often only partly related to changes in 
patient evaluated health status [81]. Furthermore, studies in the field of mental health 
have shown that it is the patients’ subjective well-being, rather than the objective medical 
condition, that determines their treatment-seeking behavior, their compliance and their 
evaluation of treatment [82]. Lastly, in policy decisions on treatment reimbursement, the 
burden of a disease has gained importance in relation to considerations on acceptable cost-
effectiveness ratios. That is, the higher the burden of disease, the more willing society is to 
accept unfavorable ratios of costs to effects. For these reasons, it has become recognized 
that patient reported outcomes such as quality of life should be incorporated in treatment 
evaluation.
The growing awareness of the importance to incorporate broader outcome measures 
in the evaluation of therapies has affected the last-decades research topics in the field 
of stuttering. An increasing number of studies into the impact of stuttering by quality of 
life or well-being instruments have been undertaken [41,42,83-85], in which both generic 
and disease-specific instruments have been applied. An example of a disease-specific 
instrument developed in the last decade is the OASES [86].This questionnaire evaluates 
the physical, social and emotional aspects of stuttering from the perspective of the 
individual who stutter. The OASES for adults (OASES-A) has become a widely-applied 
diagnostic clinical tool to assess the broad spectrum of the stuttering disorder. Although 
disease-specific instruments like the OASES may provide valuable insights into the effect 
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of stuttering on multiple aspects of daily living, their usefulness is limited in that they focus 
on the domains of quality of life that are most likely to be influenced by the disease. 
Instead, generic instruments incorporate general health-related physical, social and 
emotional aspects of quality of life. These generic health-related quality of life (HRQOL) 
instruments are therefore capable to measure the burden of a disease, regardless of the 
underlying diagnosis. In this way, the broad impact of a disorder could be measured and 
the disease burden of stuttering could be compared with that of other conditions. This 
could help the disorder of stuttering in gaining a firm foothold in the current dynamic 
health care climate. The number of studies applying generic HRQOL instruments to assess 
the impact of persistent stuttering was scarce at the onset of this thesis. In the pediatric 
field of stuttering, and speech- and language problems in general, the application of this 
kind of measures has also not gained much attention [87]. Furthermore, generic HRQOL 
instruments have not yet been applied in the evaluation of stuttering treatment, while this 
kind of instruments provides essential outcome information necessary in cost-effectiveness 
analysis [88]. The next section will explain how the measurement of HRQOL in relation to 
costs could be helpful in the evaluation of stuttering treatment.
The relevance of economic evaluations 
Rapidly increasing health care expenditures forces policy makers to make explicit decisions 
on the expenses of the health care budget. The most efficient allocation of finite health 
care resources requires not only information on the outcomes of interventions, but also 
consideration of related costs. In other words, interventions need to be judged on their 
relative value for money. The method of economic evaluations has become an increasingly 
important tool for priority settings in health care. In an economic evaluation the costs 
and outcomes of alternative health care interventions are compared [88]. Contrary to the 
medical field, in which economic evaluations have become quite well established, in the 
field of speech and language pathology economic evaluations are relatively uncommon. 
This may partly be related to the disease burden associated with most of the speech and 
language disorders expected to be relatively small, compared to medical disorders like 
cancer or heart failure. Moreover, the costs associated with speech and language disorders 
are a relatively small part of the health care budget.1 It is probably because of these reasons 
that stuttering treatment (and speech and language therapy in general) so far has escaped 
from budget restrictions set by Dutch policy makers. In light of the pressing health care 
budget, however, evidence on the relative costs and effects of stuttering treatments are 
crucial to substantiate decisions regarding choices on and reimbursement of treatments. 
In an economic evaluation, two or more alternative health care interventions are compared. 
1 Based on an estimation of at least 2500 children in the Netherlands who undergo treatment each year, the total 
annual health care costs are estimated to be at least E1,5 million.
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Usually, one intervention is a newly introduced intervention, and the other(s) consist(s) of 
usual care. The most common forms of an economic evaluation are the cost-effectiveness 
analysis (CEA) and a subtype of this analysis: the cost-utility analysis (CUA). In a CEA, effects 
are expressed in clinically relevant outcome measures related to the intervention. In the 
case of stuttering treatment, possible outcomes include (the reduction of) percentage 
syllables stuttered (%SS) or stuttering severity. In a CUA, the health outcome is the QALY, 
which stands for Quality Adjusted Life Years. The QALY combines length of life and quality 
of life in a single outcome measure. Where efficacy and effectiveness studies investigate 
the benefit of a treatment for the individual, cost-effectiveness studies investigate the 
benefit for society. CEA’s and CUA’s are therefore preferably undertaken from a societal 
perspective, that is; including all relevant costs and effects, no matter whom they are 
related to. Costs and effects of alternative health care interventions are compared through 
the calculation of an incremental cost-effectiveness ratio (ICER). This ratio expresses the 
additional costs of an intervention per additional unit of health gain on a clinical outcome 
(in case of a CEA) or per QALY gained (in case of a CUA). Since the QALY outcome in a CUA 
allows for comparison across health states, this type of economic evaluation is preferred 
for health care decision making. If the ICER of a new health intervention compared to 
usual care is below a decision maker’s willingness-to-pay threshold, the new intervention is 
considered to be cost-effective. 
OUTLINE OF THIS THESIS
The previous introduction showed the gap in the scientific evidence base underlying the 
treatment of developmental stuttering. In order to provide treatment based on the highest 
standards of care and to meet demands of policy makers, data on the impact of stuttering 
and the costs and effects of treatment is urgently needed. The main focus of this thesis is 
therefore on the impact and treatment of developmental stuttering.
The first three chapters address the impact of stuttering. Chapter 2 explores the impact of 
the disorder in early childhood, by evaluating the HRQOL of preschool children who stutter. 
For this study, baseline HRQOL data of CWS participating in the RESTART-study and data of 
a Dutch population of CWNS were compared. In addition, the relation between stuttering 
severity and HRQOL was evaluated. Chapter 3 explores the impact of persistent stuttering 
on daily life, by assessing the generic HRQOL of a convenience sample of adults who 
stutter. Evaluation of the HRQOL associated with persistent stuttering in adults will shed 
light on the disease burden we would like to prevent by treating stuttering in the preschool 
years. Since stuttering in adulthood results from a complex interaction between the core 
stuttering behaviors and emotional, cognitive and behavioral learning processes, it can 
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be assumed that psychological factors play an important role in the relationship between 
stuttering severity and HRQOL in adults. Therefore, the study described in chapter 3 
applied a comprehensive approach to investigate the relationship between stuttering and 
HRQOL and incorporated the role of coping style. The Dutch OASES for adults (OASES-
A-D) was used to assess the experience of the stuttering disorder from the perspective 
of the adult who stutter. Chapter 4 reports on the translation process and evaluates the 
psychometric properties of the OASES-A-D. 
The last three chapters of this thesis describe the results of the RESTART-trial (the Rotterdam 
Evaluation study of Stuttering Therapy in preschool children- A Randomized Trial). In this 
18-months multicenter randomized trial the Lidcombe Program (LP) was compared with 
RESTART-DCM based treatment in 199 preschool CWS. Besides the comparison of the 
clinical effectiveness, an economic evaluation was conducted. Chapter 5 presents the 
results on the relative effectiveness of both therapies. The primary clinical outcome for this 
study was the percentage of children recovered from stuttering after 18 months. Chapter 
6 reports on the cost-effectiveness and cost-utility of the LP in comparison with RESTART-
DCM based treatment. Although the pragmatic design of the RESTART-trial enhanced 
the external validity, perceptions and beliefs of clinicians with regard to the treatments 
undoubtedly influence if and how they will incorporate the trial results. Chapter 7 therefore 
describes the results of a focus group meeting, in which participating SLPs discussed their 
ideas and experiences with the LP and RESTART-DCM treatment in the context of the 
RESTART-trial. 
Chapter 8 provides an overall discussion of the results of the previous chapters, including 
limitations, implications for clinicians and policy makers, and suggestions for future research. 
To note, the chapters of this thesis are based on research articles published in or submitted 
to scientific peer reviewed journals. Therefore, the chapters can be read independently 
and some overlap exists between chapters.
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ABSTRACT
Purpose The purpose of this study is to compare the health-related quality of life (HRQOL) 
of preschool children who stutter (CWS) and a reference population of children who do not 
stutter, and to evaluate the association between stuttering severity and HRQOL. 
Methods Baseline data were used from 197 children participating in a multicenter 
Randomized Clinical Trial in the Netherlands. Information on stuttering severity and time 
since onset (TSO) of stuttering was obtained from the baseline evaluation by speech- 
language pathologists. Stuttering severity was measured using the SSI-3. HRQOL was 
assessed using proxy versions of two Child Health Questionnaires (ITQOL-97 and CHQ-
PF28), the Health Utility Index 3 (HUI3) and the EuroQoL EQ-VAS (EQ-VAS). 
Results While the outcomes on the EQ-VAS and the HUI3 showed that the HRQOL of 
CWS is slightly poorer than that of the Dutch reference population, results on the different 
dimensions of the CHQ-instruments did not reveal any difference in scores between 
stuttering children and reference groups. Within the group of CWS, two ITQOL-97 and four 
CHQ-PF28 scales showed statistically different scores for children in different SSI stuttering 
severity or TSO categories. However, the effect sizes showed that these differences were 
so small that they could be considered negligible. 
Conclusion The results of this study do not reveal a diminished HRQOL for preschool 
CWS. Future research should include a larger cohort of children with severe stuttering, 
study the longitudinal course of HRQOL and incorporate additional parameters such as the 
characteristics of the child and his environment.
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INTRODUCTION
Stuttering frequency and stuttering severity have traditionally been the primary outcome 
measures for childhood stuttering. However, these measures provide little information 
about the potentially broader impact of this disorder on daily life. Although health-related 
quality of life (HRQOL) measures have become an essential outcome in pediatric disorders 
[89,90], limited research has been conducted into the impact of speech and language 
disorders in general and stuttering in particular [87]. 
So far, research on the burden of stuttering has mainly focused on the impact of persistent 
stuttering. Several studies report a diminished functioning and/or (health-related) quality of 
life for stuttering adolescents and adults (e.g., [41,42,84,85,91]). For school aged children 
who stutter (CWS), the impact of stuttering on HRQOL has been less frequently studied. 
In fact, we are only aware of the study by Gooding and Davis [92], in which the generic 
HRQOL of 33 stuttering children and matched controls aged 8-16 years was assessed by 
the Child Health Questionnaire (CHQ-PF50). Their results did not reveal any significant 
group differences on general health, but significantly more behavioral problems were 
reported in stuttering children compared to matched controls. 
Other studies applied disease (or disorder-) specific instruments to investigate the impact 
of stuttering on the daily life of school aged children. Chun, Mendes, Yaruss, and Quesal 
[93] showed a moderate negative impact of stuttering as measured by a draft version 
of the Overall Assessment of the Speaker’s Experience of Stuttering for school aged 
children (OASES-S) in seven children aged 7 to 12 years, with a tendency toward a positive 
correlation between stuttering severity and the impact of stuttering on quality of life. 
Cook, Donlan, and Howell [94] also used a disorder-specific instrument (Fragebogen Zum 
Sprechen; FZS speech questionnaire) to assess the psychosocial impact of stuttering in 54 
children aged 9 to 20 years, and found that higher stuttering severity was correlated with 
a greater psychosocial impact. Furthermore, Kawai, Healey, Nagasawa, and Vanryckeghem 
[95] and Vanryckeghem, Brutten, and Hernandez [96] showed a negative speech-associated 
attitude for school aged CWS compared to non-stuttering peers, and Blood and Blood 
[39] reported increased vulnerability to bullying for school aged CWS. A negative speech-
related attitude and negative social reactions increase the child’s risk for developing social 
anxiety [97]. Indeed, increased levels of social anxiety have been reported in older CWS, 
albeit not consistently [97]. A social anxiety disorder is known to hamper normal social 
development and functioning and is likely to result in a diminished quality of life [40].
In the age group where stuttering starts to develop, i.e., the preschool years, Reilly et 
al. [11] were the first to apply a validated descriptive HRQOL instrument (PedsQL). The 
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results of their population-based study indicated that stuttering in young children was not 
associated with a diminished quality of life. Surprisingly, for CWS aged 4 years, a better 
social and preschool functioning was reported compared with non-stuttering children. In 
addition, a study into social anxiety in preschool CWS by van der Merwe, Robb, Lewis, 
and Ormond [98] reported no significant differences between stuttering preschoolers and 
matched controls. However, other studies suggest that stuttering in children under the 
age of six may be related to psychosocial impairment. CWS as young as 3 or 4 years of 
age seem to be aware of their speech problems and, on average, evaluate their speech 
more negatively than their non-stuttering peers [96]. Awareness of stuttering in young 
children increases with time since onset and age, and stuttering could provoke frustration 
and facilitate emotional and behavioral reactions even in early childhood (e.g., [99]). 
Furthermore, differences in temperament characteristics and emotional behavior between 
preschool stuttering and non-stuttering children were found by various researchers (for an 
overview, see [100,101]). These characteristics (such as exhibiting poorer adaptability skills 
and more negative emotions) might amplify the psychosocial effects of stuttering, although 
speculations as to this connection are highly premature. Recently, a study by Kefalianos, 
Onslow, Ukoumunne, Block, and Reilly [102] suggested that preschool CWS do not have 
innately different temperaments from control children.
Negative reactions by listeners may also give rise to psychosocial consequences of 
stuttering. Negative evaluation of perceptually salient stuttering by preschool peers has 
been reported by Ambrose and Yairi [103] and Ezrati-Vinacour, Platzky, and Yairi [104]. 
While these studies were based on research using puppet-play, one study based on real-
life interactions with peers also reported that preschool classmates reacted negatively to 
moments of severe stuttering [105]. Besides, the authors of the latter study observed that 
the stuttering preschool children had some difficulties in expressing themselves in social 
interactions, for instance in trying to take the lead in play or contributing to problem-solving 
activities. In a further study by Langevin, Packman, and Onslow [106], which focused on 
the parental evaluation of the impact of stuttering on the lives of their preschool stuttering 
children (N=77), the majority of parents reported that stuttering had a negative impact on 
their child’s life. Both in children and parents, emotional consequences were reported. For 
example, children became frustrated because of their stuttering or had a low self-esteem, 
and stuttering affected the children’s general mood. However, only 8% of the parents 
perceived that stuttering affected their child’s quality of life [106]. 
From this overview it can be concluded that, although several studies suggest impairment 
in the psychosocial domains of HRQOL in preschool CWS, so far few attempts have been 
made to perform a comprehensive study to measure this impact with validated generic 
HRQOL instruments. These instruments allow comparison of the HRQOL between 
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preschool children with and without stuttering and thereby provide a basis to evaluate 
possible consequences of stuttering across multiple clinically relevant domains. These 
insights will ultimately enable therapists to optimize treatment goals. Therefore, the aim 
of the current study is to explore the HRQOL of preschool CWS using validated generic 
instruments. 
METHODS
Participants
The study population of CWS consisted of preschool children participating in a multicenter 
Randomized Clinical Trial in the Netherlands named RESTART (the Rotterdam Evaluation 
study of Stuttering Therapy in preschool children- a Randomized Trial) which compares 
two alternative therapies for preschool CWS. All children presented to one of the 20 
participating speech clinics for stuttering treatment. For the current study, baseline data 
obtained prior to randomization were used. Ethical approval for the RESTART-study was 
gained from the Medical Ethical Committee of the Erasmus Medical Center in Rotterdam 
(MEC-2006-349). Baseline data were collected between September 2007 and June 2010. 
All children met the following inclusion criteria: (1) between the ages of 3.0 and 6.3 years1; 
(2) stuttering confirmed by a rating of stuttering severity on an 8-point scale of at least 
2 (“mild”) [34] by the parent (3) as well as by the clinician; (4) children stuttered at least 
3% of syllables; and (5) time since onset (TSO) of stuttering at least six months. Children 
were excluded if an emotional, behavioral, learning or neurological disorder had been 
diagnosed, or if there was a lack of proficiency in Dutch for children and parents. Written 
informed consent was obtained from all parents. 
In total, 199 CWS were included in the RESTART-study. Two children were excluded from 
the current study because no baseline HRQOL data were available. Thus, this study was 
based on data of 197 CWS: 146 children aged 3 to 4 years (66% boys) and 51 children aged 
5 to 6 years (80% boys). 
HRQOL reference values
To compare HRQOL values of CWS with reference values, available data from two 
representative community samples of Dutch children were used. The first sample consisted 
of children aged 3 to 46 months. Details of this population are described in [107]. For the 
purpose of the current study, data on children aged 3.0 to 3.11 years of age were used 
(n=94; 45% boys). The second sample consisted of school children aged 4 to 13 years (see 
1 All children being preschoolers, with a maximum age analogue to the maximum age for the Dutch adaptation 
of the Reynell Developmental Language Scales. 
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[108] for a detailed description of this population). From this sample, data on children aged 
5.0 to 6.11 years were selected (n=378; 52% boys).
Health-related quality of life measures
During baseline measurement, a questionnaire booklet was filled in by the caregiver. Among 
other questionnaires, these booklets contained proxy versions of three different types of 
validated HRQOL measures. The Child Health Questionnaire was applied to provide a 
generic descriptive profile of HRQOL on distinct domains relevant for children. The Health 
Utility Index 3 also provides a description of health status and HRQOL but was specifically 
used because it is a utility (preference-) based measure, thereby able to summarize overall 
HRQOL in a single score. The EuroQoL EQ-VAS was also incorporated to indicate overall 
health in a single value. Presented below is a brief summary of the applied instruments.
Child Health Questionnaire
The Child Health Questionnaire (CHQ) is a family of generic, multidimensional HRQOL 
descriptive instruments for measurement in children. In our study, the Infant and Toddler 
Quality of Life Questionnaire (ITQOL-97) was used for children aged 3 and 4 years, and the 
Child Health Questionnaire - Parent Form 28 (CHQ-PF28) for children aged 5 and 6 years.
Infant and Toddler Quality of Life Questionnaire (ITQOL-97)
The ITQOL-97 [107,109] is a HRQOL instrument which has been translated into Dutch 
following international standards and validated in a general population sample in the 
Netherlands [107]. The ITQOL has good internal consistency, with all Cronbach’s alpha 
> 0.70. Test-retest ICCs were moderate or adequate (≥ 0.50; p<0.01) and concurrent 
and discriminative validity has been shown [107]. The questionnaire consists of 97 items 
covering the following eight concepts of HRQOL in children aged 2 months to 5 years: 
physical functioning, growth and development, bodily pain and discomfort, temperament 
and moods, general behavior, getting along with others, general health perceptions and 
change in health. In addition, three parent-focused concepts are included: anxiety and 
worry due to the child’s health (parental impact: emotional), limitations in time to meet 
parents own needs as a result of their child’s health (parental impact: time) and how well 
one’s family gets along with each other (family cohesion). Following the ITQOL scoring 
manual, the item scores are summed up and transformed to scale scores ranging from 
0 (worst possible health state) to 100 (best possible health state). Thus, lower scores 
correspond to lower HRQOL.
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Child Health Questionnaire – Parent Form 28 (CHQ-PF28)
The CHQ-PF28 [108,110] is a shortened version of the CHQ-PF50. Score distributions and 
discriminative validity are comparable to its longer counterpart [108]. The questionnaire 
consists of 28 items measuring nine HRQOL concepts in children aged 5 to 18: physical 
functioning, role functioning: emotional/behavior, role functioning: physical, bodily pain, 
general behavior, mental health, self-esteem, general health perceptions and change in 
health. The same three parent-focused concepts as in the ITQOL-97 are also included 
(parental impact: emotional, parental impact: time, family cohesion), and besides these, 
the concept of limitations in time to do family activities. As in the ITQOL-97, raw item 
scores are summed up and scale scores are transformed to a 0-100 scale (0 representing 
worst health and 100 best health). Scores can be analyzed separately and can be combined 
to obtain an overall physical and psychosocial summary score. These overall scores are 
derived from weighted composites of scale scores. Summary scores of 50 represent the 
mean in a US reference population children; 10 points above or below 50 reflect one 
standard deviation difference in either direction.
Health Utility Index 3 (HUI3) 
The HUI3 [111] is a generic preference-based measure of health for children aged 5 years 
and above. It provides a comprehensive, reliable, responsive and valid measurement of 
health status and HRQOL in clinical studies [112]. This instrument has two components: 1) 
a standardized descriptive system for describing health or its impact on HRQOL; and 2) an 
algorithm for assigning values (utilities) to each health state described by the system. The 
HUI3 incorporates eight domains: vision, hearing, speech, ambulation, dexterity, emotion, 
cognition and pain and discomfort (not specified), with five to six response levels for 
each domain. In all domains, level 1 represents perfect health. Responses on other levels 
represent decrements in health states. The values attached to the various health states 
reflect preferences for health that are derived from the general population of adults, and 
range from -.36 (worst imaginable health) to 1 (best imaginable health) [112]. Because the 
HUI3 is applicable for children aged 5 years and above, in the current study only parents of 
children aged 5 and 6 years old filled in the HUI3.
EuroQoL EQ-VAS (EQ-VAS) 
The EQ-VAS [113] is a visual analog scale for directly recording an individual’s rating for his 
or her current health state. In this study a proxy version was applied: Parents were asked to 
rate their child’s current health state on a scale ranging from 0 (worst imaginable health) to 
100 (best imaginable health). A proxy version of the EQ-VAS has been previously applied in 
pediatric populations, for instance in children with attention-deficit hyperactivity disorder 
[114] and children with chronic arthritis [115] and showed good validity properties in these 
populations. The EQ-VAS was used for all participating children.
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Clinical measures
Information on stuttering severity and TSO of stuttering was obtained from the initial 
assessment by the speech- language pathologists. For the current study, the Stuttering 
Severity Index-3 (SSI-3) [116] was used as an index of stuttering severity. The stuttering 
severity score based on the SSI-3 is a weighted mean of (a) stuttering frequency, (b) duration 
of the three longest stutters and (c) physical concomitants. The following stuttering severity 
categories were distinguished for the study: (1) mild stuttering (SSI-3 score: 11-16)2; (2) 
moderate stuttering (SSI-3 score: 17-26); severe or very severe stuttering (SSI-3 score: 27 
and above). In the RESTART-trial, the speech-language pathologists calculated the SSI-3 
severity category based on video recordings in the clinic. Since it is difficult for parents (and 
often impossible) to recall the exact date of onset of stuttering, TSO was divided in three 
categories (in line with [34]): 6-12 months, 13-18 months and 19 months or longer.
Analysis
First, the distribution of scores for all HRQOL instruments were separately compared with the 
distribution of HRQOL values of the reference groups. Since most of the data distributions 
were severely skewed to the left, comparisons were based on the non-parametric Mann-
Whitney U Test. The global level of significance was defined at α = 0.05. To correct for 
multiple comparisons per questionnaire, the Bonferroni correction was performed. As 11 
different scores were compared for the ITQOL-97, the level of significance was defined 
at α= 0.05/11 = 0.0045. For the instruments applied in children aged 5-6 years, α was 
set at 0.05/15 = 0.0033 (CHQ-PF28) and 0.05/9 = 0.0055 (HUI3). In order to indicate the 
clinical significance of observed statistically significant differences, effect sizes (ES) were 
calculated by dividing the difference in mean scores between CWS and reference groups 
by the pooled standard deviation. A small effect is indicated by an ES of 0.2 until 0.5, a 
moderate effect by an ES of 0.5 until 0.8 and a large effect by an ES of 0.8 and higher [117]. 
Second, analysis of covariance (ANCOVA), adjusting for age in months, was conducted 
for group comparisons in the study population of CWS. The between-subject factors 
were SSI (3 levels) and TSO (3 levels). Eta squared values were obtained to measure the 
effect sizes. Post-hoc tests (Bonferroni) were used to perform pairwise comparisons among 
groups. This was done for all ITQOL-97 and CHQ-PF28 scales and for the HUI3 utility 
and EQ-VAS score as dependent variables. Preliminary checks were conducted to ensure 
that assumptions of ANCOVA were not violated. For a few CHQ-PF28 outcomes, the 
assumption of homogeneity of variances was not met. Therefore, for these scales analyses 
were also conducted with logarithmic transformations of HRQOL scores, which did not 
change any of the results. All data were analyzed using SPSS 19.0 (Armonk, NY: IBM Corp.).
2 Children with a stuttering frequency < 3% in the therapy setting and ≥ 3% in the home setting were included in 
the group “mild stuttering”
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RESULTS
Table 2.1 shows the clinical characteristics of the study population. Table 2.2 presents the 
mean scale scores on the ITQOL-97 and the CHQ-PF28 of the study population and the 
reference groups, and the p-value and effect-size for each scale. CWS scored higher on 
the getting along scale of the ITQOL-97, but after Bonferroni correction this difference was 
no longer significant. On all other scales no significant differences in scores between CWS 
and reference groups were found. Table 2.3 shows the mean HUI3 and EQ-VAS values 
for CWS and reference groups. CWS aged 5-6 years had lower mean scores for the HUI3 
domains speech, emotion and cognition; however, after Bonferroni correction only the 
speech domain remained significant. The effect size was large (0.99 vs. 0.95, original p 
< .01, Cohen’s d = 1.0). The HUI3 utility reflected a lower HRQOL for 5-6 year old CWS, 
revealing a moderate effect size (0.94 vs. 0.88, original p < .01, Cohen’s d = 0.60). The EQ-
VAS for all CWS showed a small to moderate effect size (92.40 vs. 88.14, original p < .01, 
Cohen’s d = 0.45). A separate analysis of EQ-VAS scores for CWS aged 3-4 years and 5-6 
years compared with reference scores revealed similar results.
TABLE 2.1. Stuttering characteristics of participating CWS
Characteristics Total group (N = 197)
Participants 3-4 years 
(N = 146)
Participants 5-6 years
(N = 51)
Stuttering severity
Mild 64 (32.5%) 48 (32.9%) 16 (31.4%)
Moderate 97 (49.2%) 72 (49.3%) 25 (49.0%)
Severe 36 (18.3%) 26 (17.8%) 10 (19.6%)
Time since onset
6-12 months 87 (44.2%) 79 (54.1%) 8 (15.7)
13-18 months 48 (24.4%) 35 (24.0%) 13 (25.5)
19 months or longer 62 (31.5%) 32 (21.9%) 30 (58.8)
 
Figure 2.1 shows the distribution of responses on the HUI3 domains for the study population 
of stuttering children aged 5-6 years and for the reference population. Compared with 
the reference population, parents of CWS more often chose level 2 and 3 of the speech 
domain (representing lower scores on this domain of health). For the domains emotion 
and cognition, the difference was mainly expressed in more level 2 problems in stuttering 
children. 
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TABLE 2.2 Results of the ITQOL-97 and CHQ-PF28 for CWS and reference groups
 
Reference groupb CWS 3-4 years
p-value Effect size (Cohen’s d)N Mean SD N Mean SD
ITQOL-97 scale
Physical functioning 91 98.86 2.80 144 97.98 10.09 .21 0.14
Growth and development 94 85.78 11.01 145 83.23 12.90 .11 0.21
Bodily pain and discomfort 93 88.17 15.94 145 90.43 11.99 .45 0.16
Temperament and moodsa 94 76.78 9.55 67 76.45 9.05 .94 0.04
General behaviora 94 72.21 12.62 65 73.96 13.47 .56 0.13
Getting along 94 71.95 8.44 145 74.72 8.86  .01* 0.32
General health perceptions 94 78.52 15.18 145 82.18 13.11 .07 0.26
Change in health 94 56.65 18.76 144 58.51 20.09 .60 0.10
Parental impact: emotional 94 90.12 10.70 145 90.76 10.08 .79 0.06
Parental impact: time 94 93.47 12.91 145 93.71 10.47 .72 0.02
Family cohesion 94 73.24 18.99 142 75.81 16.23 .42 0.15
 
Reference groupc CWS 5-6 years
p-value Effect size (Cohen’s d)N Mean SD N Mean SD
CHQ-PF28 scale
Physical functioning 378 96.30 12.38 46 96.86 13.99 .51 0.04
Role functioning-emotional/behavior 378 96.74 12.31 47 95.74 13.22 .49 0.08
Role functioning-physical 378 95.59 14.30 47 95.74 13.22 .92 0.01
Bodily pain 378 81.22 16.53 49 84.49 14.87 .19 0.21
General behavior 378 69.78 15.23 48 71.94 13.65 .38 0.15
Mental health 378 81.77 13.66 49 79.76 16.14 .53 0.13
Self-esteem 378 79.92 14.54 48 78.82 12.03 .51 0.08
General health perceptions 378 85.22 16.47 49 84.28 17.70 .88 0.06
Change in health 378 55.36 16.27 49 56.12 14.90 .56 0.05
Parental impact: emotional 378 85.52 15.72 49 85.20 15.24 .83 0.02
Parental impact: time 378 93.47 13.08 47 92.20 18.67 .99 0.08
Family cohesion 378 69.88 18.93 49 74.49 19.59 .10 0.24
Family activities 378 86.74 17.58 48 88.54 17.07 .41 0.10
Physical summary score 378 55.74 7.45 44 56.01 7.53 .74 0.04
Psychosocial summary score 378 52.01 7.13 44 51.72 5.86 .40 0.04
a Due to a failure in the data collection, analyses for these subscales were based on a smaller sample size of CWS
b Reference population from Raat et al. [107]: children 3.0-3.11 years of age
c Reference population from Raat et al. [108]: children 5.0-6.11 years of age
* p < .05, significant before Bonferroni correction
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FIGURE 2.1 Percentage distribution of responses by HUI3 domain for CWS and reference group
TABLE 2.3 Results of the HUI3 and EQ-VAS for CWS and reference groups
 
Reference groupa CWS 5-6 years
p-value Effect size (Cohen’s d)N Mean SD N Mean SD
HUI3 dimension
Vision 378 1.00 0.01 49 1.00 0.00 .98 0.00
Hearing 378 1.00 0.01 49 1.00 0.03 .90 0.00
Speech 378 0.99 0.03 49 0.95 0.05  <.01** 1.00
Ambulation 378 1.00 0.01 49 1.00 0.00 .61 0.00
Dexterity 378 1.00 0.00 49 1.00 0.00 .61 0.00
Emotion 378 0.99 0.02 49 0.99 0.02  .04* 0.00
Cognition 378 0.99 0.04 49 0.98 0.04  .05* 0.25
Pain 378 0.99 0.02 49 0.99 0.02 .81 0.00
HUI3 multi-attribute 
utility score
378 0.94 0.09 49 0.88 0.11  <.01** 0.60
 
Reference groupb All CWS
p-value Effect size (Cohen’s d)N Mean SD N Mean SD
EQ-VAS 450 92.40 8.85 183 88.14 10.14  <.01** 0.45
a Reference population from Raat et al. (2005): children 5.0-6.11 years of age
b Reference population from Raat et al. (2005): children 4.0-6.11 years of age
* p < .05, significant before Bonferroni correction
** p < .0055, significant after Bonferroni correction (α=.05/9=.0055)
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ANCOVA-analyses in children aged 3-4 years showed statistically significant main effects 
for stuttering severity for the ITQOL-97 scales temperament and moods and family 
cohesion (see Table 2.4). However, effect sizes were very small (eta squared=0.001 and 
0.002 respectively). Post-hoc tests showed that on both scales children with mild stuttering 
scored higher (indicating better health) than children with moderate and/or severe 
stuttering (see Table 2.5), but differences were not statistically significant.
TABLE 2.4 ANCOVA results
Dependent variable df F p-value Eta squared
Independent variable = stuttering severity
ITQOL-97 temperament and moods 2, 61 3.56 .035 0.001
ITQOL-97 family cohesion 2, 136 3.11 .048 0.002
CHQ-PF28 general health perceptions 2, 43 4.34 .019 0.007
CHQ-PF28 physical summary score 2, 38 3.63 .036 0.003
Independent variable = TSO
CHQ-PF28 physical functioning 2, 40 3.40 .043 0.003
CHQ-PF28 family cohesion 2, 43 4.95 .012 0.011
Note. Only significant effects are displayed
For children aged 5-6 years, statistically significant main effects for stuttering severity were 
found for the CHQ-PF28 scales general health perceptions and physical summary score, 
with very small effect sizes (eta squared=0.007 and 0.003, respectively; see Table 2.4). 
On both scales, children with mild stuttering had significantly higher scores (indicating 
better health) than children with moderate stuttering (see Table 2.5). On the scales physical 
functioning and family cohesion, statistically significant main effects were found for TSO. 
Effect sizes were again very small (eta squared= 0.003 and 0.011, respectively; see Table 
2.4). Post-hoc tests revealed higher scores for children who stuttered 19 months or longer, 
compared with children who stuttered 13-18 months (see Table 2.5).
On the EQ-VAS and HUI3 no effect of stuttering severity or TSO was established. HRQOL 
results for groups of CWS with different degrees of stuttering severity and different TSO are 
presented in respectively Appendix A2.1 and A2.2.
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TABLE 2.5 Adjusted mean ± standard error of the ITQOL-97 and CHQ-PF28 subscale scores by group 
of stuttering severity and TSO
Stuttering severity Time since onset
 Mild stuttering
Moderate 
stuttering
Severe 
stuttering
TSO 6-12 
months
TSO 13-18 
months
TSO 19+ 
months
ITQOL-97 temperament 
and moods
82.42 
(2.29)
76.61 
(1.59)
74.95 
(2.70)
ITQOL-97 family cohesion 81.37 (2.55)
74.53 
(1.97)
73.18 
(3.23)
CHQ-PF28 general health 
perceptions
89.60* 
(4.52)
74.34 
(3.81)
85.89 
(5.36)
CHQ-PF28 physical summary 
score
59.61* 
(2.11)
52.84 
(1.71)
55.33 
(2.30)
CHQ-PF28 physical 
functioning
99.64 
(4.84)
87.65 
(4.32)
100.38* 
(2.68)
CHQ-PF28 family cohesion    65.24 (6.99)
66.03 
(5.36)
82.65* 
(3.53)
Note. Only results for significant group differences in the ANCOVA-analysis are displayed. Outcomes for all HRQOL 
scales for CWS in different groups are presented in the Appendix 
* p <.05
DISCUSSION 
This study explored the HRQOL of 197 preschool stuttering children referred for treatment 
using three validated generic instruments. The outcomes on the EQ-VAS for all preschool 
children and the HUI3 utility value (only available for children aged 5-6 years old) showed 
that the HRQOL of CWS is slightly poorer than that of the norm in the Dutch population 
(small to moderate effect sizes), but results on the different health domains of the CHQ-
instruments (available for children aged 3-6 years old) did not reveal any difference in 
scores between stuttering children and reference groups. Within the group of CWS, 
two individual ITQOL-97 and four CHQ-PF28 scales showed statistically different scores 
for children with different SSI stuttering severity or TSO. However, based on the effect 
sizes, these differences were considered negligible. Thus, our study did not establish a 
meaningful effect of severity or TSO on the HRQOL of preschool CWS. 
Interestingly, the results of our study confirm the conclusion of the recent population-
based study by Reilly et al. [11]. This study suggested no general negative impact of 
developmental stuttering on the HRQOL of young children, even though the range of 
responses in the study indicated that the HRQOL of a few individual stuttering children 
was impaired. If a general HRQOL impairment were present in preschool CWS, this would 
have been likely to emerge in the data from our clinical population of stuttering children. 
All children in our study had stuttered for at least six months and their stuttering had 
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been confirmed by clinical measures, so no ambiguous or borderline cases were included. 
Furthermore, parents who seek help for a health problem for their child can be expected to 
be concerned about their child; it is typically parents’ perception of their children’s HRQOL 
that influences health care utilization [118]. However, the CHQ-instruments used in our 
study did not show more parental concerns due to the child’s health in parents of CWS 
compared to parents in the reference populations. 
Exceptions to the overall null-finding appear to be the results of our population of CWS 
showing a significantly lower mean HUI3 speech domain score (with a large effect size) and 
EQ-VAS score (small to moderate effect size), compared to the reference populations. This 
finding of a lower score on the HUI3 speech domain (representing diminished functioning 
in this domain), is not surprising in a population of CWS, since it could be interpreted as an 
acknowledgment of parents judging the speech of their children to be less favorable than 
parents of non-stuttering children. The finding of the lower EQ-VAS score cannot be easily 
interpreted; however, it is important to note that the EQ-VAS does not measure HRQOL 
through the degradation of health on distinct domains, but rather asks directly for a (proxy) 
HRQOL value. 
Since, in general, demands on the oral communication skills of young children are limited, 
impaired speech may not critically influence their daily functioning. Furthermore, very 
young children, particularly if their stuttering is mild, may hardly be aware of their stuttering 
and negative reactions from peers may still be exceptional. Finally, emotional well-being 
in young children may depend less on the social environment and more on the trusting 
relationships with their parents. On the other hand, the lower score on the temperament 
and moods scale of the ITQOL-97 for CWS with moderate and severe stuttering compared 
to children with mild stuttering might suggest that young children who stutter severely 
have more difficulties in regulating their moods and temperaments (e.g., fussiness, 
sleeping difficulties, lack of alertness). This finding possibly indicates a connection between 
temperament and stuttering severity, which would be in line with results of several studies 
into these two entities in the last decade (for an overview, see [100]). However, the effect 
size in our study was too small to be interpreted as relevant. The same holds for the lower 
scores on the family cohesion scale scores for children with mild stuttering in this age 
group. With regard to the higher family cohesion score (again with a small effect size) for 
children aged 5-6 years who stuttered for more than 19 months compared to children 
who stuttered 13-18 months, one could speculate that families of these children had 
become closer, for instance to compensate for problematic relationships with peers or to 
protect or additionally support their stuttering child. Higher family cohesion for families of 
non-healthy children has also been reported by Bannink, Maliepaard, Raat, Joosten, and 
Mathijssen [119]. 
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Physical problems were not a priori anticipated in our study group of CWS. Although our 
data suggest a relationship between physical dysfunctioning and stuttering, the effect sizes 
were too small to support a firm conclusion. Besides, this association may also have been 
caused by the coincidental presence of more children with physical problems in the groups 
of CWS aged 5-6 years with moderate stuttering and the group who stuttered for 13-18 
months. A review of the available data on the physical state of CWS aged 5-6 years old 
confirms that relatively many children with moderate or severe stuttering (n=7; 14%) were 
being checked by a doctor regularly and/or were using medicines (e.g., for eczema or otitis 
media), compared with none of the children with mild stuttering. 
Since this was the first study of its kind, there are a number of limitations which need 
to be considered. Firstly, different HRQOL instruments had to be used for different age 
groups. This hampered a direct comparison of results across all age groups. The EQ-
VAS was the only instrument that could be used for all children. Splitting the groups also 
resulted in relatively small groups; the group with severe stuttering in children aged 5-6 
years was particularly small (n=10). Therefore, in some cases the conditions for establishing 
a statistical significant result (i.e., sufficient statistical power) could not be fully met, for 
instance with regard to the low mean score on the mental health domain of the CHQ-PF28. 
This also holds for the other domains. Since the current study was part of a larger study in 
which HRQOL was a secondary outcome measure, an a priori power calculation was not 
possible for this study. Nevertheless, the mostly small effect sizes found in our study do 
strengthen our conclusions on the null-finding. 
Secondly, although a combination of generic and disorder-specific instruments is generally 
recommended in HRQOL research [88], currently no stuttering-specific HRQOL measure 
for young children exists. It might be argued that the incorporated HRQOL measures in 
the current measurements are not specific enough to detect a HRQOL impairment, even 
though they cover emotional and social domains of health. While the scale general health 
perceptions of the CHQ-instruments is known to be highly sensitive in somatic pediatric 
conditions, the sensitivity of the CHQ-instruments for conditions related to mental health 
has yet to be further investigated [120]. 
Thirdly, the reference data for the ITQOL-97 were only available for children aged 3.0-3.11 
years, while our study population consisted of children aged 3.0-4.11 years. However, the 
fact that in our study population the scores did not differ between children aged 3 and 4 
years, supports the validity of our conclusions. 
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Finally, the HRQOL results are based on parent-reported data. The use of parental proxies 
was essential considering the age of the children in this study. However, it is known that the 
adequacy of proxy ratings may be confounded by certain characteristics such as parental 
emotions and stress [121-123]. It was not possible to take these into consideration in the 
current study. Furthermore, correlations between child and proxy reports are known to 
be high for observable, physical domains but lower for less observable domains like pain 
and anxiety [124]. Thus, the impact of stuttering on the emotional and social HRQOL 
domains, which have been shown to be most affected in adults who stutter, might not be 
well estimated by proxy reports. However, a difference would not necessarily have to mean 
that the child reports a lower HRQOL. For instance a study into chronic pain in children 
showed the opposite, i.e., parents rated their child’s HRQOL lower than the child himself 
[125]. The relationship between HRQOL ratings by stuttering children and proxies needs 
to be explored in future studies. Additional research incorporating child self-report during 
follow-up at school age would expand on our findings.
CONCLUSION
In conclusion, while stuttering that persists into adolescence and adulthood is commonly 
associated with a reduced HRQOL [41,42,84,85,91,92,126], the results of the current 
study do not reveal a diminished HRQOL for preschool stuttering children from a clinical 
population. Intervention during the preschool years may be crucial to try to prevent 
stuttering becoming a chronic, severe condition and thus potentially decrease an individual’s 
well-being. To provide more insight into the broader health consequences of stuttering in 
children, we would recommend further research, which would include a larger cohort of 
children with severe stuttering and study the longitudinal course of HRQOL. Incorporating 
additional parameters, such as child functioning and characteristics of both the child (e.g., 
temperament and presence of social anxiety) and the environment (e.g., family climate 
and parental stress), could expand on this study and provide a more comprehensive 
interpretation of HRQOL results in children who stutter. 
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APPENDIX
TABLE A2.1 Results on the ITQOL-97, CHQ-PF28, HUI3 and EQ-VAS in CWS for different stuttering 
severity groups
Mild stuttering Moderate stuttering Severe stuttering
N Mean SD N Mean SD N Mean SD
ITQOL-97 item scale
Physical functioning 48 99.79 1.08 71 96.28 14.15 26 99.36 1.64
Growth and development 48 84.95 11.20 71 82.72 10.71 26 81.44 19.78
Bodily pain and discomfort 48 92.71 10.12 71 89.38 12.67 26 89.10 13.07
Temperament and moodsa 20 80.31 9.78 35 75.30 8.77 12 73.38 6.85
General behaviora 16 80.39 15.69 36 70.65 12.09 13 73.94 11.02
Getting along 48 75.30 10.07 71 73.35 7.82 26 77.41 8.76
General health perceptions 48 84.85 12.12 71 80.65 13.39 26 81.45 13.84
Change in health 48 58.33 19.52 70 58.21 20.73 26 59.62 20.10
Parental impact: emotional 48 92.71 9.26 71 89.54 11.09 26 90.52 8.26
Parental impact: time 48 96.00 7.27 71 92.28 11.57 26 93.41 11.90
Family cohesion 48 80.10 17.37 68 74.12 15.31 26 72.31 15.31
CHQ-PF28 item scale
Physical functioning 15 100 0.00 21 93.65 20.36 10 98.89 3.51
Role functioning-emotional/behavior 15 100 0.00 22 92.42 17.61 10 96.67 10.54
Role functioning-physical 15 100 0.00 22 93.94 16.70 10 93.33 14.05
Bodily pain 16 90.00 10.33 23 83.48 16.68 10 78.00 14.76
General behavior 16 70.86 14.15 22 74.17 13.88 10 68.79 12.83
Mental health 16 80.21 17.18 23 83.70 12.68 10 70.00 18.92
Self-esteem 16 82.29 10.49 23 77.65 12.44 10 75.83 13.29
General health perceptions 16 91.88 13.09 23 77.54 19.55 10 87.63 14.83
Change in health 16 54.69 13.60 23 57.61 13.97 10 55.00 19.72
Parental impact: emotional 16 91.41 9.92 23 84.24 18.16 10 77.50 11.49
Parental impact: time 14 97.62 6.05 23 88.41 24.84 10 93.33 11.65
Family cohesion 16 73.13 22.50 23 72.83 19.35 10 80.50 15.36
Family activities 15 89.17 18.82 23 86.41 18.43 10 92.50 10.54
Physical summary score 13 59.58 1.69 21 53.50 9.87 10 56.62 4.14
Psychosocial summary score 13 53.70 4.72 21 52.12 5.54 10 48.30 6.88
HUI3 dimension
Vision 15 1.00 0.01 24 1.00 0.00 10 1.00 0.00
Hearing 15 1.00 0.00 24 0.99 0.04 10 1.00 0.00
Speech 15 0.96 0.04 24 0.96 0.04 10 0.94 0.05
Ambulation 16 1.00 0.00 24 1.00 0.00 10 1.00 0.00
Dexterity 16 1.00 0.00 24 1.00 0.00 10 1.00 0.00
Emotion 15 0.99 0.02 24 0.99 0.02 10 0.98 0.03
Cognition 16 0.98 0.05 24 0.98 0.04 10 0.98 0.03
Pain 15 1.00 0.00 24 0.99 0.03 10 0.99 0.03
HUI3 multiattribute utility score 15 0.90 0.12 24 0.88 0.11 10 0.86 0.11
EQ-VAS 62 88.94 9.89 88 87.42 10.93 33 88.58 8.44
a Due to a failure in the data collection, analyses for these subscales were based on a smaller sample size of CWS
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Table A2.2 Results on the ITQOL-97, CHQ-PF28, HUI3 and EQ-VAS in CWS for different time since 
onset (TSO) groups
TSO 6-12 months TSO 13-18 months TSO ≥ 19 months
N Mean SD N Mean SD N Mean SD
ITQOL-97 item scale
Physical functioning 77 97.45 12.69 35 98.74 6.89 32 98.44 4.56
Growth and development 78 82.46 14.43 35 85.70 11.49 32 82.40 10.04
Bodily pain and discomfort 78 91.45 12.23 35 91.07 11.08 32 87.24 12.16
Temperament and moods a 44 75.63 9.55 9 81.64 7.54 14 75.69 7.58
General behavior a 38 72.11 12.65 12 75.71 17.83 15 77.23 11.57
Getting along 78 74.22 8.82 35 76.02 9.30 32 74.51 8.59
General health perceptions 78 82.33 12.57 35 83.18 13.22 32 80.72 14.54
Change in health 78 60.26 20.72 34 56.62 17.74 32 56.25 21.06
Parental impact: emotional 78 90.61 10.92 35 90.61 9.92 32 91.29 8.21
Parental impact: time 78 93.76 10.84 35 93.02 10.04 32 94.35 10.29
Famlily cohesion 78 74.94 16.58 34 76.91 17.84 30 76.83 13.55
CHQ-PF28 item scale
Physical functioning 8 98.61 3.93 10 87.78 28.90 28 99.60 2.10
Role functioning-emotional/behavior 8 95.83 11.79 10 90.00 22.50 29 97.70 8.60
Role functioning-physical 8 100.00 0.00 10 90.00 22.50 29 96.55 10.33
Bodily pain 8 82.50 16.69 12 88.33 13.37 29 83.45 15.18
General behavior 8 68.91 12.47 11 66.59 15.30 29 74.81 12.96
Mental health 8 79.17 14.77 12 73.61 20.67 29 82.47 14.15
Self esteem 8 83.33 12.60 11 79.55 8.63 29 77.30 12.97
General health perceptions 8 80.00 22.64 12 78.30 20.16 29 87.93 14.67
Change in health 8 56.25 11.57 12 58.33 22.19 29 55.17 12.28
Parental impact: emotional 8 79.69 11.45 12 83.33 16.28 29 87.50 15.67
Parental impact: time 8 95.83 7.72 11 83.42 30.46 28 94.64 13.65
Family cohesion 7 68.57 23.22 12 63.33 19.46 30 80.33 16.86
Family activities 8 87.50 11.57 12 87.50 19.22 28 89.29 17.91
Physical summary score 8 56.43 4.34 9 52.56 14.13 27 57.03 4.69
Psychosocial summary score 8 51.25 6.46 9 50.18 6.35 27 52.37 5.65
HUI3 dimension
Vision 8 1.00 0.01 11 1.00 0.00 30 1.00 0.00
Hearing 8 1.00 0.00 11 1.00 0.00 30 0.99 0.04
Speech 8 .94 0.05 11 0.97 0.05 30 0.95 0.05
Ambulation 8 1.00 0.00 12 1.00 0.00 30 1.00 0.00
Dexterity 8 1.00 0.00 12 1.00 0.00 30 1.00 0.00
Emotion 8 0.98 0.03 11 0.99 0.02 30 0.99 0.02
Cognition 8 0.95 0.04 12 0.97 0.07 30 0.99 0.02
Pain 8 0.99 0.02 11 0.98 0.03 30 0.99 0.02
HUI3 multiattribute utility score 8 0.82 0.14 11 0.87 0.14 30 0.90 0.09
EQ-VAS 82 87.27 10.70 42 88.56 9.22 58 89.07 9.22
a Due to a failure in the data collection, analyses for these subscales were based on a smaller sample size of CWS


Health-related quality of life 
 of adults who stutter 
 
With Clazien Bouwmans
Marie-Christine Franken
Elly Stolk
Journal of Communication Disorders 2011
42 | Chapter 3
ABSTRACT
Although persistent developmental stuttering is known to affect daily living, just how great 
the impact is remains unclear. Furthermore, little is known about the underlying mechanisms 
which lead to a diminished quality of life (QOL). The primary objective of this study is to 
explore to what extent QOL is impaired in adults who stutter (AWS). In addition, this study 
aims to identify determinants of QOL in AWS by testing relationships between stuttering 
severity, coping, functioning and QOL and by testing for differences in variable scores 
between two AWS subgroups: receiving therapy versus not receiving therapy. A total of 
91 AWS filled in several questionnaires to assess their stuttering severity, daily functioning, 
coping style and QOL. The QOL instruments used were the Health Utility Index 3 (HUI3) 
and the EuroQoL EQ-5D and EQ-VAS. The results indicated that moderate to severe 
stuttering has a negative impact on overall quality of life; HUI3 derived QOL values varied 
from .91 (for mild stuttering) to .73 (for severe stuttering). The domains of functioning that 
were predominantly affected were the individual’s speech, emotion, cognition and pain 
as measured by the HUI3 and daily activities and anxiety/depression as measured by the 
EQ-5D. AWS in the therapy group rated their stuttering as more severe and recorded 
more problems on the HUI3 speech domain than AWS in the non-therapy group. The EQ-
VAS was the only instrument that showed a significant difference in overall QOL between 
groups. Finally, it was found that the relationship between stuttering severity and QOL was 
influenced by the individual’s coping style (emotion-oriented and task-oriented). These 
findings highlight the need for further research into stuttering in relation to QOL, and for 
a broader perspective on the diagnosis and treatment of stuttering, which would take into 
consideration quality of life and its determinants. 
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INTRODUCTION
How stuttering affects the overall quality of life (QOL) of adults who stutter (AWS) has 
not yet been extensively researched. This is surprising since about 1% of the adult 
population stutters [7] and because it is known that AWS often experience negative 
affective, behavioral, and cognitive reactions. Moreover, stuttering significantly limits the 
speaker’s ability to participate in daily activities [86]. AWS frequently experience disabling 
levels of social anxiety [127-129]. Whether this occurs, depends on their fear of a negative 
evaluation in social relations because of their stuttering, and whether or not they act upon 
that fear by adoption of a strategy of avoidance [130]. Recognizing the complexity of 
the stuttering disorder in adults, researchers have established the need to document not 
only speech symptoms, but also broad-based outcome parameters such as QOL (e.g., 
[41,75,78,86]). Recently, a special edition of the Journal of Fluency Disorders dedicated to 
the QOL of people who stutter also raised awareness for the topic [9,77,131]. Until now, 
the magnitude of and mechanisms underlying the QOL effects of stuttering in adults have 
not been fully explored. The purpose of this study is to evaluate QOL in AWS by means of 
a comprehensive assessment.
A review of existing literature with respect to the QOL in AWS revealed that the majority of 
studies use a narrow conceptualization of QOL. That is, most studies investigated the QOL 
of AWS by focusing on the influence that stuttering has on the specific life domains which 
are believed to be most affected by stuttering (e.g., [42,83-85,132]). For example, Hayhow 
et al. [84] showed the major adverse effects of stuttering on school life and occupational 
choice. The negative impact of stuttering on school performance, relationships with 
teachers and classmates, and performance at work was confirmed by Klompas and Ross 
[85], who interviewed 16 AWS. Klein and Hood [42] found that the majority of the AWS 
perceived their stuttering to be a handicap in relation to employment opportunities and 
job performance. By exploring specific life domains potentially affected by the condition 
stuttering, these studies provide significant, but only limited, information on QOL. A 
disadvantage of such condition-specific QOL studies is that little insight is gained into the 
overall QOL (e.g., [41,75,133]). In other words, although these studies provide insight into 
problems associated with stuttering, not all aspects of QOL relevant to a person are taken 
into account. In addition, due to the incorporation of dissimilar domains, condition-specific 
QOL instruments cannot be used to compare different health conditions.
In contrast to condition-specific QOL instruments, generic QOL instruments embrace a 
broad conceptualization of QOL by measuring a comprehensive set of domains. A common 
element in these generic QOL instruments is the incorporation of physical, emotional 
and social domains of health. These domains are relevant for anyone, irrespective of the 
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specific health problem. As a result, generic QOL instruments are suitable for comparison 
of stuttering to other health states. Well-known examples are the Medical Outcomes Study 
Short Form 36-Item Health Survey (SF-36) and the Nottingham Health Profile (NHP). A 
limitation of these descriptive generic QOL instruments is that they do not quantify how 
each dimension contributes to overall well-being. That is, if some domains are significantly 
affected but others are not, the effect on overall QOL cannot be established. To overcome 
this problem, QOL researchers frequently move beyond a multidimensional generic 
description of health by attaching a single value to the overall health status [133]. This 
value or utility summarizes all the positive and negative aspects of health into one single 
QOL index, which is usually set between 0, which corresponds to a health state valued 
as equivalent to death, and 1, which corresponds to perfect health. Such QOL values 
can be established in two ways. Firstly, health states can be estimated by using validated 
preference-based techniques [134]: Visual Analogue Scale (VAS), Time Trade-Off (TTO) or 
Standard Gamble (SG). Alternatively, a special class of generic QOL instruments can be 
used, for which QOL values are available for all health states described by the instrument 
[135]. Well known examples are the EQ-5D, Health Utilities Index (HUI) and the SF-6D 
(derived from the SF-36) [136]. 
So far, only two studies have attempted to gain insight into overall QOL of AWS by using 
generic QOL instruments or by preference-based techniques. Craig et al. [41] used the SF-
36 to explore the negative impact caused by stuttering in a population of AWS and adults 
who do not stutter (AWNS). The authors showed that, compared to a non-stuttering control 
group, stuttering affects social and emotional functioning, as well as vitality and mental 
health status. The effect sizes (standardized mean difference between the groups) on these 
domains varied between .28 and .59, indicating small to moderate QOL impairments in 
AWS. Because the associated SF-6D utilities were not reported by Craig et al. [41], the effect 
on overall QOL remains unclear. The study by Bramlett, Bothe and Franic [137] is the only 
study that we are aware of that adopted a preference-based approach to estimate utilities. 
Bramlett et al. [137] obtained overall QOL values for mild, moderate and severe stuttering 
from 75 AWNS using the three validated preference-based techniques mentioned before: 
VAS, TTO and SG. The results suggested that QOL is negatively affected by stuttering. 
Using the TTO method, non-stuttering adults valued their own health at .98 (SD .07), while 
they rated mild, moderate and severe stuttering at respectively .93 (SD .14), .85 (SD .18) 
and .63 (SD .24) [137]). Considering that a QOL weight of .63 has been found for living 
with home dialysis (Sackett and Torrance, 1978 in [137]), the results suggest that severe 
stuttering has a substantial impact on a person’s overall QOL. However, the differences in 
QOL values between methods were substantial: VAS and SG resulted in QOL values of .44 
(SD .20) and .81 (SD .19) respectively for severe stuttering. In addition, the applied methods 
provided little or no insight into the determinants (i.e., the underlying mechanisms) that 
lead to QOL impairments.
HRQOL of adults who stutter | 45
3
Thus the purpose of this study is to explore to what extent overall QOL is impaired in 
AWS and to investigate the determinants of such QOL impairment. Based on the 
conceptualization of QOL by Wilson and Cleary [79], the determinants measured in this 
study are stuttering severity, functioning and coping. Differences in stuttering severity, 
functioning, coping and QOL are examined between AWS who were in therapy and those 
who were not. Both groups are included because we hypothesize that studying QOL solely 
in a clinical population might lead to observing a greater reduction in QOL than when also 
taking into account the QOL of AWS who do not seek therapy. In terms of impaired quality 
of life, AWS who present themselves to a clinic might be those who are most severely 
affected by their condition. This could either be because their level of stuttering is more 
severe or because they have poorer coping skills and are more bothered by the effect of 
stuttering on their social interactions. Busschbach, Rikken, Grobbee, De Charro, and Wit 
[138] observed a lower QOL for adults with a short stature who had presented themselves 
to a clinic compared with a population based sample of short adults. It is thus considered 
important to include both AWS who were in therapy and AWS who were not in order to 
account for variability in the determinant variables of QOL in both groups and to provide 
a broad view of QOL. These insights could provide valuable support in designing possible 
starting-points for diagnosis, therapy, and measuring end points in clinical trials [139,140]. 
CONCEPTUALIZATION OF QOL
The empirical evaluation of QOL in AWS in this study is based on the theoretical 
conceptualization of QOL published by Wilson and Cleary [79]. This conceptual framework 
shows how different health measures can be combined to constitute a broad assessment 
of QOL. This section will explain how the QOL model extracted from the original Wilson 
and Cleary [79] model is built up. 
The core of the model (Figure 3.1) is the relationship between symptoms, functioning 
and general health perception, the latter often referred to as health-related quality of life 
(HRQOL) or briefly as QOL (in this paper). Symptoms are defined as perceptual judgments 
of an abnormal physical, emotional, or cognitive state. Functioning refers to the ability 
of the individual to perform particular defined tasks. Basic domains of functioning that 
are commonly measured are physical, social, role and psychological functioning [135]. By 
measuring functioning on generic domains, the impact of a condition can be assessed in 
terms that are relevant to any individual. General health perception or (Hr)QOL reflects 
an overall, subjective evaluation of health status, in relation to symptoms and functional 
problems. 
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The model highlights the direct and indirect relationships between the adjacent outcome 
levels (how symptoms impact on functioning, and functioning on QOL), which can be 
assessed using condition-specific and generic outcome measures. In addition, the model 
takes into account that characteristics of the individual as well as characteristics of the 
environment might impact on the experience of symptoms, daily functioning and QOL and 
their relationships. These factors may have a direct or indirect impact on QOL. Examples 
of individual characteristics that affect QOL are psychological characteristics, personality 
and individual expectations. Examples of environmental characteristics are social support 
and the employment environment. The model does not precisely prescribe which of these 
factors may be relevant for exploration of QOL. 
  
 
Symptom 
Status 
Functional 
Status 
Characteristics of 
the individual 
Characteristics of the 
environment 
Quality of 
Life 
FIGURE 3.1 Conceptualization of determinants of quality of life, adapted from “Linking clinical 
variables with health-related qualify of life. A conceptual model of patient outcomes” [79]
OPERATIONALIZATION OF QOL IN AWS
This section indicates and motivates the selection of instruments for the operationalization 
of the Wilson and Cleary [79] model in this study. The instruments will be described in more 
detail in Section 4.3.
Overall QOL
To address the first aim of this study, to measure to what extent overall QOL is impaired in 
AWS, we assessed the primary outcome level (Quality of Life) by measuring QOL values for 
the health states reported by the participants. As described in Section 1, these values can 
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be obtained by using generic QOL instruments for which QOL values for all health states 
are available. We decided to use two widely applied the Health Utility Index 3 (HUI3; [111], 
the EuroQoL EQ-5D and the EuroQoL EQ-VAS [113]). These are brief and easy to use self-
completed questionnaires. 
Symptom status
The symptom status level can be assessed by measuring the level of stuttering severity 
experienced (e.g., [141]). In the current study, the level of stuttering severity was rated 
using two self-assessment scales. Self-assessment scales have shown to be correlated 
well with objective stuttering measures and other self-evaluation instruments [142] and 
rating by speech-language pathologists [141]. In addition to the self-assessment scales, a 
comprehensive stuttering instrument was applied; the Overall Assessment of the Speaker’s 
Experience of Stuttering for adults (OASES, [86]).
Functioning status
In line with the Wilson and Cleary [79] model, functioning status was also measured in 
a generic way. The functional profiles provided by the HUI3 and EQ-5D were used as 
indicators of functioning. The domains that are measured by these instruments were 
considered as potentially relevant with regard to stuttering. That is, functioning restraints 
in AWS could be expected in the social, role and psychological domains, for instance 
communication in social situations or at work (e.g., [86]). 
Characteristics of the individual
With respect to the individual and environmental characteristics, various studies suggest 
that coping style is an important determinant in QOL in AWS (e.g., [83,143-145]. Coping 
refers to the conscious response or reaction to events that are perceived as stressful [146]. 
An association between coping and QOL in AWS may be expected because individuals 
can adopt different strategies to reduce stress levels caused by their diminished ability to 
speak fluently. These coping styles may differ in their effectiveness to prevent negative 
QOL effects. Coping models have been frequently used to explain successful adjustment 
to chronic diseases, by showing the active role that patients may exert in managing the 
challenges that emanate from their condition [147]. Stuttering might well be a condition 
for which the applied coping style strongly influences the experienced QOL, since AWS are 
frequently confronted with their speech limitations [148]. In the current study, coping style 
was analyzed using the Coping Inventory for Stressful Situations (CISS) [149]. Environmental 
characteristics were not explicitly measured in this study, since it was argued that the main 
environmental factors related to QOL in AWS are also related to coping. That is, the social 
environment can be perceived as more or less demanding with regard to fluent speech and 
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therefore influence coping ability, and, adversely, coping styles could influence how people 
choose their current environment.
METHODS
Participants 
The study population consisted of AWS who were not receiving therapy and AWS who 
either had just started therapy or were on a waiting list for therapy at the time of the 
investigation. AWS in therapy (the T group) were recruited from 14 stuttering and/or 
speech and language therapy centers throughout the Netherlands and from a family 
system therapy program for persons who stutter. AWS not receiving treatment (the NT 
group) were recruited informally, by asking relatives and acquaintances of the researchers 
to invite individuals who stutter and who were currently not in treatment to participate in 
the study. In addition, a Dutch social networking website for persons who stutter (Hyves-
stuttering) was used for recruitment of this group. 
 
Data collection
All data were collected between February and November, 2008. Study questionnaires were 
distributed by mail. All participants received a small gift for their participation. Besides 
the outcome measures listed below, all participants were asked to complete a socio-
demographic checklist. 
Measurement
Symptom status
Self-assessment scale of speech (SA scale)
The primary instrument to assess symptom status was a self-assessment scale of speech 
(SA scale) [142]. Participants were asked to rate their speech on a scale ranging from 1 (very 
poor) to 10 (very good). Only the endpoints of the scale were defined (see Figure A3.1 in 
the Appendix). No normative score is available for this SA scale. Instead, the instrument 
is criterion-referenced in relation to the Dutch standards (e.g., for school performances) 
with 1 being the worst and 10 being the best score. A SA score of 6 can be interpreted as 
speech being sufficiently good.
Speech satisfaction scale
In addition to the SA scale, participants rated their speech satisfaction on a Likert scale with 
five response categories ranging from “not at all satisfied” to “very satisfied” (see Figure 
A3.1 in the Appendix). This speech satisfaction scale takes into account more explicitly that 
symptom status is influenced by intra-individual characteristics. 
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Overall Assessment of the Speaker’s Experience of Stuttering for adults (OASES)
Finally, the OASES [86] was used to assess symptom status. The OASES is a validated 
questionnaire which evaluates the experience of the stuttering disorder from the 
perspective of the AWS. It consists of four parts, each of which examines different aspects 
of the stuttering disorder: (I) general perspectives about stuttering, (II) affective, behavioral 
and cognitive reactions to stuttering, (III) functional communication difficulties and (IV) 
impact of stuttering on the speaker’s quality of life. Impact ratings scores can be calculated 
for each individual section and for all sections in total and provide an indication of the 
impact of stuttering on various aspects of the speaker’s life. Although it is emphasized that 
the impact ratings are not exchangeable with stuttering severity ratings, they may provide 
an indication of the severity of stuttering [86]. Yaruss and Quesal [86] also presented 
normative scores. Impact scores between 20.0 and 29.9 refer to mild stuttering, scores of 
30.0-44.9 to mild-to-moderate stuttering, 45.0-59.9 to moderate, 60.0-74.9 to moderate-
to-severe and 75.0-100 to severe stuttering [86]. For this study, the OASES was translated 
into Dutch, using the well-established method of forward-translation and back- translation. 
While sections III and IV of the OASES include outcomes pertaining to functioning and 
overall QOL, in this study the instrument is classified as a symptom measure, because the 
OASES has a condition-specific focus; it does not tap all aspects of functioning and QOL. 
 
Functioning status and QOL 
Health Utility Index 3 (HUI3), EuroQoL EQ-5D and EQ-VAS
General functioning and QOL were measured simultaneously using two widely applied 
generic instruments that measure functioning and provide a QOL value for the health 
states that could be described by the instrument: The HUI3 [111] and EQ-5D [113]. Both 
instruments generate a descriptive health profile of a person’s functioning in society on 
generic, basic domains of life (i.e., physical, mental and social domains). As such, the results 
of these descriptive systems display a profile of functioning. In addition, a population-
weighted health index (or value) is produced, based on the descriptive system. This value 
reflects the general population’s perception of the desirability of a health status. In other 
words, it represents how good or how bad a health state is according to the general 
population. Values range from -.59 (worst imaginable health state) to 1 (full health) for 
the EQ-5D [150], and from -.36 to 1 for the HUI3 [111]. The values represent overall QOL 
scores. 
Both the HUI3 and EQ-5D were included because their responsiveness to stuttering has 
not yet been explored. Although these instruments conceptualize health and QOL similarly, 
the health concept is operationalized differently so that differences in responsiveness may 
be expected. The EQ-5D consists of five domains: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression, with three response levels for each domain. The 
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HUI3 incorporates eight domains: vision, hearing, speech, ambulation, dexterity, emotion, 
cognition and pain and discomfort (not specified), with five to six response levels for each 
domain. While, in general, the two descriptive systems lead to similar conclusions about 
QOL, differences between instruments on QOL values in AWS could be expected. This is 
because the HUI3 explicitly deals with QOL problems related to speech, while for the EQ-
5D inferences about the impact of stuttering on QOL could only be inferred from reduced 
functioning in other domains like for example anxiety/depression. Although the EQ-5D is 
currently the most used instrument of the two, the HUI3 is considered preferable in studies 
focusing on vision, speech or hearing, since these domains are included in the HUI3 and 
not in the EQ-5D [151]. For stuttering, however, evidence as to the performance of these 
instruments is lacking.
The EQ-5D was administered in conjunction with the EQ-VAS [113]. The EQ-VAS is a visual 
analogue scale (similar to a thermometer) for recording an individual’s rating for his or 
her current health state. Valuations range from 0 (worst imaginable health) to 100 (best 
imaginable health). A relevant distinction between the EQ-VAS versus the EQ-5D and HUI3 
is that the EQ-VAS values QOL from the perspective of the respondent himself instead of 
the general population. 
Characteristics of the individual: coping
Coping Inventory for Stressful Situations (CISS)
Coping style was measured using the Dutch version of the CISS [149]. Like other coping 
instruments, the CISS explores an individual’s ability to cope with problems by measuring 
the extent to which that individual applies the various coping styles generally available 
[147]. Three coping styles are identified by the CISS: task-oriented (T) coping style, 
emotion-oriented (E) coping style, and avoidance-oriented (A) coping style. The distinction 
between task and emotion-oriented coping is generally accepted. Task-oriented coping is 
aimed at actively managing the stressful situation itself, while emotion-oriented coping is 
aimed at thinking or feeling in a different way about the stressful situation and so reducing 
the negative emotional consequences [152]. Both types of coping are important, if used 
properly [152]. The avoidance-oriented coping style refers to the actions aimed at avoiding 
or withdrawing from the stressor or the feelings that are evoked by the stressor (e.g., 
daydreaming about other things or meeting friends) [149]. 
Each coping style is assessed according to 16 items, making a total of 48 items. For each 
item, respondents indicate on a Likert scale ranging from 1 (not at all) to 5 (very much) to 
what extent they apply a certain coping strategy during a stressful situation. An example 
item for T-coping in the CISS is “Think about the event and learn from my mistakes”, an 
example item for E-coping is “Blame myself for being too emotional about the situation” 
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and an example item for A-coping is “Take some time off and get away from the situation”. 
Studies of the construct validity of the CISS have shown that CISS-T reflects an active 
and adaptive coping strategy, while CISS-E reflects a more negative way of dealing with 
emotions. CISS-A could be considered as an active coping strategy [149]. Raw scores can 
be transformed into normative scores, which are available for the working population and 
students. Normative scores for the Dutch CISS are classified into seven categories, ranging 
from 1 (very low use of coping style) to 7 (very high use of coping style). Internal consistency 
and validity of the CISS is reported to be satisfactory [149]. 
Analysis
SPSS software version 15.0 (SPSS Inc., Chicago, IL, USA) was used for all the statistical 
analyses. Categorical variables were described by tabulations and percentages and tested 
for differences between the T and NT group by Chi-square tests. Continuous variables 
were described by means and standard deviations and tested for group differences by 
independent samples T-tests (2-tailed). Cohen’s d was used to interpret effect sizes. Cohen 
defined effect sizes as “small, d= .2; medium = .5 and large = .8” [117].
The primary research question in this study (“To what extent is overall QOL impaired 
in AWS?”) was addressed by calculating the scores on the HUI3, EQ-5D and EQ-VAS. 
In addition, QOL scores were calculated for and compared between stuttering severity 
groups. For this analysis, the following stuttering severity categories were created: SA 
scale: mild = score 8-10; moderate = score 5-7; severe = score 1-4; and for the speech 
satisfaction scale: mild = score 5 (reflecting high speech satisfaction), moderate = score 2-4 
(reflecting low to normal speech satisfaction), severe = score 1 (reflecting very low speech 
satisfaction). For the OASES, the original normative categories were applied. 
To answer the second research question (“What are the determinants of QOL in AWS?”) 
correlation analyses were conducted to explore the relationships between self-assessment 
of speech, speech satisfaction, OASES Total impact score, coping style, functioning and 
QOL. Speech satisfaction and coping style utilized Spearman rank correlations; all other 
comparisons utilized Pearson product-moment correlations. Multiple linear regression 
analyses were performed to explore the associations of the explanatory variables with 
QOL. Three regression analyses were run, with respectively the HUI3, EQ-5D and EQ-VAS 
as dependent variables. In the first step, the SA score (representing symptom status) was 
entered. To determine the effect of self-assessment of stuttering on QOL with and without 
the influence of demographic variables, the second step included adding demographic 
variables (age, gender, education level, marital status), which were entered all at once. 
In step three, the coping scores for CISS-E, CISS-T and CISS-A were entered. Lastly, the 
grouping variable (T-NT) was entered. The adjusted R2 value reflects how well the model 
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fits the data. In addition to the correlation and regression analyses, comparison of the T 
and NT group scores provided insight into the determinants of QOL in AWS.
RESULTS
Characteristics of participants and response rate
A total of 91 AWS participated in this study: 38 AWS in the NT group and 53 AWS in the 
T group (Table 3.1). Significant group differences were found for age (t(89) = 2.390, p = 
.019) and gender (χ2(1)= 4.670, p = .031). The response rate for the NT group contacted 
informally was 92%. In addition, four people responded to the appeal on the Hyves-
stuttering website. Two of them were added to the NT group. The other two people were 
currently in treatment, and consequently added to the T group. Twenty-nine participants in 
the T group had just started conventional stuttering therapy (mean number of sessions 2.1; 
S.D. 1.9); six were on a waiting list. Ten people had just entered a family system therapy 
program for persons who stutter and eight were still on a waiting list for this program.
Symptom status
SA scores and speech satisfaction scores
The results for the SA scale and the speech satisfaction scale are displayed in Table 3.2. 
For the total group, the mean SA score of 6 corresponds to a rating of speech being 
sufficiently good. The mean satisfaction score was close to the category “neither satisfied 
nor dissatisfied.” There was a significant group difference (T versus NT) for both the SA 
scores, t(89) = 3.235, p = .002, effect size = .27, and the speech satisfaction scores, t(89) = 
4.136, p < .001, effect size = .43. 
OASES Impact scores
Table 3.2 also presents the OASES Impact scores. The mean Total Impact score of 48.4 in 
the total group represent moderate stuttering. The range of 25.6 to 74.4 indicates that the 
study population did not contain people with severe stuttering according to the OASES. 
The OASES Total Impact scores differed significantly between the T and NT group, t89) = 
-3.728, p < .001, effect size = .80. Significant differences were also found for the individual 
OASES sections, with higher Impact scores for the T group: Section I: t(89) = -2.380, p = 
.019, effect size = .51; Section II: t(89) = -3.044, p = .003, effect size = .64; Section III: t(88) 
= -3.580, p = .001, effect size = .76; Section IV: t(89) = -3.382 , p = .001, effect size = .73.
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TABLE 3.1 Demographics
Total group 
(N=91)
T group 
(N=53)
NT group 
(N=38) p-value
N (%) N (%) N (%)
Gender* .031
   Male 63 (69.2) 32 (60.4) 31 (81.6)
   Female 28 (30.8) 21 (39.6)  7 (18.4)
Age in years* 36 (14.68) 33 (12.43) 40 (16.59) .019
Educational level .900
   Low  8 (8.8)  5 (9.5) 3 (7.9)
   Middle 28 (30.8) 17 (32.1) 11 (28.9)
   High 55 (60.4) 31 (58.4) 24 (63.2)
Marital status .172
   Single / divorced 46 (50.6) 30 (56.6) 16 (42.1)
   Married 45 (49.4) 23 (43.4) 22 (57.9)
Job status .191
   Paid work 60 (65.9) 33 (62.3) 27 (71.1)
   Student 20 (22.0) 15 (28.3)  5 (13.2)
   Other 11 (12.1)  5 (9.4)  6 (15.7)
Stuttering ever diagnosed by a SLPa .872
   Yes 74 (81.3) 44 (83.0) 30 (78.9)
   No 14 (15.4)  8 (15.1)  6 (15.8)
   Unknown  3 (3.3) 1 (1.9) 2 (5.3)
Onset of stuttering .066
   Onset before 7 years 69 (75.8) 37 (69.8) 32 (84.2)
   Onset ≥ 7 years 22 (24.2) 16 (30.2)  6 (15.8)
Age of onset in years if onset ≥ 7 years 10.8 (5.34) 11.7 (6.10) 8.7 (1.40) .307
a SLP: Speech-language pathologist
* p < .05 (difference T-NT group, 2-tailed)
TABLE 3.2 Speech characteristics
Total group 
(N=91)
T group  
(N=53)
NT group  
(N=38) p-value
Mean (SD) Mean (SD) Mean (SD)
SA score** 6.0 (1.48) 5.6 (1.44) 6.6 (1.35) .002
Speech satisfaction score** 2.9 (0.97) 2.5 (0.89) 3.3 (0.90) .000
OASES Total Impact score** 48.4 (10.88) 51.8 (10.39) 43.7 (9.86) .000
Impact score Section I* 58.0 (9.68) 60.0 (9.23) 55.2 (9.71) .019
Impact score Section II** 51.9 (13.64) 55.4 (12.68) 47.0 (13.56) .003
Impact score Section III** 45.6 (12.32) 49.3 (11.91) 40.5 (11.10) .001
Impact score Section IV** 39.3 (13.35) 43.1 (12.98) 34.0 (12.10) .001
* p < .05 (difference T-NT group, 2-tailed) 
** p < .01 (difference T-NT group, 2-tailed)
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Functioning status and QOL
Descriptive dimensions of functioning 
Table 3.3 displays the health profiles for the EQ-5D and the HUI3 by means of frequencies 
of AWS reporting no problems on the dimensions. The distribution on the speech domain 
of the HUI3 differed significantly between groups (χ2(1)= 7.595, p = .006), with the T group 
reporting more problems. For the domains pain/discomfort and anxiety/depression of the 
EQ-5D and vision, emotion, cognition and pain and discomfort of the HUI3 no significant 
group differences were established. For the domains mobility, self-care and usual activities 
of the EQ-5D and hearing, ambulation and dexterity of the HUI3 the number of people in 
the “problems” cells was too small to allow statistical analyses.
TABLE 3.3 Functioning profiles and quality of life scores
HUI3 dimension
Total group (N=91) T group (N=53) NT group (N=38)
p-valueN (%) reporting no 
problems
N (%) reporting no 
problems
N (%) reporting no 
problems
Vision 48 (52.7) 30 (56.6) 18 (47.4) .384
Hearing 88 (96.7) 51 (96.2) 37 (97.4) a
Speech** 65 (71.4) 32 (60.4) 33 (86.6) .006
Ambulation 88 (96.7) 52 (98.1) 36 (94.7) a
Dexterity 88 (96.7) 51 (96.2) 37 (97.4) a
Emotion 38 (41.8) 21 (39.6) 17 (44.7) .626
Cognition 68 (74.7) 39 (73.6) 29 (76.3) .768
Pain and discomfort 53 (58.2) 28 (52.8) 25 (65.8) .216
EQ-5D dimension N (%) reporting no problems
N (%) reporting no 
problems
N (%) reporting no 
problems
Mobility 88 (96.7) 52 (98.1) 36 (94.7) a
Self-care 90 (98.9) 52 (98.1) 38 (100) a
Usual activities 86 (94.5) 48 (90.6) 38 (100) a
Pain/discomfort 75 (82.4) 42 (79.2) 33 (86.8) .348
Anxiety/depression 73 (80.2) 43 (81.1) 30 (78.9) .796
Overall QOL score Mean (SD) Mean (SD) Mean (SD)
HUI3 .85 (.16) .84 (.19) .88 (.12) .355
EQ-5D .93 (.12) .92 (.14) .94 (.10) .520
EQ-VAS** 83.2 (11.9) 80.4 (12.9) 86.9 (9.3) .007
a Chi-square tests could not be performed because the number of people in the “problems” cell was too small
** p < .01 (difference T-NT group, 2-tailed)
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QOL values
Table 3.3 also displays the overall QOL scores for the HUI3, EQ-5D and EQ-VAS. There 
were no significant differences between the T and NT group for the HUI3 and EQ-5D. 
However, both groups differed significantly on the EQ-VAS: t(89) = 2.772, p = .007, effect 
size = .81, with a lower score for the T group. Two people in the T group had a very low 
HUI3 score (.09 and .17), indicating a very low QOL. Removing these outliers did not result 
in a change in the mean scores for HUI3, EQ-5D and EQ-VAS.
QOL scores differentiated by stuttering severity levels
To explore differences in QOL scores due to stuttering severity, the QOL scores for the total 
group, differentiated by stuttering severity level, are displayed in Table 3.4. Compared with 
perfect health (valued at 1), the HUI3 and EQ-VAS scores show a reduction in QOL for adults 
with mild stuttering (reflected as a high score on the SA scale, a high satisfaction score 
and a mild OASES Impact score). Furthermore, Table 3.4 shows that QOL reduces with 
increasing stuttering severity level, irrespective of how stuttering severity was quantified. 
The HUI3 shows a larger reduction of QOL than the EQ-5D and EQ-VAS.
TABLE 3.4 Quality of life scores by stuttering severity level
HUI3 score 
Mean (SD)
EQ-5D score
Mean (SD)
EQ-VAS score
Mean (SD)
SA score
Mild (score 8, 9)a n = 11 .91 (.13) .96 (.09) 85.9 (10.17)
Moderate (score 5, 6, 7) n = 65 .88 (.13) .93 (.13) 83.1 (11.54)
Severe (score 2, 3, 4) a n = 15 .73 (.24) .88 (.14) 81.4 (14.94)
Speech satisfaction score
Mild (score 5) n = 4 .95 (.07) 1.00 (.00) 96.3 (4.11)
Moderate (score 2, 3, 4) n = 72 .86 (.16) .93 (.12) 82.6 (11.76)
Severe (score 1) n = 5 .73 (.24) .88 (.17) 82.0 (14.47)
OASES Total impact rating
Mild n = 5 .96 (.07) 1.0 (.00) 92.0 (7.29)
Mild-to-moderate n = 30 .92 (.08) .96 (.09) 84.3 (12.60)
Moderate n = 45 .83 (.15) .91 (.14) 82.3 (10.31)
Moderate-to-severe n = 11 .74 (.28) .88 (.15) 79.6 (16.51)
a No respondents rated their speech with a score of 1 or 10
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Characteristics of the individual: coping scores
The internal consistency of the CISS in this study was satisfactory (Cronbach’s alpha ranging 
from .78 to .90). The mean transformed coping scores for the total group for CISS-T were 
3.3 (SD = 1.67), for CISS-E 3.9 (SD = 1.65), and for CISS-A 2.4 (SD = 1.37). The mean scores 
for CISS-E coping are close to average, while the other coping style scores appear to be 
below average. There were no significant differences between the T and NT group. 
Association between symptom status, coping, functioning and QOL
Exploration of the relationships between SA score, speech satisfaction score, OASES Total 
Impact score, coping and QOL (Table 3.5) revealed that all stuttering symptom measures 
correlated significantly with each other. In addition, all QOL measures correlated significantly 
with one or more stuttering symptom measures, with a lower QOL score reflecting more 
severe stuttering. Overall, the strongest correlations were established for the HUI3, which 
correlated significantly with all three subjective stuttering measures. The mean EQ-5D QOL 
score was related to the mean SA score and OASES Total Impact score, but not to the 
mean speech satisfaction score. The EQ-VAS score only correlated significantly with the 
OASES Total Impact score. CISS-E was negatively associated with speech satisfaction and 
the OASES Total Impact score, and was the single coping style significantly related to all 
QOL measures. CISS-A was positively associated with speech satisfaction, while CISS-T did 
not correlate significantly with any of the subjective stuttering measures. 
TABLE 3.5 Correlations between SA score, speech satisfaction score, OASES Total impact score, 
coping and overall quality of life 
SA score
Speech 
satisfaction 
score
OASES 
Total 
Impact 
score
CISS-T CISS-E CISS-V HUI3 score
EQ-5D 
score
SA score
Speech satisfaction score 0.724**
OASES Total Impact score -0.701** -0.638**
CISS-T -0.053 0.034 -0.074
CISS-E -0.197 -0.251* 0.483** -0.041
CISS-V 0.193 0.253* -0.083 0.240* 0.090
HUI3 score 0.365** 0.357** -0.483** 0.159 -0.395** 0.012
EQ-5D score 0.206* 0.194 -0.336** 0.030 -0.367** -0.210 0.713**
EQ-VAS score 0.058 0.137 -0.218* 0.063 -0.382** -0.029 0.548** 0.451**
* p < .05
** p < .01 (2-tailed)
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Correlations between symptoms and relevant subscales of the HUI3 and EQ-5D 
(representing functioning) are shown in Table 3.6. The speech and emotion domains of 
the HUI3 correlated significantly with all three stuttering measures. The cognition and pain 
domains of the HUI3 and the domains daily activities and anxiety/depression of the EQ-5D 
all significantly correlated with one stuttering symptom measure.
TABLE 3.6 Correlations between SA score, speech satisfaction score, OASES Total impact score and 
domains of functioning
HUI3 
speech
HUI3 
emotion
HUI3 
cognition
HUI3 
pain and 
discomfort
EQ-5D 
daily 
activities
EQ-5D 
anxiety/
depression
SA score .327** .274** -.207 *
Speech satisfaction score .294** .324**
OASES Total impact score -.307** -.384** -.324** -.254* .346**
Note. Only significant correlations are displayed
* p< .05
** p < .01 (2-tailed)
Regression analysis
The regression model which was used to simultaneously evaluate the effect of each 
determinant on QOL (Table 3.7) explained 36% of the variation in HUI3 scores (adjusted 
R2 full model). Significant independent explanatory variables were SA score (p = .006), age 
(p = .003), gender (p = .001), marital status (p = .045), CISS-T score (p = .023) and CISS-E 
score (p = .000). Group identification (group ID) did not contribute to the variation in HUI3 
score. The same regression analyses with the EQ-5D score as dependent variable showed 
only a significant effect of CISS-E (p = .000, total adj. R2 = .186). Regression analyses run 
with the EQ-VAS as dependent variable showed, in addition to CISS-E, also a significant 
effect of age (p =.001), gender (p = .000), marital status (p = .005) and group ID (p = .000). 
The total adjusted R2 was .312.
DISCUSSION
The objectives of the present study were (1) to investigate to what extent QOL is impaired in 
AWS and (2) to identify determinants of QOL in AWS. The latter was pursued by exploring 
relationships between stuttering severity, coping, functioning and QOL and by testing 
for differences in variable scores in two subgroups: the NT group and the T group. The 
results of this study show that stuttering severity affects overall QOL considerably. HUI3 
derived QOL values were .91 for mild stuttering and .73 for severe stuttering. AWS who 
had just begun or were about to begin therapy rated their stuttering as more severe and 
recorded more problems on the HUI3 speech domain than AWS who were not in therapy. 
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However, the results with respect to the differences in overall QOL between the T and 
NT group varied. While differences in overall QOL were not significant according to the 
HUI3 and the EQ-5D, according to the EQ-VAS they were. The effect size was .81, which 
can be considered as large [117]. The correlation analysis between stuttering severity and 
domains of functioning in the total group showed that a higher stuttering severity was 
mainly associated with limitations in the domains of speech and emotion. Lastly, regression 
analysis showed that the relationship between stuttering severity and overall QOL was 
influenced by task-oriented and emotion-oriented coping style. 
With regard to the extent to which QOL in AWS is affected, our study could not confirm that 
the impact of severe stuttering on overall QOL was as great as suggested by Bramlett et al. 
[137]. QOL values for severe stuttering in our study ranged from .73 to .88, while Bramlett 
et al. found QOL values between .44 and .81 for severe stuttering [137]. There could be 
two reasons for this difference. Firstly, this might be related to the somewhat wider range 
of stuttering severity in the study by Bramlett et al. [137]. Although a substantial number 
of participants in the current study had low scores on the SA-scale, which represents 
severe stuttering, none of the participants was classified as severe stuttering by the 
OASES. Secondly, the difference in QOL values may be due to differences in the way 
QOL values were obtained. Bramlett et al. derived their QOL values by direct valuation 
of vignettes describing stuttering: AWNS rated hypothetical states of stuttering and their 
own health state [137]. In the current study, QOL was indirectly assessed by using the HUI3 
and EQ-5D. In this way QOL values (from the general public) were derived by applying a 
mathematical algorithm to the health states that were described by the AWS. These health 
states were generic, that is, they had no specific reference to stuttering. Therefore, the 
indirect instruments applied in the current study might not have been responsive enough 
to stuttering, resulting in an upward bias. In other words, the impact of stuttering on QOL 
might actually be greater than found in our study. Alternatively, it could be hypothesized 
that the absence of anchor points referring to other conditions worse than severe stuttering 
led to a downward bias in the direct assessment approach by Bramlett et al. [137]. This is 
known as contextual bias [153]. The two studies have no single measure in common to 
explore whether the negative impact on QOL has been underestimated in our study or 
overestimated in the Bramlett et al. study [137], or both. 
In the current study, as in the study of Bramlett et al. [137], substantial differences in 
QOL values were established using different instruments. Comparing the three QOL 
measurements for the most severe stuttering state, the impairment on the HUI3 was 
greater than on the EQ-5D and EQ-VAS. This difference may be explained by inclusion of 
the speech domain in the HUI3, which improves its responsiveness to stuttering. This might 
also clarify why the HUI3 measurement showed QOL impairment for the mildest forms of 
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stuttering, but EQ-5D measurement showed relatively little or none. Ceiling effects for the 
EQ-5D, as reported in other relatively healthy populations [154,155], may have contributed 
to a limited responsiveness of this instrument in AWS. Accordingly, the EQ-5D might have 
overestimated QOL, although the alternative hypothesis, that the HUI3 has underestimated 
QOL, cannot easily be abandoned. By inclusion of speech as a domain, the emphasis on 
the speech problems may be larger than their impact on QOL warrants. 
In theory, EQ-VAS outcomes could help to identify whether QOL was underestimated by 
the HUI3 or overestimated by the EQ-5D, since the EQ-VAS measures QOL directly and 
not via its impact on basic domains of functioning. Therefore, the VAS scale is not prone to 
possible misrepresentation of QOL, which could occur if the HUI3 and the EQ-5D do not 
include all the relevant domains. In addition, the EQ-VAS values QOL from the perspective 
of the respondent himself instead of the general population. However, neither hypothesis 
could be supported, since the results indicate that the EQ-VAS was less responsive than 
both the EQ-5D and HUI3 for changes at the symptom level. An end of scale bias might 
have limited the responsiveness of the EQ-VAS. Subjects tend to avoid using scale ends 
[88,156], which implies that the QOL effect of mild health problems is difficult to measure 
on a VAS scale. Support for this hypothesis is found in the result that EQ-VAS scores were 
limited to a smaller range of the scale than HUI3 and EQ-5D scores. Thus, unfortunately, 
the EQ-VAS does not provide the key to whether the EQ-5D overestimated QOL, or the 
HUI3 underestimated it.
Our findings that stuttering affects functioning in a negative way are in line with the results 
of other studies (e.g., [41,85,132]). The domains that significantly correlate to stuttering 
severity in our study correspond to a great extent with the domains affected in the Craig 
et al. study [41], that is mainly social and psychological dimensions. An interesting finding 
of the current study is the positive correlation between stuttering severity as measured by 
the OASES and the pain domain of the HUI3. This result may reflect the broad definition 
of the HUI3 pain domain, which covers pain and discomfort. Alternatively, AWS reporting 
physical pain, especially in the breast region, when asked what they feel in their body when 
they speak, stutter or try to avoid stuttering, is a quite common response in the clinical 
experience of the third author. Besides, it may be hypothesized that stuttering affects 
physical well-being because of higher stress levels associated with the experience of social 
anxiety [130]. There is evidence for a common neural basis for regulating social pain and 
physical pain [157]. As a result, the physical pain threshold can be triggered by social pain. 
The regression analyses into the relationships between stuttering severity, coping and 
overall QOL identified coping as a mediating factor in QOL in AWS, in addition to stuttering 
severity and demographic variables. The results of the HUI3 regression analysis suggested 
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that both stuttering severity and coping style can be directly related to QOL in equal 
measure. Two types of coping were associated with QOL. Higher scores on the CISS-E 
(emotion-oriented coping) were correlated with lower QOL. While it is known that dealing 
with emotions in a constructive way positively influences the adjustment to a chronic 
disease [147], higher CISS-E scores reflect a more negative way of dealing with emotions 
(e.g., denial, mental or behavioral distance, brooding), presumably resulting in a greater 
psychological impact and a lower QOL [149]. The regression analysis also revealed that 
higher task-oriented coping scores were associated with better QOL, reflecting that task-
orientation is an active and adaptive way of coping which influences QOL in a positive way 
[158]. QOL might be maximized by individuals who apply the various strategies flexibly 
depending on the circumstances that they have to deal with [152]. 
The differences in the results between the therapy group and non-therapy group in this 
study provide further insight into the underlying mechanisms of QOL in AWS. The groups 
differed significantly in stuttering severity, in score on the speech domain of the HUI3 and in 
overall QOL as assessed by the EQ-VAS. There were no group differences in coping scores. 
The regression analysis with the EQ-VAS as dependent variable was the only analysis that 
revealed group ID as a significant predictor of overall QOL. These results suggest that AWS 
who seek treatment do this because they desire symptom relief, and not because they are 
poor at coping. 
Elements in our study design that might evoke questions about the external validity are 
related to the choice of including a T and NT group of AWS and to the use of self-assessed 
measures to establish stuttering severity. The NT group was included because we wanted 
to cover the maximum range of QOL values in the group of AWS and hypothesized that 
QOL might be higher in AWS not seeking treatment and/or that relationships between 
stuttering, coping and QOL might differ between groups. The representativeness of the 
NT group cannot be established, due to the lack of detailed information about the Dutch 
AWS population not receiving treatment. Furthermore, the results show that there are 
between group differences, namely a lower stuttering severity and a better subjective 
QOL, as measured with the EQ-VAS, for the NT group. The difference in stuttering severity 
was also reflected in a better HUI3 speech QOL value for the NT group. These results 
imply that outcomes obtained in clinical populations cannot simply be generalized to 
the population of AWS as a whole and vice versa. With regard to the applied speech 
measures, we are confident that self-identification of stuttering in the NT group and self-
assessed stuttering severity has not negatively affected the external validity, because 81% 
of the AWS in the study reported having been previously diagnosed as stuttering by a 
professional. Furthermore, Huinck and Rietveld [142] showed that correlations between 
a self-assessment scale of speech satisfaction and measures which reflect overt stuttering 
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behavior are relatively strong, indicating a high validity of a simple and cost-effective 
speech rating scale. This suggests that our study results would provide a valid estimation 
of QOL in all AWS. 
Our study presents evidence that stuttering in adults is a serious problem affecting health. 
A broadly based outcome measure such as QOL could provide a means of evaluating the 
impact of stuttering on daily life. QOL measures could therefore be applied in therapy 
evaluation studies, or in evaluating the relationship between the cost and benefit of 
stuttering interventions. Furthermore, the relevance of coping for QOL in AWS, which 
was demonstrated in this study, shows that a good understanding of the determinants 
of QOL is essential to develop rational and cost-effective treatments: “The development 
of treatment strategies requires not only that we identify the key factors that combine to 
determine function and quality of life, but also that we understand their relative importance 
and the degree to which they can be altered or modified” ([79] p. 63). Our study is a first 
step in exploring the determinants of QOL in relation to stuttering. The effect of coping 
on the relationship between stuttering severity and QOL which was established in this 
study suggests that addressing coping style could be a useful component in the process 
of diagnosing and selecting treatment approaches for AWS. Using a coping instrument 
during the assessment phase indicates how an individual copes with stressful situations 
in daily life. If an AWS is using an inadequate coping pattern, therapeutic goals could be 
identified which would enable the AWS to change his personal coping style to deal more 
effectively with stressors that provoke stuttering or the stuttering behavior itself, thereby 
reducing its negative impact on QOL. For instance, if a client displays relatively high scores 
on the emotion-oriented coping scale and low task-oriented coping scores, treatment 
goals might be focused on learning task-oriented coping strategies and becoming less 
dependent on emotional ways of dealing with stress. This idea is supported by Hayhow 
et al. [84] who showed that AWS have the desire to get help in managing their stuttering 
and in developing coping strategies. We would therefore recommend that more studies 
be done on coping in relation to stuttering, such as the ones recently reported by Plexico 
and colleagues [83,143-145].
In conclusion, by using generic QOL measures, it was shown that the health condition 
of moderate to severe stuttering substantially reduces the QOL in AWS as compared to 
the perfect health state. This result, and the significant relationship between stuttering 
severity, coping style and QOL, highlights the need for further research in order to clarify 
the conceptualization of QOL in relation to stuttering, as a foundation for the further 
development of effective therapies for the disorder of stuttering. 
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APPENDIX 
1. If you had to score your own speech (range 1-10), how would you score it?  
Circle a score 
 
 
          1 2 3 4 5 6 7 8 9 10 
 
 
1= very bad 
10= very good 
 
 
2. How satisfied are you with your speech? 
Mark the corresponding box with a cross. 
 
 
 
 
            Not satisfied       Not satisfied     Satisfied nor      Satisfied          Very satisfied 
            at all        dissatisfied 
 
 
 
 
 
 
 
FIGURE A3.1 Self-assessment scale of speech
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ABSTRACT
The Overall Assessment of the Speaker’s Experience of Stuttering for adults (OASES-A) 
[86,159] is a patient-reported outcome measure that was designed to provide a 
comprehensive assessment of “the experience of the stuttering disorder from the perspective 
of individuals who stutter” [86]. This paper reports on the translation process and evaluates 
the psychometric performance of a Dutch version of the OASES-A. Translation of the 
OASES-A into Dutch followed a standard forward and backward translation process. The 
Dutch OASES-A (OASES-A-D) was then administered to 138 adults who stutter. A subset of 
91 respondents also evaluated their speech on a 10-point Likert scale. For another subset 
of 45 respondents, a clinician-based stuttering severity rating on a 5-point Likert scale was 
available. Thirty-two of the respondents also completed the Dutch S-24 scale [160]. The 
OASES-A-D showed acceptable item properties. No ceiling effects were observed. For 
30 out of 100 items, most of which were in Section IV (Quality of Life), floor effects were 
observed. Cronbach’s α coefficients for all sections and subsections surpassed the 0.70 
criterion of good internal consistency and reliability. Concurrent validity was moderate to 
high. Construct validity was confirmed by distinct scores on the OASES-A-D for groups with 
different levels of stuttering severity as rated by the speakers themselves or by clinicians. 
These results suggest that the OASES-A-D is a reliable and valid measure that can be used 
to assess the impact of stuttering on Dutch adults who stutter. 
Psychometric evaluation of the OASES-A-D | 69
4
INTRODUCTION
Research in recent decades has shown that stuttering is often associated with negative 
impact on various aspects of a speaker’s life (e.g., [41,42,85,91]). This has led to greater 
awareness among many researchers and clinicians of the need to adopt broad-based 
measures that reflect the broader stuttering disorder (i.e., the difficulties a person may 
experience as a result of producing stuttering behaviors, including negative impact on 
quality of life and subjective well-being), in decision-making, clinical practice, and research 
(e.g., [9,75,78,86,161]. One measure that was designed for comprehensively assessing the 
stuttering disorder is the Overall Assessment of the Speaker’s Experience of Stuttering 
(OASES) [86,159]. This questionnaire evaluates “the experience of the stuttering disorder 
from the perspective of individuals who stutter” ([86], p. 90). The design of the OASES 
was based on the World Health Organization’s International Classification of Functioning, 
Disability, and Health (ICF) [80]. There are three versions of the OASES: The OASES-A was 
designed for adults, ages 18 and above; the OASES-T [162] was designed for teenagers, 
ages 13-17; and the OASES-S [163] was designed for school-age children, ages 7-12.
Empirical data have provided preliminary support for the reliability and validity of the 
OASES-A, based on samples collected in the United States [86]. However, analyses 
conducted to date have not thoroughly examined several aspects of the psychometric 
properties of the instrument, one of which is convergent validity [75]. Further, data from 
individuals residing in locations other than the United States have only recently become 
available (e.g., [93,164-167]. The adult version of the OASES has been translated into 
Spanish [159] and, at the time of this writing, there are ongoing efforts to translate the 
various versions of the OASES into approximately 15 other languages worldwide [168]. 
Key aspects of the translation process involve validation of the translation and evaluation 
of the psychometric data that result from administration of the translated version to native 
speakers of the target languages.
Among researchers and clinicians in the Netherlands, a desire exists to have a well- 
functioning Dutch patient-reported outcome measure in order to be able to assess those 
aspects of the stuttering disorder that are directly relevant to the lives of people who 
stutter. To fulfill this need, we translated the English OASES-A into Dutch. In the present 
study, we describe the translation process and evaluate the psychometric performance 
of the Dutch version of the OASES-A. We aim to contribute to the evidence base of the 
performance of the OASES-A in general, and the Dutch translation in particular. 
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METHODS
The OASES-A questionnaire was first published in 2006 [86] based on preliminary research 
that had been conducted over the prior 10 years (e.g., [169]). Below, we describe the 
characteristics of the original instrument, the translation process of the Dutch version and 
the psychometric evaluation.
OASES-A
The OASES-A is a 100-item, self-report questionnaire that aims to measure the experience 
of the stuttering disorder from the perspective of adults who stutter. It consists of four 
sections, each of which examines different aspects of the stuttering disorder: (I) general 
perspectives about stuttering (20 items); (II) affective, behavioral and cognitive reactions 
to stuttering (30 items); (III) functional communication difficulties (25 items) and (IV) impact 
of stuttering on the speaker’s quality of life (25 items). Responses are rated on a Likert 
scale with response choices ranging from 1 to 5. Higher scores indicate a greater impact 
of the disorder. Impact rating scores can be calculated for each individual section and for 
all sections in total. These scores provide an indication of the degree of negative impact 
experienced by a speaker as a result of stuttering. As a self-report measure, the OASES-A 
is designed to supplement clinician-based measures of observable stuttering severity. 
Although it is emphasized that the impact ratings are not exchangeable with stuttering 
severity ratings, they may provide an indication of the overall severity of the speaker’s 
experience of stuttering [86].
In this paper, the Impact scores for the Dutch version of the OASES-A were calculated in 
accordance with the first version of the OASES-A [86], except where indicated otherwise. 
Scoring for the 2006 version of the OASES-A involved three steps. First, the number of points 
the respondent indicated was calculated for each section. Second, the total number of items 
completed by the respondent was computed and multiplied by 5 (since each item is based 
on a 5-point scale) to obtain the total number of possible points in each section. Third, 
the number of points was divided by the number of possible points and multiplied by 100. 
Impact scores were categorized as follows: 20.0-29.9 refer to mild impact, 30.0-44.9 to mild-
to-moderate impact, 45.0-59.9 to moderate impact, 60.0-74.9 to moderate-to-severe and 
impact, 75.0-100 to severe impact. The scoring system in the current versions of the OASES-A 
(beginning with the 2008 version and continuing with the 2010 publications) is different, 
in that the section and overall impact scores are based on the same 1 to 5 range as the 
individual item scores. Note that it is possible to convert between the two scoring systems by 
simply dividing the scores from the 2006 version by 20 to yield scores on the 1 to 5 scale used 
in the 2008 and 2010 versions. Detailed background information and explanations about the 
development of the OASES-A can be found in publications by Yaruss and Quesal [86,159].
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Translation of the OASES-A
The original published English version of the OASES-A [86] was translated into Dutch 
following a standard forward and backward translation process [170] to ensure conceptual 
equivalence and clear and easy understanding of the Dutch version of the OASES-A. Initially, 
items and response choices in the American version of the OASES-A were translated into 
Dutch independently by two native Dutch speakers who were fluent in English. Then, a first 
consensus version was produced from the two forward translations. This Dutch consensus 
version was back-translated into English independently by two qualified translators who are 
native English-speakers and fluent in Dutch. The research team, which had requested the 
translation, then compared the back translations with the original version. Problematic items 
or response choices were discussed in a meeting by the translators and the research team. 
A linguistically and conceptually comparable translation generally requires that careful 
attention be paid to cultural differences that might lead to different meanings in the target 
and original language [170,171]. Three items were identified as potentially reflecting 
conceptual differences between the OASES-A and the Dutch translation. These items 
were carefully discussed in the meeting and consensus was reached regarding the most 
appropriate translation. The second consensus version of the Dutch OASES-A (hereafter 
referred to as the OASES-A-D) was pilot tested in a sample of six individuals who stutter. In 
keeping with recommendations for creating a valid translation [170], pilot testing was also 
completed with three individuals who did not stutter to ensure that the comprehensibility of 
the translation was not limited only to people who already possessed some understanding 
of the stuttering disorder. Participants were asked to complete the questionnaire and 
comment on the questions if necessary. As a result of the pilot testing, a missing word was 
added to question II.B.6. No other problems were detected in terms of item acceptance, 
comprehensibility, or wording or in the consistency of response patterns. This version was 
used in all subsequent testing.
Data collection procedures
For the psychometric evaluation of the OASES-A-D, we made use of two existing datasets in 
which the OASES-A-D had been administered to adults who stutter. All data were collected 
between February 2008 and April 2009. The first dataset (N=91) originated from a study 
into the quality of life in adults who stutter (hereafter referred to as the “QOL study”). The 
QOL study included both people who were not receiving therapy and people who had 
just registered for therapy at the time of the investigation. Demographic characteristics 
(gender, age, educational level, marital status and job status), OASES-A-D data, and a self-
assessment score of speech (SA scale score; [172]) were available from that study. The SA 
scale was applied to evaluate the participant’s perception of his or her stuttering severity. 
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Participants were asked to rate their speech on a scale ranging from 1 (very poor) to 10 
(very good). Only the endpoints of the scale were defined. Further details of the QOL study 
can be found in Koedoot et al. [91].
The second dataset (N=51) originated from stuttering therapists working in clinics throughout 
the Netherlands. The therapists asked adults who stutter who had registered for or who 
were involved in therapy to complete the OASES-A-D and the Dutch S-24 Modification of 
the Andrews and Cutler [72] adaptation of Erickson’s scale of communication attitudes (S-
24) [160]. The S-24 is a self-completed questionnaire which measures the communication 
attitudes of persons who stutter. Besides the two self-reported questionnaires, the therapists 
also rated the stuttering severity of their clients on a 5-point Likert scale with the following 
categories: 1 = mild, 2 = mild-moderate, 3 = moderate, 4 = moderate-severe, and 5 = 
severe stuttering. When rating severity, the therapists were asked to take into account the 
speaker’s total experience of the disorder, including cognitive, emotional, motor and social 
aspects. In the rest of the paper this scale is referred to as the Clinical Assessment (CA) 
scale. Since all therapists had many years of experience in diagnosing and treating people 
who stutter and because they are accustomed to classifying stuttering severity of clients in 
terms of mild, moderate and severe stuttering, the CA scale was considered an appropriate 
measure of stuttering severity. The S-24 data were available for 32 participants and the CA 
scale data for 45 participants.
In total, 142 people who stutter completed the OASES-A-D (91 participants in the QOL 
study and 51 participants recruited by therapists). The data from four participants were 
excluded in the present study because they were less than 18 years of age. Thus, this study 
was based on the responses of 138 participants. Demographic characteristics of these 
participants are presented in Table 4.1. More men than women participated in our study. 
The male: female ratio of 2.7:1 is generally comparable with ratios presented in literature 
(e.g., [7]). Compared to data of Statistics Netherlands (CBS, http://www.cbs.nl/en-GB/
menu/home/default.htm) a relatively high proportion (that is, 50%) of the participants had 
received higher education. There were no respondents with a minority ethnic background 
(e.g., Moroccan, Turkish or Surinamese). 
Item characteristics
The OASES-A-D item performance characteristics that were studied included item 
distributions and percentage floor and ceiling effects (i.e., the percentage of respondents 
scoring at respectively the lowest and highest scale level).
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TABLE 4.1 Demographics
N Dutch population normsa
Gender
   Male 101 (73.2%) 49.5%
   Female 37 (26.8%) 50.5%
Age (years)
Mean (SD) 34.5 (12.8) 40.1
Range 18-74 -
Educational levelb
   Low 6 (6.8%) 33%
   Middle 36 (40.9%) 31%
   High 44 (50%) 27%
   Missing 2 (2.3%) 9%
Marital statusb
   Single / divorced 43 (48.9%) -
   Married 45 (51.1%) -
Job status*
   Paid work 60 (68.2%) -
   Student 17 (19.3%) -
   Other 11 (12.5%) -
a Statistics Netherlands, 2009 figures
b Only available for participants in the QOL study 
Reliability
Internal consistency refers to the extent to which items within each domain are interrelated, 
thus reflecting the degree to which they measure the same concept. Cronbach’s α coefficient 
is the most widely applied method to assess internal consistency (e.g., [173]). A coefficient 
of above 0.70 suggests a good internal consistency and reliability [174], however, if α is too 
high, this may suggest a high level of item redundancy [175]. In addition to the Cronbach’s 
α scores of Sections I to IV, we assessed each subsection of Section II to IV individually, 
since pooling the scores within a section could inflate Cronbach’s α due to the large 
number of items. The division of Section I (General information) in three subsections was 
done merely for convenience in scoring the record form; the items are not conceptually 
related. Therefore, Cronbach’s α values were not calculated for these subsections. 
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Validity
In keeping with the original validation process of the English version of the OASES-A, 
concurrent validity was evaluated by calculating Spearman correlation coefficients for each 
section of the OASES-A-D and for the Total Impact score with the Dutch version of the 
S-24. Based on the results of the publication by Yaruss and Quesal [86], the S-24 scores 
were expected to have high correlations with the OASES-A-D Impact scores from Section 
II, and moderate correlations with the other sections. In addition, the correlation between 
the OASES-A-D, the SA, and the CA scores were used for assessing concurrent validity. A 
strong correlation was considered to be over .60, a moderate correlation between .30 and 
.60, and a low correlation below .30 [176].
The method of known-groups comparisons was used to evaluate the construct validity of 
the OASES-A-D. Known-groups validity is defined as the ability to distinguish between 
clinically relevant subgroups of respondents. We tested if OASES-A-D Total Impact scores 
could discriminate between participants with different stuttering severity levels. Severity 
levels were determined by both self-assessed severity (SA scale score) and clinician-
assessed severity (CA scale score). Because of the relatively small sample sizes for some 
categories of stuttering severity, the following categories of the SA scale were merged to 
reach a sufficient number of respondents in each category: mild = score 7 - 10; moderate = 
score 4 - 6; severe = score 1 - 3. For the CA scale, the categories were combined as follows: 
mild = score 1 - 2; moderate = score 3, severe = score 4 - 5. 
We also tested whether the OASES-A-D Total Impact score was dependent on the 
demographic characteristics age and education. For the variable age, a correlation 
coefficient was calculated. For educational level, three groups were compared: low (primary 
education), middle (secondary education) and high (advanced degree). 
Statistical methods
Values are reported as mean +/- 1 SD or as absolute number and percentage. One-way 
analysis of variance (ANOVA) and Tukey post-hoc tests were employed to evaluate the 
statistical significance of differences in OASES-A-D Impact scores for groups with different 
levels of stuttering severity and different educational levels. All correlations were based on 
non-linear Spearman rank correlations, and a Bonferroni correction was applied to maintain 
an overall α of .05. Analyses were performed in SPSS version 17.0 (SPSS Inc.). 
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RESULTS
Stuttering characteristics
Table 4.2 presents the mean scores on the OASES-A-D and the other stuttering measurement 
instruments (i.e., the SA scale and CA scale) applied in this study. To facilitate comparison 
of results from the OASES-A-D with the current version of the OASES-A, as well as results 
obtained from translations of the OASES-A in other languages, Table 4.2 also reports the 
mean scores in accordance with the 5-point scale scoring system introduced in Yaruss and 
Quesal [159] and used in all three of the current OASES record forms. All other tables and 
results in this paper use the scoring system from the original 2006 publication, as described 
above in Section 2.1.
Item characteristics
All but 15 of the 100 items of the OASES-A-D exhibited ranges from the minimum possible 
score of 1 to the maximum possible score of 5. The mean score across items ranged from 
1.32 to 3.74 (SD ranging from 0.65 to 1.46). No ceiling effects (defined as > 30 % of patients 
having the maximum score of 5) were observed. Floor effects were observed for 30 out of 
100 items, most notably in Section IV (Quality of Life) with 14 items. Section IV.D (which 
measures the impact of stuttering on job and education) showed floor effects for four out 
of five items, indicating that respondents experienced relatively little negative impact from 
stuttering in these settings. Section IV.E (which measures the impact of stuttering on overall 
well-being) showed floor effects for six out of eight items.
TABLE 4.2 Stuttering characteristics
Stuttering instrument
Mean, SD based on original 
scoring procedures described in 
Yaruss & Quesal [86]
Mean, SD based on revised 
scoring procedures described in 
Yaruss and Quesal [159]
OASES-A-D Impact scores
Section I 56.8 (10.37) 2.84 (0.52)
Section II 52.2 (12.66) 2.61 (0.63)
Section III 46.5 (11.86) 2.32 (0.59)
Section IV 40.1 (13.21) 2.00 (0.66)
Total 48.7 (10.45) 2.44 (0.52)
SA scorea 6.11 (1.41)
CA scoreb 3.09 (1.12)
a Only available for participants in the QOL study
b Only available for participants recruited by therapists
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Reliability
Cronbach’s α scores for Sections I through IV, as well as for the subsections of Section II to 
IV, of the OASES-A-D are presented in Table 4.3. Cronbach’s α scores for the four sections 
were between 0.84 and 0.96. The subsections showed Cronbach’s α values between 0.78 
(Section III.C) and 0.92 (Section IV.E). 
TABLE 4.3 Cronbach α of the OASES-A-D sections
OASES-A section Number of items Cronbach’s α
I 20 0.84
II 30 0.93
II.A 10 0.9
II.B 10 0.82
II.C 10 0.81
III 25 0.94
III.A 10 0.84
III.B 5 0.86
III.C 5 0.78
III.D 5 0.8
IV 25 0.96
IV.A 3 0.8
IV.B 4 0.84
IV.C 5 0.89
IV.D 5 0.9
IV.E 8 0.92
Validity
The Total OASES-A-D Impact score, as well as the Impact scores on the four sections, 
correlated significantly with the S-24, SA and CA scale scores (Table 4.4). For the S-24 and 
the CA scale, the lowest correlations were established for Section I and the highest for 
Section IV. For the SA scale, the pattern was reversed, with a slightly lower correlation for 
Section IV. 
Table 4.5 shows that all sections of the OASES-A-D questionnaire were able to discriminate 
between groups of participants with different stuttering severity levels (according to the 
SA score or the CA score), with the exception of discriminating between participants with 
moderate and severe stuttering as assessed by the SA scale. 
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TABLE 4.4 Correlations (Spearman rho) between OASES-A-D Impact scores and S-24, SA scale and 
CA scale scores
OASES-A section S-24(N=32)
SA scale
(N=91)
CA scale 
(N=45)
Impact score Section I .587** -.609** .357*
Impact score Section II .641** -.507** .561**
Impact score Section III .761** -.543** .494**
Impact score Section IV .854** -.516** .572**
Total Impact score .838** -.615** .594**
* p < .05 level (2-tailed)
** p < .01 (2-tailed)
TABLE 4.5 Mean OASES-A-D Total Impact scores for participants with mild, moderate and severe 
stuttering according to the SA scale and CA scale, standard deviation (SD) and p-value of ANOVA-
analysis for differences of means
Stuttering severity level (SA scale) Significance (p)
Mild  
(N=38)
Moderate 
(N=46)
Severe 
(N=4) F-ratio
Mild vs. moderate 
stuttering
Mild vs. severe 
stuttering
Moderate vs. 
severe stuttering
41.7 (9.2) 51.6 (8.5) 58.4 (9.5) 16.336 <.001 .002 .314
Stuttering severity level (CA scale)  Significance (p)
Mild 
(N=13)
Moderate 
(N=17)
Severe 
(N=14) F-ratio
Mild vs. moderate 
stuttering
Mild vs. severe 
stuttering
Moderate vs. 
severe stuttering
43.1 (6.4) 51.4 (10.0) 59.2 (7.9) 12.381 .027 <.001 .037
TABLE 4.6 Correlations (Spearman rho) between OASES-A-D Impact scores and age (p > .10)
OASES-A section Age (N=138)
Impact score Section I -.039
Impact score Section II -.055
Impact score Section III -.173
Impact score Section IV -.112
Total Impact score -.111
The OASES-A-D Total Impact score, as well as the Impact scores on the sections I, II and 
IV, did not correlate significantly with age (see Table 4.6, p > .10). There was a very small 
relationship between the Impact score on Section III and age (r = -.173, p = .04), but after 
Bonferroni adjustment for the significance level (1/5 * .05 = .01) this was not significant. 
No significant differences in impact score were detected based on level of education (see 
Table 4.7, p > .10).
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TABLE 4.7 Mean OASES-A-D Impact scores for participants with low, middle and high education, 
standard deviation (SD) and p-value of ANOVA-analysis for differences of means
OASES-A section
Educational level Significance (p)
Low (N=6) Middle (N=36)
High 
(N=44) F-ratio
Low vs. 
middle 
education
Low vs. 
high 
education
Middle 
vs. high 
education
Impact score 
Section I 55.9 (8.6) 57.5 (10.9) 58.5 (8.9) .222 .925 .821 .906
Impact score 
Section II 55.3 (6.9) 52.4 (14.3) 49.9 (12.7) .649 .868 .613 .682
Impact score 
Section III 49.1 (6.5) 45.7 (12.4) 43.8 (11.8) .649 .795 .562 .755
Impact score 
Section IV 39.2 (4.2) 40.8 (13.5) 36.5 (12.2) 1.207 .953 .871 .274
Total Impact score 49.8 (4.3) 49.0 (11.4) 46.7 (9.9) .602 .982 .768 .587
DISCUSSION
In this article, we have reported on the translation and psychometric characteristics of the 
Dutch version of the OASES for adults (OASES-A-D). The OASES-A-D showed acceptable 
item properties, a good internal consistency and moderate-to-high significant correlations 
with other existing instruments. The translated questionnaire showed no ceiling effects, and 
the majority of the items exhibited ranges from the lowest possible score of 1 to the highest 
possible score of 5. For fifteen out of 100 items, the maximum score did not reach 5, which 
can be explained by the relatively small number of participants in this study with severe 
stuttering. The mean scores across items ranged from 1.32 to 3.74 (SD ranging from 0.65 to 
1.46), showing similar variability as that seen in Yaruss and Quesal [86], who found a range 
of the mean from 1.7 to 3.5 (SD 0.75 to 1.6). Floor effects were observed most frequently in 
Section IV (Quality of Life). This may suggest that the OASES-A-D questionnaire lacks some 
sensitivity on the lower end of the scale, especially in the sections on job and education 
(IV.D) and overall well-being (IV.E). However, as our sample included mainly people with 
mild or moderate stuttering, the item scores probably adequately represent the impact of 
relatively mild stuttering on these aspects of quality of life. The findings regarding potential 
floor effects thus need further empirical evaluation. 
The reliability of the translated questionnaire was assessed using only internal consistency. 
All four sections of the OASES-A-D demonstrated strong internal consistency, with 
Cronbach’s α scores greater than 0.90 for Sections II to IV, and a Cronbach’s α score of 0.84 
for Section I. Scores were thus well above the 0.70 required to support internal consistency 
[174]. They were also in line with the results on the internal consistency reported by Yaruss 
and Quesal [86], who found Cronbach’s α values between 0.92 and 0.97. Cronbach’s α 
scores for each subsection were also above 0.70. 
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To assess concurrent validity, correlations between Impact scores and the Dutch S-24, SA 
and CA scores were calculated. Overall, concurrent validity was moderate to strong. The 
highest values were obtained for the correlations between the OASES-A-D and the S-24. 
Correlations between the OASES-A-D sections with the S-24 in our study ranged from .59 
to .85. This range was in line with values found for preliminary versions of the OASES-A 
in the United States, i.e., .68 to .83 [86]. However, in our study, the highest correlation 
was established for Section IV (Quality of Life) and not, as was anticipated, for Section II 
(Reactions to Stuttering). The correlations between the Total Impact score and the two 
different measures of stuttering severity applied in this study (the SA scale, measuring 
subjective stuttering severity, and the CA scale, measuring the clinician’s rating of stuttering 
severity) were both approximately .60. Since there are fundamental differences between 
the instruments in the way stuttering is evaluated (i.e., the SA scale measures stuttering 
severity by means of a self-rating of speech on a 10-point scale, the CA scale represents a 
clinician-based judgment, and the OASES-A-D comprehensively assesses the participant’s 
experience of the stuttering disorder), these correlations are judged to represent adequate 
relationships. Finally, age and educational level had little or no influence on the OASES-
A-D Impact scores. The lack of a correlation between OASES-A-D scores and chronological 
age is consistent with prior preliminary reports [177]. These findings support the concurrent 
validity of the OASES-A-D. 
Another way to measure validity is to compare groups known to differ on relevant 
features (known-group or construct validity). All sections of the OASES-A-D were able to 
differentiate between groups of participants with different levels of stuttering severity. Only 
the moderate and severe categories of the SA scale did not show significant differences 
in mean OASES-A-D Impact score. However, this may be due to the fact that this test 
was underpowered, since only four participants in this sample reported severe stuttering 
problems. 
Our study has several limitations. First, test-retest reliability of the OASES-A-D was not 
assessed. Prior research [86,159] has revealed high test-retest reliability for the original 
English version of the OASES-A, though further research will be needed to determine the 
test-retest reliability of the Dutch version. Second, not all of the questionnaires that were 
used in our psychometric analyses were available for all participants. For the participants 
recruited by therapists, no SA score was reported. Due to the fact that the data for the 
other participants were extracted from an ongoing QOL study, not all instruments that were 
relevant for the current study were applied. As a result, the CA scale scores and S24 scores 
were missing for those participants. Third, to perform a known-group analysis, categories 
of the SA scale were combined to create three groups (mild-moderate-severe stuttering), 
since we did not have enough data to perform the analysis with five groups. The same 
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was done for the CA scale. Even after combining categories, however, the distribution 
of stuttering severity scores on the SA scale remained skewed, with only four people 
reporting severe stuttering. In future studies, it would be recommended to include a more 
balanced sample with respect to stuttering severity. Even with these limitations, however, 
results support the general conclusion that the Dutch translation of the OASES-A exhibits 
appropriate psychometric properties.
The current study yielded some results that point to areas for improvement in future 
revisions of the OASES-A-D in particular and the OASES-A in general. Particularly, 
Cronbach’s α values for Section II, III and IV were above 0.90, indicating that there might 
be redundant items in these sections. Although it typically requires only 15 or 20 minutes 
to complete, the OASES-A is a relatively long questionnaire. The potential benefit of this 
is that it provides detailed information to clinicians about their clients’ experience of the 
stuttering disorder [86,159]. Still, for some clients, the length of the form may cause some 
concern. To reduce this burden and for reasons of parsimony, a shorter questionnaire 
targeted particularly for use in research may also be beneficial (though some of the detail 
inherent in the tool that helps clinicians with treatment planning and goal setting may be 
diminished). Future research could provide more insight into the possible redundancy of 
some items. Shortening the questionnaire could be based on several arguments. First, 
additional analysis may reveal that reducing the number of items with high correlations 
within a subsection may not reduce the sensitivity of the instrument. Second, item response 
theory might provide evidence for the redundancy of items and answer categories. A 
preliminary Rasch analysis [178,179] that we performed suggested that Sections I and II 
had a better fit to the Rasch model when the answer categories were rescored to a four 
point scale. Thus, in addition to considering the length of the questionnaire, the number 
of response categories could be evaluated. Such modifications to the questionnaire are 
beyond the scope of this paper, as any adaptation would require renewed psychometric 
testing. Therefore, these and other improvements to the OASES-A remain an interesting 
avenue of future research. 
To conclude, this study provides preliminary results that the Dutch language version of 
the OASES-A is a reliable and valid instrument for providing a comprehensive assessment 
of how stuttering affects the lives of individuals who stutter. Findings are relevant both to 
individuals who are in therapy as well as to those who are not. The fact that translations of 
the various versions of the OASES are being developed for several languages will, in the 
future, facilitate the comparability of OASES results in cross-cultural settings. Furthermore, 
it provides an excellent opportunity for collaborative research between nations. 
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ABSTRACT
Objective Stuttering is a common childhood disorder. There is limited high quality 
evidence regarding options for best treatment. The aim of the study was to compare the 
effectiveness of direct treatment with indirect treatment in preschool children who stutter.
Methods In this multicenter randomized controlled trial with an 18 month follow-up, 
preschool children who stutter who were referred for treatment were randomized to direct 
treatment (Lidcombe Program; n=99) or indirect treatment (RESTART-DCM treatment; 
n=100). Main inclusion criteria were age 3-6 years, ≥3% syllables stuttered (%SS), and 
time since onset ≥6 months. The primary outcome was the percentage of non-stuttering 
children at 18 months. Secondary outcomes included stuttering frequency (%SS), stuttering 
severity ratings by the parents and therapist, severity rating by the child, health-related 
quality of life, emotional and behavioral problems, and speech attitude.
Results Percentage of non-stuttering children for direct treatment was 76.5% (65/85) versus 
71.4% (65/91) for indirect treatment (Odds Ratio (OR), 0.6; 95% CI, 0.1-2.4, p=.42). At 3 
months, children treated by direct treatment showed a greater decline in %SS (significant 
interaction time x therapy: β=-1.89; t(282.82)=-2.807, p= .005). At 18 months, stuttering 
frequency was 1.2% (SD 2.1) for direct treatment and 1.5% (SD 2.1) for indirect treatment. 
Direct treatment had slightly better scores on most other secondary outcome measures, 
but no differences between treatment approaches were significant. 
Conclusions Direct treatment decreased stuttering more quickly during the first three 
months of treatment. At 18 months, however, clinical outcomes for direct and indirect 
treatment were comparable. These results imply that at 18 months post-treatment onset, 
both treatments are roughly equal in treating developmental stuttering in ways that surpass 
expectations of natural recovery. Follow-up data are needed to confirm these findings in 
the longer term.
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INTRODUCTION
Developmental stuttering is a prevalent childhood disorder. The incidence rate is 5 to 11% 
in preschool years [11,12]. The cause of stuttering is unknown, although recent research 
indicates that structural and functional brain anomalies underlie the disorder [RW.ERROR 
- Unable to find reference:3272], with a strong genetic involvement [10,14,17,182]. Many 
children recover spontaneously; about 63% at 3 years post onset [12,34]. Knowledge 
of factors that favor the chance for recovery [34,38] can help pediatricians and speech-
language pathologists (SLPs) to identify children at risk for chronic stuttering [183]. 
Nevertheless, the chance for recovery cannot be predicted for an individual child. Since 
chances for full recovery diminish when stuttering has been present for 15 months [44] and 
persistent stuttering in adolescents and adults can have a serious mental and social impact 
[41,91,130], treatment is generally recommended to start before the age of 6 years [11,184]. 
However, the evidence base for the effectiveness of current therapies for preschool children 
who stutter is surprisingly weak as well as unbalanced in terms of published reports [66]. 
For about three decades, many preschool children who stutter around the world have 
been treated according to an indirect, multifactorial treatment approach, like treatment 
based on the Demands and Capacities Model (DCM) [47,55]. This approach aims to 
decrease demands set by the environment (e.g., parents are trained to slow down their 
habitual speech rate) and the child him- or herself (e.g., desensitization for disfluency), 
and increase the child’s capacities for speaking fluently (e.g., accurate and smooth speech 
motor movements that are age-appropriate) to arrive at a favorable balance between 
demands and capacities, eventually resulting in fluent speech. Since 2000, an increasing 
number of children have been treated according to a direct operant treatment approach: 
the Lidcombe Program (LP) for early intervention [48,185]. This direct approach teaches 
parents to give verbal contingencies after fluent and stuttered speech. With the limited 
data available at present, the direct LP offers the best evidence-based intervention for 
preschool children who stutter [66]. However, the long-term effectiveness of this treatment 
is still unclear [186]. More importantly, comparative effectiveness to current standard 
treatment has not yet been established; yet child health policy-makers, pediatricians and 
SLPs need this information to decide upon reimbursement and treatment choice. This is 
for instance illustrated by a recent proposal of the national speech-language pathology 
association of Australia (Speech Pathology Australia) to only fund treatment by the LP [187]. 
Therefore, the aim of the current study was to compare the effectiveness of direct versus 
indirect stuttering treatment in preschool children during an 18 month follow-up. 
86 | Chapter 5
METHODS
Study design, participants and setting
This parallel group randomized trial named RESTART (the Rotterdam Evaluation Study 
of Stuttering Therapy in preschool children- a Randomized Trial) included 199 preschool 
children who stutter, who were registered at one of the 20 participating speech clinics 
(including 24 SLPs) throughout the Netherlands. Eligible participants were children (1) 
aged 3.0-6.3 years, (2) with a stuttering severity rating ≥ 2 (“mild”) on an 8-point scale 
[34] provided by the parent (3) and by the clinician, (4) who stuttered ≥ 3% of syllables and 
(5) for at least 6 months. The inclusion criterion of at least 3% syllables stuttered (SS) had 
replaced the original criterion of “at least 3.3% Stuttering Like Disfluencies (SLD)” shortly 
before the start of the trial. This was based on critics on the SLD measure in literature 
and on the results of a study into the validity of the SLD measure that we conducted at 
our center. Exclusion criteria were a diagnosis of an emotional, behavioral, learning or 
neurological disorder, or a lack of proficiency in Dutch for children or parents. The exclusion 
criterion of having received treatment for stuttering during the past year was omitted after 
5 months, since it was noticed that by excluding these children, the external validity would 
be restricted. All SLPs were trained and experienced in both treatments. DCM based 
treatment training is included in the regular clinical education in the Netherlands, and all 
but one SLP had additionally been trained in the assessment and treatment of children 
who stutter to become a certified fluency expert recognized by the Dutch association of 
stuttering therapy (NVST). To ensure a uniform application of DCM based treatment, a 
treatment manual was developed in collaboration with all participating clinicians prior to 
the start of the trial. In addition, all SLPs had gone through a three day LP course taught 
by a LP Consortium trainer and had been certified to provide LP therapy. They had on 
average 15 years of experience with DCM based treatment (range 7-21 years) and 3.7 
years with the LP (range 1.5-7.6 years). Therapists’ fidelity to treatment was monitored in 
3-monthly intervision meetings, regular telephone contacts with the research team, and by 
registration forms on the content and amount of treatment filled in by the SLPs and checked 
by the research team. The intervision meetings were chaired by a LP consortium trainer 
and a DCM trainer. The trial was approved by the Ethics Committee of the Erasmus MC 
and registered at isrctn.org (ISRCTN24362190). Written informed consent was obtained 
from all parents. The trial protocol and supporting CONSORT checklist are available as 
supporting information: see S1 Checklist and S1 Protocol (online).
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Interventions
Direct treatment: The Lidcombe Program
The Lidcombe Program (LP) is a behavioral treatment based on the premise that stuttering 
is an operant behavior that can be targeted by contingencies. The LP is administered 
by parents under the direction of a clinician. Children allocated to the LP were treated 
according to the LP manual [48]. Parents were trained to deliver verbal contingencies in 
conversations with their child (e.g., “That was smooth” or “Were there any bumpy words?”) 
in a 5:1 ratio for stutter-free and stuttered speech. During the first stage of the program, 
the parent delivered contingencies during structured conversations of 10-15 minutes once 
or twice a day. The speech clinic was attended once a week. This continued until stuttering 
either disappeared or reached an extremely low level (≤1% of syllables stuttered). During 
the second stage, the use of verbal contingencies as well as the number of clinic visits was 
gradually reduced, provided that fluency was maintained.
Indirect treatment: The RESTART Demands and Capacities Model based treatment
RESTART Demands and Capacities Model based treatment (RESTART-DCM) is premised 
on the idea that positive changes in the child’s functioning and/or in the environment will 
lead to a reduction of stuttering. Following the RESTART-DCM manual [188], parents were 
trained to decrease relevant motoric, linguistic, emotional or cognitive demands, thereby 
reduce communicative pressure on the child (e.g., parents slowing down their habitual 
speech rate). If deemed necessary, the child’s capacities for fluency were subsequently 
trained (e.g., improving the child’s speech motor movements or word-finding capacity). 
Parents were required to give their child their undivided attention and practice home 
assignments 15 minutes a day, for a minimum of 5 days a week. Treatment was gradually 
reduced if the child showed acceptable speech, parents had mastered implementing a 
fluency enhancing environment and knew what to do if a relapse occurred. 
Randomization and blinding
A minimization software program (MINIM2) [189] was used by the principal investigator 
(CdeS) to allocate children to one of the treatment arms, according to factors known or 
thought of to be related to treatment outcome [190]: gender, stuttering severity in the 
clinic (based on the SSI-3 score) [116], time since onset (TSO; 6-12, 13-18, 19+ months), a 
first, second, or third degree relative with persistent stuttering (yes, no) and/or a history of 
recovered stuttering (yes, no), stuttering treatment during the past 12 months (yes, no), and 
SLP. Three stuttering severity categories were distinguished: (1) mild (SSI-3 score: 10-16); 
(2) moderate (SSI-3 score: 17-26); severe (SSI-3 score: 27+). For each participant, treatment 
allocation depended on the characteristics of the children already enrolled [190]. Judges 
of stuttering frequency were blinded to treatment allocation and measurement moment.
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Outcome assessment
The primary outcome measure was the percentage of non-stuttering children at18 months, 
operationalized as ≤1.5% syllables stuttered (SS). This criterion was obtained by applying a 
conversion ratio of 1.15 to the mean percentage of stuttered word disfluencies in children 
who do not stutter (1.29%) [191]. Parents were requested to make three audio recordings 
of 10-15 minutes each in a period of two weeks: one sample of their child speaking to a 
parent at home, one to a non-family member at home and one to a non-family member 
away from home [6,192,193]. 
Secondary outcome measures assessed at baseline, and at 3, 6, 12 and 18 months after 
start of treatment, were the frequency of stuttering (%SS), a severity rating of stuttering 
by the parent on an 8-point scale[34], and parents´ valuation of their child´s health-related 
quality of life on a proxy version of the EuroQoL EQ-VAS [113] with anchor points 0 (worst 
imaginable health) and 100 (best imaginable health). Secondary outcome measures 
assessed at baseline and 18 months were the speech attitude of the child (KiddyCAT) 
[96] and emotional and behavioral problems measured by the Child Behavior Checklist 
(CBCL) [194]. The latter consists of the scales Internalizing (anxiety, depression, withdrawal, 
and somatic complaints), Externalizing (aggressive and delinquent behavior), and Total 
problem behavior [194]. At 18 months both the SLP and the child provided a stuttering 
severity rating: the SLP on an 8-point scale [34], the child on a 4-point scale where 1= I do 
not stutter anymore and 4= I stutter a lot.
Eight SLPs not involved in the study were trained to determine the %SS of the samples in 
real time with sufficient intrajudge reliability, using an electronic, button press counter. To 
ensure sufficient interjudge reliability, 64% of all samples were scored by at least two raters. 
Disagreements in ratings were discussed and a third, blinded senior rater was consulted in 
rare cases where no agreement could be reached (cf. Boberg & Kully [195]).
Statistical analysis
An a priori power calculation to detect a difference of 15% in percentage of non-stuttering 
children (80 versus 95%) with a power of 80% in a 2-tailed test at a significance level of .05 
and allowing a 22% drop-out rate, resulted in a sample size of 98 in each group. Baseline 
factors were characterized as medians, means and standard deviations for continuous 
variables and as frequency distributions for categorical variables. Baseline comparisons 
between treatment groups and between survivors and drop-outs were assessed using χ2 
tests and independent t-tests. Participants were analyzed in the group to which they were 
randomized. 
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The effect of treatment on the primary outcome measure was analyzed by χ2 tests and 
logistic regression analysis (ENTER method). The regression analysis included the main 
effect of therapy and the interaction terms therapy*age in years, therapy*stuttering severity 
(SSI-3 score), and therapy*TSO. Confidence intervals around the obtained percentages of 
children classified as non-stuttering were calculated according to the method of Wilson 
[196,197], using a website calculator (http://www.vassarstats.net/prop1.html). In a sensitivity 
analysis, cut-off scores of 1% SS and 2% SS were applied to further assess the robustness 
of the primary outcome. 
For the secondary outcomes assessed at all measurement moments (%SS, parental 
rating of stuttering severity, and EQ-VAS) and at baseline and 18 months (KiddyCAT and 
CBCL), we applied a longitudinal repeated-measures mixed effects model with random 
intercepts, assuming missing at random. Participant was included as a random predictor; 
fixed predictors were therapy, and 4 cross-products as interaction terms: time*therapy, 
and time*therapy*age, severity, and TSO, respectively. An unstructured covariance matrix 
was assumed for the error as a more plausible autoregressive covariance structure did 
not provide a better fit. This approach was also used at level 2 of the model. Since the 
data on %SS did not meet the assumptions needed to calculate CIs for the intraclass 
correlation coefficient (ICC), interjudge reliability of the speech samples was assessed 
using Krippendorff’s alpha [198] with the option “interval data” for the macro developed 
by Hayes (2013) [199]. For the outcome %SS, an additional analysis was conducted into the 
progression in the first 3 months. CBCL outcomes at 18 months were analyzed separately 
using ANOVA-analysis. Secondary outcome measures only assessed at 18 months (severity 
ratings by clinician and child) were compared by independent t-tests. For all secondary 
outcomes, unadjusted and Holm-adjusted [200] p-values are presented, using an overall 
level of significance of α=.05 (2-sided). The Holm’s correction is generally considered a 
good alternative to the conservative Bonferroni approach [201]. Each pj is compared to 
α/(n-j+1); that is: the smallest pj (j=1) is compared to α/n, the next smallest to α/(n-1) etc.
Treatment intensity was compared by independent t-test, and a χ2 test was conducted to 
compare the number of children on treatment at the endpoint of the trial. For analysis of 
the questionnaires, instructions offered in the manuals were followed. All analyses were 
carried out in SPSS 20 (Armonk, NY: IBM Corp.).
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RESULTS
Participants
Children were enrolled between September 2007 and June 2010. Of 615 children referred 
for treatment, 416 were not eligible for various reasons (Figure 5.1). In total 199 children met 
the inclusion criteria. One child was found ineligible after inclusion and therefore excluded 
from all analyses (Figure 5.1). Baseline characteristics did not differ between treatment groups 
(Table 5.1). In the LP group 12 children were lost to follow-up as compared to 9 children in 
the RESTART-DCM group (n=21, 11% drop out rate). Children who were lost to follow-up 
did not significantly differ on any baseline characteristics (age, gender, ethnicity, educational 
level of parent, SSI-3 score, %SS, TSO, parental ratings, stuttering in family, prior treatment 
for stuttering) from children who completed the trial (p-values ranging from .11 to .91). For 
191 children, at least one outcome measurement after the start of treatment was available. 
TABLE 5.1 Baseline characteristics of participants by treatment group
Characteristic Lidcombe Program (n=98)a RESTART-DCM (n=100)a
Age in months, median; mean (SD) 51.0; 51.5 (9.5) 52.0; 54.1 (11.1)
Age in years
3b 41 (41.8) 37 (37.0)
4 39 (39.8) 31 (31.0)
5-6 18 (18.4) 32 (32.0)
Male 68 (69.4) 70 (70.0)
SSI-3 score
mildc 32 (32.7) 31 (31.0)
moderate 47 (48.0) 51 (51.0)
severe 19 (19.4) 18 (18.0)
% SS, median; mean (SD)d 4.9; 6.2 (4.4) 4.0; 5.3 (4.3)
Time since onset
6-12 months 43 (43.9) 45 (45.0)
13-18 months 25 (25.5) 22 (22.0)
19+ months 30 (30.6) 33 (33.0)
Family history of persistencye 45 (45.9) 45 (45.0)
Family history of recoverye 27 (27.6) 25 (25.0)
Prior treatment for stuttering 8 (8.2) 6 (6.0)
a Data are shown as No. (%) unless specified otherwise
b One child in the LP group was 2.11 years at time of inclusion
c Children with a stuttering frequency < 3% in the therapy setting but ≥ 3% in the home setting were included in the 
group “mild stuttering” (n=26)
d For one child in the RESTART-DCM group %SS on baseline was not available
e For one child in the LP group information on family history of stuttering was not available 
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• Not meeting inclusion criteria (n= 220)  
• Declined to participate (n= 58) 
• Other reasons (n= 138)  
Randomized to direct treatment (LP) (n=99) Randomized to indirect treatment
(RESTART-DCM treatment) (n=100) 
Completed follow-up (n=91)Completed follow-up (n=86)
Changed from the LP to RESTART-DCM 
treatment 12 months post randomization (n=1)  
3 months assessment available (n=93) 
6 months assessment available (n=91) 
12 months assessment available (n=83) 
Changed from RESTART-DCM treatment to the 
LP  12 months post randomization (n=1) 
3 months assessment available (n=89) 
6 months assessment available (n=91) 
12 months assessment available (n=89) 
Referred for stuttering treatment (n= 615) 
Randomized (n=199) 
FIGURE 5.1 RESTART trial flow diagram
a Borderline stuttering (n=97); Stuttering frequency decreased during assessment phase (n=79); Stuttering < 6 
months (n=26); Lack of proficiency in Dutch for child or parents (n=18)
b Expectations of high demands (n=31); Preference for either treatment (n=27)
c Start treatment for other speech/language disorders (n=41);Preference for treatment center closer to parent’s home 
(n=21); Problematic or complex home situation (n=43); Parents did not show up (n=5); Other reasons (n=28)
Speech samples
The mean number of available audio samples for a child at a measurement moment was 2.9 
(range 1-6). At least 85% of all samples had a length of ≥300 syllables. The mean intrajudge 
reliability [202] of measurement of %SS was 83%. Krippendorff’s alpha for samples with 2 
ratings at baseline and after 3, 6, 12 and 18 months, respectively, was 0.849, 0.896, 0.817, 
0.795, and 0.830; all significant, with significance obtained by bootstrapping. All scores 
represent good reliability [203].
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Primary outcome
At 18 months, audiotapes were available for 173 children. For 1 child in the LP and 2 in 
the RESTART-DCM group audiotapes were missing and replaced by videotapes made in 
the clinic. For 1 child in the LP group, both audio and videotapes were lacking. Thus, 
the final analysis at 18 months was based on 176 children. In total, 76.5% (65/85; 95%CI: 
66.4-84.2) of children in the LP group were classified as non-stuttering at 18 months 
compared to 71.4% (65/91; 95%CI: 61.4-79.7) of children in the RESTART-DCM group. This 
difference was statistically non-significant (χ2(1)=0.579, p=.45). Nor did logistic regression 
analysis indicate therapy or other factors as significant predictors of being classified as non-
stuttering (therapy: OR, 0.6; 95% CI, 0.1-2.4; p= .42; Table 5.2). Applying cut-off criteria of 
1% SS and 2% SS did not significantly affect the results. 
Secondary outcomes
The results for all secondary outcome measures at baseline and 18 months and the results 
for the mixed model analyses are presented in Table 5.2. For the outcome %SS, the effect 
of therapy type was non-significant. However, a significant interaction between time and 
therapy type was detected (adjusted p= .008), indicating that the %SS differed for therapy 
groups at different time points. The effect of time was also significant (adjusted p= .002), 
indicating that in both treatment groups the average %SS decreased significantly over 
time. Effect sizes were small (Table 5.2). 
Figure 5.2 shows that in both groups most improvement in %SS occurred in the first 
3 months of therapy. For this interval, an effect of therapy type was found (β=2.30; 
t(217.38)=2.10, p= .04), as well as a significant interaction between time and therapy type 
(β=-1.89; t(282.82)=-2.81, p= .005). Compared to the RESTART-DCM group, the LP group 
had a slightly higher mean %SS at baseline and showed a greater decline, resulting in a 
lower %SS at 3 months. Significant interactions with very small effect sizes were also present 
between time, therapy type, and stuttering severity (β=0.25; t(173.94)=2.51, adjusted p= 
.01) and time, therapy type, and TSO (β=-0.21; t(172.85)=2.40, adjusted p= .02) (Figure 5.3).
For the outcome parental rating of stuttering severity, a significant effect of time (adjusted 
p< .001) as well as a significant interaction between time and therapy type (adjusted 
p< .001) was detected. Figure 5.2 shows a slightly greater decline in scores for the LP 
group over the period of 18 months. The interaction between time, therapy type and age 
was significant (adjusted p< .001) but showed a very small effect size (Table 5.2). For the 
outcomes EQ-VAS and KiddyCAT, no significant effect of therapy type or any other factor 
was found (Table 5.2; Figure 5.2). 
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Stuttering frequency (%SS)    
         
No. of children      
LP 98 92 85 83 85 
RESTART-DCM 99 88 89 86 91 
                         
 
                             
No. of children      
LP 98 92 85 83 85 
RESTART-DCM 99 88 89 86 91 
 
            Note. Scale ranges from 0 (no stuttering), 1 (borderline stuttering),  to 7 (very severe stuttering) [11] 
 
           
No. of children      
LP 90 91 78 79 80 
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FIGURE 5.2 Change in three secondary outcome measures during 18-month follow up 
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For all CBCL scale scores, the factor therapy type was significant (Table 5.2), but this effect 
was attributable to significantly higher scores for the LP group at baseline. At 18 months, 
no significant differences were found (Internal scale: F(1,196)=-1.04, unadjusted p= .32, partial 
eta squared=.006; External scale: F(1,196)=1.04, unadjusted p= .31, partial eta squared=.006; 
Total problem scale: F(1,196)=1.12, unadjusted p= .29, partial eta squared=.006). For the 
CBCL External scale, a significant interaction with a small effect size was established 
between time, therapy type and age: older children showed a greater decline in score, 
particularly in the LP group.
For the severity rating by the clinician as well as by the child at 18 months, significant 
interactions between therapy type and age were established (Clinician: adjusted p= 
.01; Child: adjusted p=.01). However the small eta-squared values (0.079 and 0.088, 
respectively) suggest that these differences are negligible. 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5.3 Change in %SS during first three months
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Treatment intensity
The number of treatment sessions and treatment hours did not differ significantly between 
groups (Table 5.3). At 18 months, 27.6% (27/99) children in the LP group compared to 
35.0% (35/100) children in the RESTART-DCM group were still on treatment, a difference 
that was also not statistically significant (χ2(1)=1.277, p=.26).
TABLE 5.3 Treatment intensity by treatment group
LP (N=98) RESTART-DCM (N=97) p-value
Number of treatment sessions, 
median; mean (SD; SE) [range] 21; 22.2 (11.2; 1.1) [2-51] 17; 19.5 (10.3; 1.0) [2-59] .08
LP (N=95) RESTART-DCM (N=93) p-value
Number of treatment hours, 
median; mean (SD; SE) [range] 18.3; 19.6 (10.9; 1.1) [1.4-51] 15.5; 18.0 (9.7; 1.0) [3.0-55.2] .20
DISCUSSION
The RESTART-trial found that both direct and indirect treatment for preschool children who 
stutter reduced stuttering during 18 months of follow-up. The direct approach reduced 
stuttering frequency more quickly during the first three months of treatment, however, 
the difference was not significant anymore by 18 months. Most outcome measures were 
slightly in favor of the direct approach (LP), but the few significant interaction terms were 
deemed negligible due to their small effect sizes. For most children, stuttering frequency 
plateaued after three months, while about 30% of children were still on treatment after 18 
months. 
The direct LP and indirect RESTART-DCM treatment are based on different premises and 
assumptions regarding mechanisms underlying treatment effect (i.e., delivering verbal 
contingencies versus balancing demands and capacities for fluent speech, respectively). 
However, since results for both treatments were comparable, it could be hypothesized 
that their common components have a larger influence on recovery than their unique 
components (cf. Imel & Wampold [204]). In psychotherapy and counseling, this is known 
as the “dodo bird phenomenon” [205]. According to this hypothesis, treatments that are 
intended to be therapeutic are equally efficacious. Studies suggest that 30-70% of therapy 
outcome can be attributed to common factors, including good therapeutic relationships 
[204]. Unfortunately, little is known about the unique mechanisms that lead to change 
in stuttering behavior in both treatments [206-208]. Common components of the LP and 
RESTART-DCM treatment may include consideration of maintaining factors, an increase 
in one-on-one time that parents spend with their child, a boost of encouragement and a 
reduction of linguistic demands for the child [209], and emotional support for the parents. 
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Our results do not enable us to distinguish the potential effect of treatment from 
spontaneous recovery. Spontaneous recovery in the general population at 36 months post 
onset has been estimated to be 63% or higher [34]. An estimate of the mean time since 
onset of stuttering at the endpoint in our study is 33 months. Thus, our percentages of 
children classified as non-stuttering exceed this estimate by about 10% (p=.02; based on 
statistical test for comparing two proportions from different populations). Furthermore, the 
chance of spontaneous recovery in our clinical study population is likely to be lower than 
in the general population, because this chance is known to diminish after 12 to 18 months 
[34,44] and 56% of children within our study stuttered for at least 12 months.
Strengths of our study are the large sample size with minimal loss to follow-up, the 
broad range of outcome measures, the large number of measurement moments, and the 
relatively long follow-up period (double the time in Jones et al. [6]). Participating therapists 
in the RESTART-study worked in usual-care centers throughout the Netherlands. Thus, the 
treatments were studied in a variety of regular clinical settings with therapists unconnected 
to the developers of the therapies [207,210], therefore employing a practical study design 
ensuring a high external validity. A limitation of our study is that a high number of children 
appeared ineligible for participation. Results may therefore not be fully generalizable to 
all preschool children presenting to a clinic with stuttering. Another limitation is that the 
applied follow-up time is insufficient to decide conclusively whether a child has recovered 
from stuttering. This requires a period of about 5 years [34,211], to account for the possibility 
of a relapse. Therefore, we intend to follow-up all children under study.
CONCLUSIONS
At 18 month post-treatment onset, the evidence suggests that both direct and indirect 
treatment for stuttering can be recommended. However, direct treatment decreased 
stuttering more quickly during the first three months. Future research investigating the role 
of client and clinician factors, the effectiveness of a combined direct and indirect approach, 
and the cost-effectiveness of a limitation of treatment time or frequency may shed further 
light on the effectiveness of stuttering treatment in preschool children. 
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ABSTRACT
Purpose The purpose of this study was to evaluate the incremental cost-effectiveness and 
cost-utility of the Lidcombe Program (LP) compared with treatment based on the Demands 
and Capacities Model (RESTART-DCM) for preschool children who stutter.
Methods A cost-effectiveness and cost-utility analysis were carried out alongside a 
Randomized Clinical Trial (the RESTART-study). In total, 199 children in 20 speech clinics 
participated. Outcome measures included the number needed to treat, based on the 
percentage of children who did not stutter at 18 months, and Health-related quality of life 
(EQ-VAS and HUI3) at 3, 6, 12 and 18 months. Health-related quality of life scores were 
used to calculate quality adjusted life years (V-QALYs for the EQ-VAS and U-QALYs for 
the HUI3). Direct and indirect costs were measured by cost questionnaires. Missing data 
were multiply imputed. Percentages of children who did not stutter in both groups were 
compared by a chi-square test. Between-group differences in mean QALYs and costs, as 
well as cost effectiveness and cost-utility ratios, were evaluated by applying bootstrapping 
techniques.
Results After 18 months, health outcomes were slightly better in the LP group, although 
only the difference in V-QALYs was statistical significant (0.018; 95% CI: 0.008 to 0.027) 
with a small effect size (Cohen’s d=0.17). Mean costs for the LP group were significantly 
higher compared to the RESTART-DCM group (€3199 versus €3032), again with a small 
effect size (Cohen’s d=0.14). The incremental cost-effectiveness ratio was €3360 for one 
additional child who did not stutter with the LP, and the estimated cost-utility ratios were 
€10413 (extra cost per extra V-QALY) and €18617 (extra cost per extra U-QALY). The results 
indicated a high probability that the LP is cost-effective compared to RESTART-DCM 
treatment given a threshold for willingness-to-pay of €20.000 per QALY.
Conclusions Differences in effects and costs between the LP and RESTART-DCM treatment 
were small. Cost-effectiveness and cost-utility ratios were in favor of the LP. The LP is 
considered a good alternative to RESTART-DCM treatment in Dutch primary care.
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INTRODUCTION
Persistent stuttering can lead to a decreased health-related quality of life (HRQOL) in 
the psychological, emotional and social domains of functioning [41,91,130], as well as to 
substantial health care costs [212]. To prevent stuttering becoming persistent, treatment is 
best initiated in the preschool years. Treatment should preferably result in a high percentage 
of children recovering from stuttering at acceptable societal costs. Information on costs 
and effects of available stuttering treatments could help clinicians and policy makers in 
decisions on therapy choice and reimbursement. Although the last decade has shown an 
increasing number of studies into the efficacy of stuttering therapy in preschool children, 
there is a lack of evidence on the cost-effectiveness of available treatments. 
Two widely applied treatment approaches for preschool children who stutter are treatment 
based on the Demands and Capacities Model (DCM) [47,55] and the Lidcombe Program 
(LP) [185]. In the Netherlands, children are commonly treated according to the former 
approach. Currently, about 10% of Dutch speech-language pathologists (SLPs) working in 
private practices are also trained in the LP. The LP is supported by a larger body of evidence 
than any other treatment [66], but a head-to-head comparison against other types of 
treatment is presently unavailable. However, it is known that the LP requires a relatively long 
maintenance phase after fluent speech has been attained. The LP is therefore expected to 
be more costly than DCM based treatment. The average number of treatment sessions for 
DCM based treatment has been estimated at 12 sessions [47], while the LP requires almost 
double. This raises the question whether the presumably higher treatment cost of the LP 
is compensated by a greater proportion of recovered children, fewer relapses, and better 
individual speech outcomes, as suggested by Onslow et al. [185]. 
An economic evaluation can provide insight into the costs and effects of a new health 
care intervention compared to usual care. All types of economic evaluations assess costs, 
but health consequences can be measured in different ways [88]. The most common 
forms of economic evaluation are cost-effectiveness analysis (CEA) and cost-utility analysis 
(CUA). In a CEA, the health consequences are expressed in terms of natural units (i.e., 
survival or a desired clinical outcome like recovery), while in a CUA the effects are valued 
in terms of generic measures of health, such as quality adjusted life years (QALYs) [88]. 
The comparison of costs and effects of a new intervention with usual care results in an 
incremental cost-effectiveness or cost-utility ratio. This metric can be used to judge 
whether the additional effects are large enough to justify the extra costs. To get the most 
benefit from resources available to society and, accordingly, to guide implementation and 
reimbursement decisions, an economic evaluation should be conducted from a societal 
perspective. This implies that all costs and health benefits are included, regardless of to 
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whom costs are related to or who receives the benefits [88]. In the field of speech-language 
pathology economic evaluations are scarce, but crucial to provide a basis for decisions 
on implementation and reimbursement of therapies. The aim of the present study was to 
determine the incremental cost-effectiveness and cost-utility of the LP compared to DCM 
based treatment. 
MATERIALS AND METHODS
Study design
The economic evaluation was performed alongside a prospective randomized clinical 
trial in the Netherlands (the RESTART-study) with a time horizon of 18 months. Data was 
collected between September 2007 and January 2012. A societal perspective was adopted 
for the economic evaluation. Details of the study design and the interventions have been 
previously published [213]. The trial was approved by the Ethics Committee of the Erasmus 
MC, the Netherlands, and has been registered at isrctn.org as ISRCTN24362190. 
Participants and setting
Children were included by 24 SLPs in 20 speech clinics throughout the Netherlands. 
Inclusion criteria were: (1) age between 3.0 and 6.3 years; (2) stuttering confirmed by a 
rating of stuttering severity on an 8-point scale of at least 2 (“mild”) [34] by the parent (3) 
as well as by the clinician; (4) at least 3% of syllables stuttered (SS); and (5) stuttering for at 
least six months. Exclusion criteria were: (1) diagnosis of an emotional, behavioral, learning 
or neurological disorder; and (2) lack of proficiency in Dutch for children or parents. The 
method of minimization was applied to allocate children to one of the treatment arms 
[189]. In total, parents of 199 children gave their informed consent and these children were 
included in the study. This sample size allowed us to detect a 15% difference in percentage 
of children who did not stutter at 18 months, assuming a power of 80% with an alpha-level 
of .05.
Interventions
The Lidcombe Program (LP) is a behavioral treatment based on operant methods. Children 
allocated to the LP were treated according to the “manual for the Lidcombe Program 
of early stuttering intervention” [48]. The intervention mainly comprises delivering verbal 
contingencies during conversations when the child is speaking mostly stutter-free (e.g., 
“That was smooth” or “Were there any bumpy words?”). Parents are trained by the 
therapist how to deliver the contingencies during weekly clinic visits. Treatment consists of 
two stages. The median number of clinic visits for stage 1 has been estimated to be 11 [48] 
to 15 [214]. When stuttering either disappears or reaches a satisfactorily low level, the child 
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enters stage 2. This maintenance phase comprises at least seven treatment sessions [48], 
and has been recently estimated to include 8 to 12 sessions [214]. Combining the most 
recent estimates, the mean total treatment time is 22 to 27 sessions. 
DCM based treatment is premised on the assumption that stuttering develops when a 
child lacks the capacities to speak as fluently as the environment demands. Therefore, 
treatment aims to achieve a favorable balance between environmental demands (e.g., 
parents slowing down their habitual speech rate) and demands by the child him- or herself 
and the child’s capacities for speaking fluently (e.g., improving the child’s speech motor 
movements or his word finding capacity). Children allocated to DCM based treatment were 
treated according to the RESTART-DCM treatment manual [188]. This manual was designed 
before the onset of the trial, in order to standardize the DCM based treatment approach 
(hereafter referred to as: RESTART-DCM treatment). At the onset of the treatment, the child 
attends the clinic every week. The intensity of treatment is gradually reduced if stuttering 
frequency decreases. The mean number of sessions is estimated to be 12, however with 
a high variability [47]. In the pilot study that was accomplished before the RESTART-study, 
the mean number of treatment sessions of DCM based treatment of one hour each in the 
first three months was 11, and three-quarter of children were still on treatment at the end 
of the three months [56].
Data collection
At baseline, relevant demographic characteristics (e.g., age, gender, and risk factors 
for persistency and recovery of stuttering) were assessed. At baseline and 3, 6, 12 and 
18 months post-treatment onset, parents were asked by the SLP to make three audio 
recordings of daily conversations of the child outside the clinic and fill in questionnaires 
on health outcomes, resource use and costs. Questionnaires on resource use and costs 
asked about the last three months. To account for costs in the period between six and nine 
months post-treatment onset, an extra questionnaire was filled in by parents at nine months.
Health outcomes
The primary outcome used for the CEA was the number needed to treat (NNT), based on 
the absolute percentage of children in both groups who did not stutter at 18 months. The 
NNT stands for the average number of patients who need to be treated for one patient to 
benefit compared with a control. The absolute percentages could not directly be applied 
in the calculation of the cost-effectiveness ratio, as the implication of the costs to obtain 
one percent more non-stuttering children with either treatment depends on the population 
size (i.e., €500 for one percent more children who do not stutter in a population of 1000 
children differs from, for example, €500 for one percent more children who do not stutter 
in a population of 2000 children). Thus, for a meaningful application of the percentages of 
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non-stuttering children in the CEA, these percentages were converted into the NNT. In the 
RESTART-trial, the NNT stands for the number of children who need to be treated with the 
LP in order to have one extra child defined as non-stuttering at 18 months post-treatment 
onset, compared to RESTART-DCM treatment. The NNT is the inverse of the absolute 
difference in rate of non-stuttering and is computed as 1 / (pLP – pRESTART-DCM), in which p 
stands for the rate of the event “non-stuttering” in the treatment group. Non-stuttering 
was operationalized as ≤1.5% SS [191] on audio recordings made by parents. The audio 
recordings were scored for %SS by SLPs who were not involved in the study and who were 
blinded for therapy and measurement moment. Missing audio recordings were replaced 
by video recordings made in the clinic (n=1 for the LP group; n=2 for the RESTART-DCM 
group). Further details, along with full details on clinical outcomes, can be found in de 
Sonneville-Koedoot et al. [213].
The primary outcome for the CUA was HRQOL as measured by proxy versions of the 
EuroQoL EQ-VAS [113] and the Health Utility Index-3 (HUI3) [111] at baseline and 3, 6, 12 
and 18 months post-treatment onset. The EQ-VAS [113] is a visual analogue scale ranging 
from 0 (worst imaginable health) to 100 (best imaginable health). It was applied for all 
children under study to derive a direct rating of the child’s current health state by parents. 
The HUI3 [111] is a preference-based measure of HRQOL. That is, health descriptions by 
parents on a standardized system were linked to empirical values that represent the strength 
of preferences of the general public for those health states (utilities). The HUI3 descriptive 
system consists of eight domains (vision, hearing, speech, ambulation, dexterity, emotion, 
cognition and pain and discomfort), with five to six response levels for each domain. The 
utilities range from -.36 (worst imaginable health) to 1 (best imaginable health) [111]. The 
HUI3 is only applicable for children aged 5 years and older; for younger children no generic 
preference-based measure of health exists.
HRQOL values were converted into quality adjusted life years (QALYs) by the area 
under the curve method. This implies that the time spent in a particular health state was 
multiplied by the value or utility for that health state. If, for instance, a child would be 
in perfect health (utility of 1) at baseline as well as at 3 months post start treatment, the 
amount of QALYs generated in the first three months (a quarter) is (1*0.25)=0.25 QALYS. 
If a child’s utility score changes from 0.80 at baseline to 0.90 at 3 months, this would 
generate: (0.85*0.25)=0.2125 QALYs. QALYs are commonly based on HRQOL utilities 
(e.g., as obtained by the HUI3). In the current study, HRQOL values as obtained by the EQ-
VAS were also applied to estimate QALYs. For a review of the criticism on and advantages 
of using value-based QALYs (V-QALYs) instead of utility-based QALYs (U-QALYs) in cost-
utility analysis we refer to Parkin and Devlin [215].
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Resource use and costs 
In line with Dutch guidelines for pharmacoeconomic research [216], a societal perspective 
was adopted. Consequently, direct health care costs, direct non-health care costs and 
indirect non-health care costs were measured (Table 6.1). Data on the number and duration 
of treatment sessions, which were expected to have the largest impact on the total costs, 
were collected directly from registrations by the SLPs. Parental questionnaires included 
questions on the number of contacts with other healthcare providers to stimulate fluent 
speech (e.g., physiotherapist, assistance to parents in upbringing), extra material bought 
by parents to do the treatment at home (e.g., toys, books), transport to the speech clinic 
(travel distance, volume and means of transport), time invested on homework assignments, 
hours of absenteeism from paid work due to a clinical visit and duration of a visit to the 
clinic (including travel time). The unit-cost of a treatment session was derived from a cost 
analysis conducted by the NZa (Dutch Health care Authority) for the year 2009 [217] and 
adjusted for 2010 using consumer price indices [218]. In order to account for differences 
in duration of treatment sessions, the price per minute of therapy was calculated. For the 
calculation of all other costs, reference prices derived from the Dutch manual for costing 
[219] were used (Table 6.1). All costs were estimated for the year 2010 and are presented 
in Euros. 
TABLE 6.1 Resources and unit prices
Resources Euro Source
Direct health care costs   
Treatment for stuttering 34.26 [per half hour] NZa Cost research
Additional treatmenta 33 – 36 [treatment session] Dutch Costing Manual (2010)
Extra material for therapy at home price given by parents  
Direct non health care costs   
Travel by car 0.20 [per kilometer] Dutch Costing Manual (2010)
Travel by public transport ticket price Dutch Costing Manual (2010) 
Homework assignmentsb 12.50 [per hour] Dutch Costing Manual (2010) 
Indirect non health care costs   
Absenteeism from paid workc 32.25 [per hour] Dutch Costing Manual (2010) 
Productivity losses for unpaid workd 12.50 [per hour] Dutch Costing Manual (2010) 
a Additional treatment consisted of speech/language therapy (n=5), physiotherapy (n=2), manual therapy (n=2), 
osteopathy (n=1) and children’s coach (n=1). The price per children’s coaching session is valued at the price for a 
session of ‘remedial therapy.’
b Time investigated by parents in homework assignments was valued as opportunity costs for housework [219] 
c To account for differences between age groups and gender in productivity costs, the mean productivity costs for 
the age group 35 to 40 years were used
d Productivity losses for unpaid work consisted of time invested by parents into a visit to the clinic (including travel 
time). These costs were valued as opportunity costs for housework [219]
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Data analysis
Health outcomes, resource use and costs
Intention-to-treat analyses were conducted based on group allocation, regardless of actual 
intervention received or adherence to the intervention. One child was excluded for all 
analyses because just after start of treatment it was decided that he had not fulfilled all 
inclusion criteria. The between-group difference in percentage of non-stuttering children 
at 18 months, that was applied to calculate the NNT, was compared by a c2 test.  The level 
of significance was set at α=.05. 
Missing data are common in economic evaluations alongside RCTs and are due to 
incomplete questionnaires, participants who do not show up at measurement moments or 
who drop out from the trial. If those with complete data differ from those with incomplete 
data, bias may influence the results. Analysis of complete cases may also lead to a loss 
of statistical power. Therefore, missing data in QALYs and costs were multiply imputed. 
Multiple imputation is a technique is in which each missing value is replaced by at least 
one simulated value [220,221]. This technique reflects the uncertainty that is inherent when 
replacing missing data [220,222]. Usually, m=10 is found to be sufficiently large [223]. Thus, 
we created ten different data sets. We applied the commonly recommended Monte Carlo 
Markov Chain approach to impute missing data [224]. Variables included in the model 
were therapy, age at baseline, gender, stuttering severity ratings by clinician and parent, 
stuttering frequency, scores on the Child Behavior Checklist (CBCL) [194], HRQOL scores 
and costs. After the multiple imputation procedure, the estimates from the 10 different 
datasets were pooled using a formula described by Rubin [221].
Because of the skewed distribution of QALYs and costs, bootstrapping (1000 replications) 
was used to obtain 95% uncertainty intervals around the estimated means of QALYs and costs 
in both treatment groups. This was done for the 10 datasets that were obtained by multiple 
imputation. The resulting 10,000 (10x1000) bootstrap replications for the LP and RESTART-
DCM treatment were compared and the differences in QALYs and costs were calculated 
by the 95% uncertainty interval. Resource use was calculated on the observed data before 
imputation and compared by independent t-tests. The level of significance was set at α=.05. 
Cost-effectiveness and cost-utility
To estimate the incremental cost-effectiveness ratio (ICER) of the LP compared to RESTART-
DCM treatment, the difference in total costs between treatment groups was multiplied by 
the number of children that need to be treated by the LP in order to have one additional 
child defined as non-stuttering at 18 months post-treatment onset. The ICER thus expresses 
the extra monetary investment needed in order to have one additional child who did not 
stutter at 18 months. 
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To estimate the incremental cost-utility ratios (ICURs), results of the bootstrap replications 
were graphically plotted on cost-utility planes. These planes show the estimated incremental 
cost per QALY gained and display the uncertainty around the ratios. ICURs were calculated 
for QALYs based on the EQ-VAS (V-QALYs) and on the HUI3 (U-QALYs). In addition to the 
cost per QALY taking a societal perspective, we estimated the ICURs including only the 
direct costs. Acceptability curves (CEACs) were used to present the probability that the LP 
is more cost-effective than RESTART-DCM treatment for different values of the willingness-
to-pay threshold [88]. The WTP threshold represents the maximum cost a decision maker is 
willing to spend per unit of health outcome (i.e., QALY) gained by a new intervention. Thus, 
this is the maximum acceptable cost-utility ratio.
Sensitivity analysis
Two sensitivity analyses were performed to test the robustness of the results. In sensitivity 
analysis one (SA1), costs and QALYs in the second year were discounted. Discounting 
decreases the value of costs and benefits in after the first year. Costs in the period between 
12 and 18 months were discounted with 4% and QALYs achieved in this period with 1.5%. 
This is in line with Dutch guidelines [216]. In a second sensitivity analysis (SA2), the impact 
of imputation of missing data was tested by solely including children that completed the 
trial (i.e., complete case analysis). 
Statistical analysis
Analyses were performed using SPSS version 20 (Armonk, NY: IBM Corp.). CEACs were 
constructed using MS Excel 2010.
RESULTS
Participant flow and baseline characteristics
The participant flow of the 199 children randomized to the LP (N=99) and RESTART-DCM 
treatment (N=100) is presented in Figure 6.1. In total, 11 children missed one or more 
measurement moments and 21 children (11%) dropped out from the study. Reasons for 
not completing the trial included relocation (n=4), families being unavailable (n=6), lack 
of motivation for participation because of fluent speech (n=2), family problems (n=6), and 
one SLP who stopped participating in the trial shortly after inclusion of children (n=3). In 
total, 177 children completed the 18-month assessment (86 in the LP group and 91 in the 
RESTART-DCM treatment group). Children who completed the study and children who 
dropped out did not significantly differ on baseline characteristics. For 191 children, at 
least one outcome measurement after start of treatment and at least one cost booklet were 
available. They were therefore included in the economic evaluation. Baseline characteristics 
of all randomized children are presented in Table 6.2.
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• Not meeting   inclusion criteria   (n=220)
• Declined to participate  (n=58)
• Other reasons  (n=138)
Referred for treatment (n=615) 
Randomized  (n=199) 
Allocated to the LP (n=99)  Allocated   to RESTART -DCM treatment    (n=100)  
Lost to follow -up  (n=12) 
2 relocated   
3 not contactable  
5  withdrew due to private circumstances 
1 withdrew due to loss of motivation 
1  SLT stopped participation in trial  
Excluded from analysis  (n=1) 
Lost to follow -up  (n=9) 
2 relocated  
3 not contactable  
1 withdrew due to private circumstances 
1 withdrew due to loss of motiviation  
2 SLT stopped participation in trial  
Completed follow  -up   (n=91)Completed follow -up (n=86)
Changed from the LP to RESTART -DCM 12   
months  post randomization (n=1)
Three  months assessment available   (n=93) 
S ix   months assessment available (n=91) 
Twelve  months assessment available   ( n=83)  
Changed from RESTART -DCM treatment to 
the LP 12 months post randomiz ation  (n=1) 
Three  months assessment available (n=89) 
S ix   months assessment available  (n=91)  
Twelve months assessment available   (n=89) 
Included in intention  -to-treat analysis (n=96)  Included in intention  - to-treat analysis   (n=95)
FIGURE 6.1. RESTART trial enrollment, randomization, and assessment
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TABLE 6.2 Baseline characteristics of participants by treatment group
Characteristic Lidcombe Program  (n=98)a
RESTART-DCM treatment 
(n=100)a
Age in months, median; mean (SD) 51.0; 51.5 (9.5) 52.0; 54.1 (11.1)
Age in years   
3b 41 (41.8) 37 (37.0)
4 39 (39.8) 31 (31.0)
5-6 18 (18.4) 32 (32.0)
Male 68 (69.4) 70 (70.0)
SSI-3 score   
mildc 32 (32.7) 31 (31.0)
moderate 47 (48.0) 51 (51.0)
severe 19 (19.4) 18 (18.0)
% SS, median; mean (SD)d 4.9; 6.2 (4.4) 4.0; 5.3 (4.3)
Time since onset   
6-12 months 43 (43.9) 45 (45.0)
13-18 months 25 (25.5) 22 (22.0)
19+ months 30 (30.6) 33 (33.0)
Family history of persistencye 45 (45.9) 45 (45.0)
Family history of recoverye 27 (27.6) 25 (25.0)
Prior treatment for stuttering 8 (8.2) 6 (6.0)
a Data are shown as No. (%) unless specified otherwise
b One child in the LP group was 2.11 years at time of inclusion
d Children with a stuttering frequency < 3% in the therapy setting but ≥ 3% in the home setting were included in the 
group “mild stuttering”
d For one child in the RESTART-DCM group %SS on baseline was not available
e For one child in the LP group information on family history of stuttering was not available
Health outcomes
The percentage of children who did not stutter at 18 months has been reported in de 
Sonneville-Koedoot et al. [213] and were respectively 76.5% ((65/85)*100) in the LP group 
versus 71.4% ((65/91)*100) in the RESTART-DCM group. The difference of 5.1% was 
statistically non-significant (c2(1)=0.579, p=.45). The NNT was (1/0.051=) 20; i.e., if 20 
children are treated by the LP instead of RESTART-DCM treatment, on average one more 
child will be defined as non-stuttering after 18 months. 
Table 6.3 lists the EQ-VAS and HUI3 scores at baseline and at follow-up. Both groups 
started with relatively high mean HRQOL-scores at baseline and showed a slight increase in 
scores over time. The mean EQ-VAS score in the LP group was lower at baseline and higher 
at the end of the 18-month period than in the RESTART-DCM group; V-QALYs gained in 
this group were therefore slightly and significantly higher (LP: 1.36; RESTART-DCM: 1.34; 
difference: 0.018 (95% CI: 0.008 to 0.027)). The effect size was small (Cohen’s d=0.17; 
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[117]. For children aged 5 years and older, U-QALYs based on the HUI3 in 18 months were 
1.38 for the LP group and 1.37 for the RESTART-DCM group. The difference in U-QALYs did 
not reach statistical significance (0.013; 95% CI: -0.006 to 0.03). 
TABLE 6.3 HRQOL over the 18-month follow-up period
 
 
 
EQ-VAS HUI3
LP (n=98) RESTART-DCM treatment (n=100) LP (n=18)
RESTART-DCM treatment 
(n=33)
mean (SD) mean (SD) mean (SD) mean (SD)
Baseline 88.01 (9.86) 88.34 (9.69) 0.88 (0.13) 0.88 (0.11)
3 months 89.57 (10.24) 88.60 (10.61) 0.92 (0.12) 0.88 (0.15)
6 months 91.05 (7.40) 89.63 (8.85) 0.89 (0.13) 0.90 (0.11)
12 months 91.27 (9.15) 89.64 (11.96) 0.95 (0.09) 0.94 (0.10)
18 months 91.42 (8.81) 90.56 (9.60) 0.95 (0.10) 0.94 (0.10)
Abbreviations: EQ-VAS: EuroQol Visual Analog Scale; HUI3: Health Utility Index-3
TABLE  6.4 Mean resource use per child for both treatment groups during the 18-month follow-up 
period and the percentage of participants using this resource
Resources
 LP  
(n=98)
RESTART-DCM  
treatment (n=100)     
n mean SD n mean SD mean 95% UI
Direct health care costs
Stuttering treatment 
[sessions] 98 22.2 11.2 97 19.5 10.3 2.7 -.3 5,8 .08
Stuttering treatment 
[minutes] 95 1198 656 93 1080 584 117.7 -61.1 296,6 .20
Additional treatment 
[sessions]a 95 .38 1.60 92 .23 1.42 .1 -.3 ,6 .52
Direct non health care costs 
Travel by car 
[kilometers] 95 453.9 543.5 94 305.9 370.8 148.0 14.5 281,5 .03
Homework 
assignments [hours]b 92 59.9 62.3 92 62.6 58.3 -2.7 -20.3 14,9 .76
Indirect costs 
Absenteeism from 
paid work [hours] 95 1.39 4.27 93 1.75 5.24 -.4 -1.7 1,0 .61
Productivity losses 
for unpaid work 
[hours]d
95 32.5 22.8 93 25.5 19.6 7.0 .8 13,1 .03
Results in this table are based on analysis of observed data, before imputation. 
a Additional treatment as specified in Table 6.1
b For four children the number of hours invested in homework estimated by parents was unrealistically high, therefore 
these were defined as outliers and excluded from analyses
c Productivity losses for unpaid work consisted of time invested by parents into a visit to the clinic (including travel time)
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Resource use
Table 6.4 shows the mean utilization of resources in both groups over 18 months. Children 
in the LP group had slightly more treatment sessions (22.2) than children in the RESTART-
DCM group (19.5). The difference was not statistically significant (p=.08). The larger travel 
distance and higher productivity losses for unpaid work (i.e., time invested by parents into 
a visit to the clinic, including travel time) in the LP group compared to the RESTART-DCM 
group just reached statistical significance (p=.03 for both comparisons). 
Costs
Detailed cost comparisons are listed in Table 6.5. The average costs refer to the costs per 
child. The mean total costs for the LP group were significantly higher than for the RESTART-
DCM group (difference €168, 95% CI: €61 to €277), but the effect size was small (Cohen’s 
d=0.14). The higher costs were largely due to higher treatment costs and thus to a greater 
number of treatment sessions for the LP group. 
TABLE 6.5 Mean costs in Euros per child for both groups and difference between groups during the 
18-month follow-up period
 
LP 
(n=98)  
RESTART-DCM treatment 
(n=100) mean difference
mean s.e. 95% UI mean s.e. 95%  UI mean 95% UI 
Direct health care costs 1474 719 1430 1519 1334 645 1294 1374 140 80 201
Stuttering treatment costs 1422 693 1379 1465 1287 618 1249 1326 135 76 192
Additional treatment costsa 26 85 21 32 27 104 21 34 -1 -10 7
Extra material costs for 
therapy at home 25 41 23 28 19 29 18 21 6 3 9
Direct non health care costs 1177 728 1132 1223 1215 779 1167 1262 -38 -103 29
Travel costs (includes 
travel by car and by public 
transport)
111 109 105 118 79 71 75 84 32 24 40
Costs associated with time 
invested in homework 
assignments
1065 716 1022 1111 1136 760 1089 1183 -70 -134 -6
Total direct costs 2650 1047 2587 2716 2549 1130 2480 2619 102 6 197
Indirect costs 548 259 532 565 483 223 470 497 65 44 87
Costs associated with 
absenteeism from paid work 58 137 50 67 75 184 63 86 -17 -31 -3
Costs associated with 
productivity losses for unpaid 
work
490 248 475 507 409 206 396 421 82 62 102
Total costs 3199 1203 3125 3275 3032 1272 2955 3109 168 61 277
a Additional treatment as specified in Table 6.1
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Cost-effectiveness
Table 6.6 presents the difference in costs and effects as well as the incremental cost-
effectiveness ratio (ICER) and cost-utility ratios (ICURs) from a societal perspective and if 
only direct costs are included. Based on the NNT of 20 and the difference in costs of €168, 
the estimate of the incremental cost per NNT was (20 * €168 =) €3360. Thus, an extra 
investment of €3360 would result in one more child classified as non-stuttering with the LP 
compared to RESTART-DCM treatment. The incremental cost per V-QALY estimate (based 
on the EQ-VAS) was €10413 for the LP compared with RESTART-DCM treatment. For 
children aged 5 to 6 years, the ICUR based on the HUI3 amounted to €18617. Uncertainty 
around these ratios is illustrated in the cost-effectiveness planes (Figure 6.2 and 6.3). Each 
of the 10000 points represents a pair of incremental cost and effect value replicates for 
the LP group compared with the RESTART-DCM group, produced by the bootstrapping 
technique. Most cost-effect pairs for the ICUR are located in the northeast quadrant (99.8% 
of the ratios for cost per V-QALY and 89.2% for cost per U-QALY), indicating that the LP is 
associated with a higher HRQOL after 18 months and higher costs compared to RESTART-
DCM treatment. If only direct costs were included, the ICER was €2040, the ICUR based 
on V-QALYs €6373 and the ICUR based on U-QALYs €12110 (Table 6.6). Again, most cost-
effect pairs were located in the northeast quadrant: 98.2% and 75.1%, respectively (Figures 
A6.1 and A6.2 in the Appendix).
TABLE 6.6 Difference in mean health outcomes and costs (with 95% confidence intervals) and 
incremental cost-effectiveness ratios (ICERs) and cost-utility ratios (ICURs) of the LP group compared 
to the RESTART-DCM treatment group 
 Societal perspective Including only direct costs
Health outcomes   
Percentage of children who do not stutter at 18 months 5.1 (-0.08 to 0.18)
V-QALY (EQ-VAS) 0.018 (0.008 to 0.027)
U-QALY (HUI3) 0.013 (-0.006 to 0.03)
Costs (€)   
For all children 168 (61 to 277) 102 (6 to 197)
For children aged 5 to 6 years 228 (2 to 454) 90 (-102 to 279)
Cost-effectiveness ratios   
ICER: Costs per NNT 3360 2040
ICUR: Costs per extra V-QALY gained 10413 6373
ICUR: Costs per extra U-QALY gained 18617 12110
Abbreviations: EQ-VAS: EuroQol Visual Analog Scale; HUI3: Health Utility Index-3
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FIGURE 6.2 Cost-effectiveness plane for the difference in V-QALYs (based on EQ-VAS) gained in 18 
months
FIGURE 6.3 Cost-effectiveness plane for the difference in U-QALYs (based on HUI3) gained in 18 
months
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Figure 6.4 presents the CEACs for the ICUR based on V-QALYs and on U-QALYs. It shows 
the probability that the LP is cost-effective compared with RESTART-DCM treatment, at 
different levels of WTP for a QALY. At a societal WTP of €20.000 per V-QALY, the probability 
is 0.95. At a WTP of €35.000 per V-QALY, the probability rises to 0.99. For the WTP for a 
U-QALY these probabilities are 0.55 and 0.74, respectively.
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FIGURE 6.4 Acceptability curves for the LP compared to RESTART-DCM treatment
Sensitivity analysis
Results from SA1, in which costs and effects were discounted, were comparable with the 
results from the main analysis (data not shown). Complete case analysis (SA2) was done 
for the outcomes percentage of children classified as non-stuttering (LP: n=85, RESTART-
DCM treatment: n=91) and EQ-VAS (LP: n=61, RESTART-DCM treatment: n=67). For the 
outcome HUI3, complete data was only available for 21 children in the LP group and 12 
children in the RESTART-DCM group. Therefore, complete case analysis for this outcome 
was not performed. For the outcome percentage of non-stuttering children, the mean 
difference in effect for complete case analysis was similar compared with the main analysis 
(5.0% in favor of the LP, 95% CI: 1.1 to 8.9). The costs for the LP group were €2591 versus 
€2852 for the RESTART-DCM group. The mean cost difference of €260 (95% CI: €138 to 
€383) was larger than found in the main analysis. This resulted in a higher cost per NNT 
estimate than established in the main analysis: (20 * €260 =) €5200. For the health outcome 
V-QALYs, the mean difference in effect was 0.01 (95% CI: 0.002 to 0.02). Mean total costs in 
the LP were €2975 and in the RESTART-DCM group €2927 (difference: €48; 95%CI: -€67 to 
€169). This resulted in a lower estimate of cost per V-QALY than in the main analysis: €5410 
(i.e., extra costs of €5410 for each V-QALY gained).
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DISCUSSION
This is the first study to report both costs and effects of stuttering therapy in preschool 
children. It was demonstrated that, over the first 18 months after treatment onset, there is 
a high probability that the LP is slightly more costly than RESTART-DCM treatment but also 
leads to slightly better health outcomes. Differences in total costs and V-QALYs (quality-
adjusted life years based on the EQ-VAS) were statistical significant but effect sizes were 
small; percentage of children who did not stutter at 18 months and U-QALYs (based on the 
HUI3, only applicable for children aged 5-6 years) were not statistically significant between 
groups. Due to the marginal between-group difference in cost (€168), small differences 
in effects resulted in relatively low cost-effectiveness and cost-utility ratios. The costs per 
extra child classified as non-stuttering at 18 months with the LP compared to RESTART-
DCM treatment were €3360. The costs to obtain extra improvement in HRQOL by the LP 
compared to RESTART-DCM treatment were €10413 per extra V-QALY and €18617 per 
extra U-QALY. 
Study design
The RESTART-trial employed a practical study design, ensuring a high external validity 
and allowing for economic evaluation [220]. Unfortunately, the study did not provide an 
opportunity to evaluate the cost-effectiveness of stuttering treatment after the time horizon 
of 18 months. Treatment was not completed in 28% of children allocated to the LP and 
35% of children allocated to RESTART-DCM treatment [213], so total treatment costs are 
expected to incline after 18 months. Furthermore, follow-up data is needed to confirm 
the difference in percentage of non-stuttering children on longer term and to establish 
long-term HRQOL effects of stuttering. Our study into the HRQOL of adults who stutter 
has shown that mainly severe stuttering in adulthood is associated with a lower HRQOL 
[91]. Thus, in order to accurately predict the long-term comparative cost-effectiveness of 
stuttering treatment, data on stuttering severity, follow-up costs and health effects need to 
be incorporated, for instance in a statistical model. Anticipating on this, the slightly higher 
percentage of children on treatment at 18 months in the RESTART-DCM group suggests 
that the difference in treatment costs might further reduce. Moreover, if treatment effects 
would remain similar over life time, the 18-month time horizon possibly underestimates the 
difference in QALYs gained between therapies. For both reasons we consider our current 
estimate of the cost-effectiveness of the LP compared with RESTART-DCM treatment 
conservative; more favorable results for the LP would most likely have been obtained by 
applying a longer time horizon. 
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Health-related Quality of Life
Mean HRQOL values were high at baseline and increased only slightly during follow-up, 
resulting in almost comparable between-group EQ-VAS and HUI3 scores at 18 months. 
While this suggest that stuttering at preschool age does not generally impair HRQOL, 
several limitations to our assessment of HRQOL must be noted. First, in economic 
evaluations from a societal perspective, preference-based health state values are preferred 
over ratings of health states by patients or proxies (i.e., parents). Currently, however, no 
HRQOL instrument is available for QALY computation for children under the age of five 
years. This made the use of the proxy EQ-VAS version indispensable. It also yielded the 
only generic outcome applicable for all children under study. We transformed EQ-VAS 
scores into values applicable for QALY computation, which has also been done in other 
studies (e.g., [225]). Second, the overall increment in mean EQ-VAS score over 18 months 
in both groups was slightly lower than the increment in mean HUI3 score. This result may 
be attributed to limited responsiveness of the EQ-VAS to changes in mild problems, 
which arise as a result of the end-of-scale bias (see [88], and [91] for a discussion on this 
bias in relation to stuttering). Moreover, it is not evident that stuttering is perceived as a 
health problem by parents [226]. However, since the HUI3 scores at 18 months showed 
almost no differences in HRQOL between treatment groups for children aged 5 and 6 
years and the between-group differences in V-QALYs were comparable to the difference 
in U-QALYs, we believe that the use of the EQ-VAS (and, accordingly, the computation of 
V-QALYs) was warranted. A last limitation related to the HRQOL measurement is the use of 
proxies in general. It is known that the adequacy of proxy ratings may be confounded by 
characteristics such as parental emotions and stress [121-123].
Costs
Examination of the costs revealed that the total difference of €168 was mainly due to direct 
treatment costs being higher for the LP group (€1422 versus €1287). This was anticipated, 
since the LP is known to require a relatively long maintenance phase. It appeared that, 
although a slightly higher percentage of children in the RESTART-DCM group was on 
treatment at 18 months, children who terminated treatment in the LP group had on 
average followed more treatment sessions than children in the RESTART-DCM group. Few 
parents reported use of other healthcare services and costs for practice material were low 
for both groups. Time spent on homework assignments was less in the LP group than in 
the RESTART-DCM group (59.9 versus 62.6 hours). This probably reflects a difference in 
therapy method. RESTART-DCM treatment requires parents to spend 15 minutes a day on 
homework, while the LP gradually integrates the use of contingencies in daily activities. All 
parents may have had difficulties in estimating time spend on homework assignments, as 
indicated by the relatively high percentage of missing data for this resource use. 
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Exclusion of the homework related costs did not lead to different results (data not shown). 
Travel costs per session were higher for the LP group. Although this result was obtained 
coincidentally, it might also be the case in real world, since fewer Dutch SLPs are trained 
in the LP than in RESTART-DCM treatment. Thus, parents probably need to travel a longer 
distance in order to receive treatment according to the LP. The larger number of treatment 
sessions and travel costs associated with the LP resulted in higher total costs associated 
with productivity losses for this group, and thus in higher indirect costs. Exclusion of the 
indirect costs did not alter the conclusion that the LP was more costly. 
Cost-effectiveness
The benefit for the LP over RESTART-DCM treatment in terms of percentage children 
classified as non-stuttering and amount of QALYs gained was minimal, but so were the 
extra costs. Whether or not the LP can be regarded a cost-effective approach depends 
on the maximum willingness-to-pay for such small improvements in health. Extra costs 
to gain one extra case of non-stuttering were estimated at €3360. There is, however, no 
consensus about the maximum WTP for a clinical outcome as “non-stuttering”. Therefore, 
health economists prefer to express treatment benefits in a generic outcome such as the 
QALY. When evaluated against the threshold of €20.000 per QALY that is often suggested 
as an upper limit in the Netherlands, the results on the U-QALYs indicate a probability 
of 55% that the LP is a cost-effective therapy compared with RESTART-DCM treatment. 
This amounted to 74% using a threshold of €35.000. Based on V-QALYs, the LP would 
be considered cost-effective compared to RESTART-DCM at lower levels of WTP: 95% 
certainty for a WTP threshold of €20.000 and 99% for a threshold of €35.000 per QALY. 
Complete case-analysis resulted in even a lower ICUR, but this ratio is probably biased as 
a result of the small sample size. Different parents, different SLPs, and different health care 
funders will have individual perceptions and judgements on the clinical and financial value 
of these results. In addition, health care resources used and unit costs for other countries 
can differ somewhat, due to variation in organization and financing of health care. For 
Dutch daily practice, the results clearly indicate that the LP can be considered a cost-
effective alternative to RESTART-DCM treatment. 
An interesting future topic of research, that could result in potential cost savings, is to 
reconsider the relation between treatment duration and health outcomes. In both groups, 
quite a large number of children were still on treatment at the end of the trial, including 
about 20% of children who were classified as non-stuttering. This might suggest that 
criteria for terminating treatment in daily practice are too stringent. It can be questioned if 
active monitoring may not be as sufficient as active treatment in order to accomplish the 
goal of barely noticeable stuttering that both treatments strive for, a topic that is however 
beyond the scope of this study.
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CONCLUSIONS
In conclusion, differences in effects and costs between the LP and RESTART-DCM treatment 
were small and cost-effectiveness and cost-utility ratios were in favor of the LP. This indicates 
that the LP is a good alternative to RESTART-DCM treatment in Dutch primary care. 
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ABSTRACT
Purpose To explore the attitudes and beliefs of speech-language pathologists (SLPs) with 
regard to the Lidcombe Program (LP) and Demands and Capacities (DCM) based treatment, 
and how these might have changed as a result of participating in the RESTART-study. 
Methods A focus group meeting with 13 SLPs was organized. The discussion was structured 
using questions on therapy preference, attitudes about and explicit comparison of both 
treatments and treatment manuals, and learnings of trial participation.
Results Four main themes were identified. Firstly, a change in attitude toward treatment 
choice was observed. Secondly, this was related to a change in beliefs about the potential 
of both treatments. Thirdly, aspects of the treatments regarded as success factors were 
considered. Lastly, learning outcomes and increased professionalism as a result of 
participating in the RESTART-trial were discussed. 
Conclusions This study showed how attitudes and beliefs of SLPs with regard to the 
LP and DCM based treatment evolved during a randomized trial. This work increases 
our understanding of the role of attitudes and beliefs in the uptake and utilization of 
therapies and demonstrates the importance of collecting qualitative data. Results and 
recommendations should prove of value in implementing the RESTART-trial results and in 
training of SLPs.
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INTRODUCTION
Early intervention is currently considered best practice in therapy for children who stutter 
[10,184,227]; however, there is limited evidence as to the relative effectiveness of therapies 
for preschool children who stutter. A recent multicenter Randomized Controlled Trial (RCT) 
conducted in the Netherlands compared the effectiveness and cost-effectiveness of two 
widely applied therapies: treatment based on the Demands and Capacities Model (DCM) 
and the Lidcombe Program for early stuttering intervention (LP). The RESTART-study 
(acronym for the Rotterdam Evaluation study of Stuttering Therapy- A Randomized Trial) 
was conducted in the period September 2007 to December 2011. The study included a 
total of 199 preschool children who stutter and 24 speech-language pathologists (SLPs). 
Although a RCT is generally perceived to be the most highly regarded research method, 
it is also acknowledged that not all kinds of questions can be addressed by this method 
[228]. Moreover, daily clinical practice is known to be greatly influenced by subjective 
factors, such as a clinician’s own perceptions and experiences [229]. 
With DCM based treatment being the standard treatment in a large part of the world, and 
an increasing number of clinicians becoming experienced in the LP, a growing number of 
SLPs are nowadays in the position to make a choice between treatments. However, little 
research data is available as regards clinicians’ views on both treatments, factors governing 
their therapy selection process, or their treatment delivery. This is all the more relevant 
since these treatments are premised on different ideologies and, accordingly, apply a 
fundamentally different therapy approach [45,46]. DCM based treatment uses an indirect 
approach, based on the theoretical model that stuttering is a multifactorial disorder [52-54] 
with physical, linguistic, psychological, and/or environmental factors influencing the onset 
and development of stuttering. Accordingly, treatment focuses on manipulating child 
related and environmental factors assumed to influence the child’s speech fluency. Contrary 
to DCM based treatment, the LP directly targets the child’s speech fluency. Treatment is not 
explicitly based on a theory of the onset and development of stuttering, but assumes that 
manipulating the child’s speech production by using operant conditioning procedures will 
lead to increased fluency. One of the essential components of the LP is the use of parent 
verbal contingencies for stutter-free speech and for stuttering [48]. Thus, basically SLPs 
can choose between a more holistic and a more technical-behavioral approach to treat 
preschool children who stutter. Presumably it is their experiences, views and opinions that 
will shape their decisions in this matter.
Perceptions of clinicians or other stakeholders on stuttering treatment for children have only 
marginally been addressed in literature. There are no studies available on the perspectives 
of clinicians for DCM based treatment, while only three explorative studies addressed the 
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experiences of Australian SLPs with the LP. A study by Harrison, Ttofari, Rousseau, and 
Andrews [230] showed that the main reasons for SLPs consulting an expertise center were 
limited progress with the LP, or difficulties with the treatment when working with relatively 
unusual clients. Studies by Rousseau, Packman, Onslow, Dredge, and Harrison [231] and, 
more recently, O’Brian et al. [232], revealed that around half of the clinicians surveyed did 
not deliver the LP in the prescribed format. These examples illustrate that engagement of 
clinicians in the evaluation of a therapy can provide improved understanding of the uptake 
and utilization of that treatment. Evaluation of SLPs perceptions is also critical with regard 
to the translation of research evidence into practice. Strong personal preferences, non-
adherence to manuals or perceived barriers to treatment implementation can all influence 
how study results will find their way into daily practice. Since therapists participating in 
a trial could be regarded as “early adopters” [233], it is of particular relevance to obtain 
insight into their attitudes, beliefs and experiences. 
Therefore, it was decided to explore of the attitudes, beliefs and experiences of the 
clinicians participating in the RESTART-trial by means of a focus group study. By explicitly 
using group interaction as methodology, a focus group interview is an ideal way to generate 
qualitative good data about participants’ experiences and opinions on a defined set of 
issues [234,235]. The interaction between participants enables an in-depth discussion of 
issues, which can therefore lead to the generation of rich data [236]. The purpose of this 
focus group study was to explore the attitudes and beliefs of SLPs participating in the 
RESTART-trial with regard to the LP and DCM based treatment (RESTART-DCM based 
treatment1), and how these might have changed during their experiences of participating 
in the trial. The questions used for the focus group discussion are outlined in the methods 
section. 
METHODS
Participants
Twenty-four SLPs throughout the Netherlands participated in the RESTART-study. All had 
received training for DCM based treatment in their regular education and in addition had 
followed the formal LP training. In the final phase of the project (once the inclusion of 
children had ended and the final cohort was completing the last measurements), the SLPs 
still involved in the project (n=20) were invited to attend the focus group meeting. Thirteen 
SLPs participated in the focus group. All but one was engaged in the RESTART-study from 
the beginning of the trial. Demographic characteristics are displayed in Table 7.1. 
1 Whenever we refer to treatment based on the Demands and Capacities Model as it has been adapted for use in 
the Netherlands, we describe it as ‘RESTART-DCM treatment’ [188].
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TABLE 7.1 Demographic characteristics of participants
Characteristic Mean (range)
Female; No. (%) 13 (100%)
Age in years 50 (43-63)
Years of experience DCM based treatment 14.5 (7-21)
Years of experience LP 3.0 (1.5-7.0)
Work in private practice; No. (%) 13 (100%)
Note. Data are shown as mean (range) unless specified otherwise
Procedure
Participation in the focus group was voluntary. To compensate for loss of income and 
travelling expenses, participants received a small fee. The focus group was held at the 
location as where participants had had regular quarterly meetings during the trial and 
lasted approximately 2 hours and 45 minutes (with a 15 minute break). A protocol outlining 
the relevant themes and order in which they were to be discussed was developed by the 
authors. Since participants had met each other in quarterly discussion meetings during the 
previous 3 years and 10 months of the trial, the researchers and participating SLPs were 
quite familiar with each other. While this created a comfortable setting for discussion, it also 
brought the risk of bias in the data (for example, participants would not feel comfortable 
expressing their true feelings about the project, or presumed shared understanding might 
inhibit expressing shared experiences). Therefore, the focus group was moderated by an 
experienced senior researcher, unknown to the participants. She had been informed about 
the therapies and RESTART-study by the other authors. Assistant interviewers were the first 
and last author. The first author is the primary investigator; the last author is the initiator of 
the RESTART-study and also a SLP. 
In the focus group meeting, the interviewers adopted the role of process facilitators 
(checking time, ensuring the protocol was followed, asking follow-up questions, etc.) and 
were conscious of being open to accommodate both positive and negative experiences 
expressed by the informants. They were also conscious of the importance of encouraging 
the participants to express views of a different nature, including both positive and 
negative views. Participants who were relatively quiet were encouraged to contribute to 
the discussion by the interviewers particularly inviting them to respond to the question at 
hand. After discussion of each question, and before moving on to the next question, the 
moderator explicitly asked if anyone wanted to add anything else to the discussion. Where 
appropriate after discussion of a specific question, the moderator counted and recorded 
the number of participants holding a particular view.
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The set of questions a-priori formulated for the discussion covered the following main 
themes:
·	 Therapy preference -LP versus RESTART-DCM- prior to the RESTART-study. What 
determined their choice and in which situations did the therapists choose to deviate 
from the therapy they generally preferred? 
·	 Therapy preference in the final stage of the RESTART-study.
·	 Overall impression of and attitudes to both therapies prior to the RESTART-study, and 
how these may have changed during the trial (e.g., flexibility, level of difficulty, goals 
that could be achieved).
·	 Attitudes to both treatment manuals (e.g., feasibility, clarity, completeness).
·	 Explicit comparison of treatments and treatment manuals (e.g., components that are 
unique and/or essential for therapy success, common elements, time investment for 
SLPs).
·	 Experiences with the trial and recommendations for follow-up research.
Data analysis
The interview was recorded (audio only) with permission of the respondents and transcribed 
verbatim by the first author. The first and second author independently coded the 
transcripts (manually) in two phases following Creswell’s [237] ten steps for qualitative data 
analysis. The first coding phase was an inductive phase in which the transcript of the focus 
group was reviewed for recurring themes related to the questions addressed in the focus 
group discussion. Each author made a coding list of primary and secondary themes that 
emerged from the data. These were discussed to standardize terminology and ensure that 
both coders applied the terms in a consistent manner. The transcript was then revisited and 
coded with the standard terminology and then discussed by the authors a second time. 
The predominant themes that emerged were then written in a thematic content analysis by 
the first and second author. To ensure investigator triangulation, this analysis was checked 
and commented on by the third and fourth authors (one of whom had been present at the 
focus group meeting). This served as internal peer review of the interpretation of the data 
[237]. The focus group quotes were translated from Dutch to English by the second author 
(a native speaker of English, with certified fluency in Dutch) and checked for accurate 
use of nuance and diction by the first and last authors (native Dutch speakers). All data 
(recordings and transcripts) were treated confidentially in accordance with institutional 
policies for storing and analyzing data. All personal identifiers that could link statements 
to respondents have been removed in this manuscript; participants are identified by a 
number.
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RESULTS
Four main themes emerged from the analysis of the focus group interview. The themes are 
described in Table 7.2 and summarized and exemplified with quotes below. 
TABLE 7.2 Overview of findings
Themes Subthemes
(1) Changing attitudes towards the 
choice of treatment
·	 Strength of specific preferences had decreased
·	 More nuance and flexibility
·	 Parent’s preferences and child-specific criteria play greater role
(2) Changing beliefs about the 
potential of the treatments
·	 Increased awareness of structure of RESTART-DCM treatment
·	 More flexibility in applying RESTART-DCM treatment
·	 Slightly more positive about the LP than before
·	 Appreciation of clear structure of the LP
·	 Appreciation of rapid effect of the LP
·	 Limited possibilities of LP in case of lack of progress
(3) Attitudes towards success 
factors of the treatments
·	 Key-factors RESTART-DCM: slowing down tempo of speech 
and communication, training in turn taking, changing aspects 
of parent-child communication (e.g., applying basic rules for 
communication
·	 Key-factors LP: Verbal contingencies, structure of stage 2 for 
monitoring fluency maintenance
·	 Similarities between RESTART-DCM treatment and the LP:
1. Initial one hour weekly sessions;
2. Parents are trained to practice with their child at home in 
one-to-one situations;
3. 15 minutes of practice every day;
4. Overall intensity of time investment for parents is the 
same;
5. Importance of pleasant parent-child interaction;
6. Aim is to increase fluent speech;
7. SLP needs to constantly refine the treatment to enhance 
fluency.
(4) Learning outcomes and 
increased professionalism as 
a result of participating in the 
RESTART-trial
·	 Now start clinical contact with a comprehensive assessment of 
the child’s speech and language
·	 Increased expertise with RESTART-DCM treatment due to 
working with the manual
·	 Regular meetings with clinicians led to increased learning
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1. Changing attitudes toward the choice of treatment 
Seven therapists reported they had a preference for RESTART-DCM treatment before the 
start of the trial, five had a preference for the LP and one said she had no preference at all. 
Although four therapists reported a slight change of general preference from one therapy 
to the other, all therapists revealed that, in contrast to the beginning of the trial, their 
preferences and decisions to use one method or the other now reflected more nuance and 
flexibility; the strength of a specific preference had decreased. 
For the majority of the therapists, their former preferences were mainly constituted by 
personal perceptions, while post-trial, other factors had become more important in 
selecting a treatment. For example, participants who preferred RESTART-DCM treatment 
at the start of the trial, mentioned specific perceptions of this treatment, for example it was 
familiar to them and more comprehensive than the LP. Participants who preferred the LP, on 
the other hand, most often mentioned the clarity and structure of the program.
I (…) It just ‘suited’ me and I was familiar with it. I could use it in any situation. (resp 12, 
explaining her former preference for RESTART-DCM treatment)
At the final stage of the trial, therapists indicated being open to starting with either therapy 
and giving more weight to what suits a specific child and family.
I actually no longer really have a preference. I think that I give the parents and the child 
more room to decide and that the choice depends less on me. (resp 1, explaining the 
change experienced during the trial)
Thus, when selecting a treatment program for a preschool child who stutters, in general 
the therapists at the end of the trial applied different criteria to their starting criteria. All 
participants indicated that they discuss both therapies with parents and let preferences 
of parents play an important role in the choice for a specific therapy. Moreover, several 
therapists mentioned greater use of child-specific criteria on which they now base their 
choice. Six therapists mentioned that they were inclined to start with RESTART-DCM 
treatment in younger children because of the more indirect approach of the therapy. Other 
child-specific factors mentioned that influence choice of therapy were stuttering severity 
(two participants said that in case of mild stuttering they would start with RESTART-DCM 
treatment), abilities and temperament of the child (two participants said that they who 
would start with the LP in precocious children), speech and language problems (as an 
indication to start with RESTART-DCM based treatment; mentioned by one participant) and 
the child’s attitude regarding his/her speech abilities (mentioned three times). However, 
therapists did not agree on how the child’s attitude influences their current therapy choice: 
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in case of a negative speech-attitude, two SLPs would prefer RESTART-DCM treatment 
while one SLP would prefer the LP. 
2. Changing beliefs about the potential of the treatments
The focus group discussion brought up that, for the majority of therapists, changes in 
attitudes toward treatment selection as described above were related to subtle changes in 
beliefs about the potential of both therapies. Participants felt that participating in the trial 
broke through preconceptions about the therapies. That is, the aspect of randomization 
forced them to abandon their initial attitudes about what would be the best treatment for a 
specific child, and the results they achieved with either therapy showed them more clearly 
the potential of each therapy in its own right. We discuss each of these in turn. 
With regard to RESTART-DCM treatment, the most important theme that emerged during 
the discussion was that the therapists had an increased awareness of how the therapy was 
structured. This was a result of working with the treatment manual that was constructed 
for the trial, as well as of shared insights and experiences from other therapists during the 
quarterly meetings with the group of participating therapists. Some therapists specifically 
mentioned the clear structure of the theoretical framework of the RESTART-DCM treatment, 
while others pointed to the practical tools it affords and the basis it provides for explaining 
the therapy to parents.
In the past, I never really felt that I had a theoretical basis for what I was doing. It was 
piecemeal – I pulled one part from one book and one from another and shaped these 
into some sort of coherent approach. Now, I have a integral approach in my head and 
can select what I need. (resp 2)
I have the feeling that I am now more convincing as a therapist in my conversations with 
parents. I have something to offer. (resp 12) 
However, the structure of the RESTART-DCM treatment manual did not lead to rigidity in 
adopting the DCM approach. Rather, therapists mentioned an increase in flexibility due to 
the structure and clearness of the manual.
DCM based treatment is much clearer now, partly because of the protocol and the 
discussions we had. Where it used to be fairly open with regard to what you can do with 
DCM – you could call almost anything DCM – or at least, that seemed to be the general 
feeling that I experienced, now I have a clearer perception of what it is. So, ok, that is 
how we approach it, those are the things that we are looking at. (resp 5)
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As this participant mentioned, the RESTART-DCM treatment manual was instrumental in 
providing structure to the treatment. It was described as clear and full of practical tips, 
but the participants also recognized that not all aspects of therapy can be covered in a 
manual. It was a useful starting point, but also provided therapists the room to shape their 
own approach in practice. How they did this, generally depended on their education, prior 
experience and beliefs.
For example, look at the emotional capacity. When you are working with that aspect, 
you use all the knowledge of the child that you have at that moment. But the treatment 
manual is not a pre-programmed instruction. (resp 1)
In addition to the perceived structure of RESTART-DCM treatment, a few therapists 
mentioned that their focus in therapy had shifted from decreasing the demands on the 
child to a combination of decreasing the demands and increasing the child’s capacities. 
Language training in particular has become a more prominent goal for therapists. 
With regard to the LP, in general, therapists were slightly more positive about the program 
than they had been before. They appreciated the clear structure and the perceived effect 
of the therapy within a relatively short period. They stated that the LP provided a very 
clear method for parents to work with. However, some therapists also reported the limited 
possibilities of the program if there is no, or minimal, progress in fluency in the first few 
months. They considered this was mainly related to the explicit goal of the LP as well as 
to the operant method ( i.e., applying verbal contingencies to effectuate fluent speech). A 
lack of progress in the first months of the LP can also lead to decreased motivation on the 
part of parents, as mentioned by one participant.
With Lidcombe, you are pretty much stuck with the contingencies. And, of course, at a 
certain moment, those contingencies lose their effect! When it takes longer. (resp 12)
(...) I personally feel that I now have a better idea about the danger signals. Within the 
first three months, it should be working! And then you just have to be stricter, otherwise 
you do indeed lose the effect of the contingencies. (resp 2)
Three participants mentioned a positive side-effect of the LP, namely parents spontaneously 
praising their child in other situations than when their child speaks stutter-free.
When the parents say something like, “I’ve been giving more compliments or have 
become nicer or more patient (…) in general in my parenting.” (resp 6)
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(…) That parents indeed say, “You have done that well!” But then about something 
completely different. That they are actually delivering contingencies for just about 
everything is quite funny, actually. (resp 2)
3. Attitudes toward success factors of the treatments
Key features of RESTART-DCM treatment which were mentioned as unique for this therapy 
are: slowing down the tempo of speech and communication, training in turn taking, 
and teaching parents to intentionally change aspects of their communication with their 
child (e.g., applying basic rules for communication and/or change specific aspects of 
communication that are supposed to trigger stuttering). The group discussion made clear 
that participants did not consider these factors as the only success factors; in their view 
there is no one factor which holds the key to success for RESTART-DCM treatment. One 
comment from the therapists: 
Parents are also transformed into good communicators. (resp 2)
signals how participation in the process increases the communication skills of parents.
For the LP, a key factor for success was generally agreed to be the verbal contingencies, 
which are an essential part of the treatment [68]. Contingencies both after stutter-free 
speech as well as after unambiguous stuttering were considered to be necessary. Next to 
the contingencies, another factor considered as unique to the LP is the structure of transfer, 
especially in stage 2.
What I actually like, and what is really a part of Lidcombe, is stage 2. I often criticize it 
but….(resp 13)
What? (resp 10)
Stage 2. That it is structured and clear. Uh, that the line for the parents is short and 
simple: is it still going well, yes or no? That you are able to make a gradual transition 
and also have a good idea of when to sound the alarm. (resp 13)
This participant is referring to stage 2 of the LP where guidance is offered to the SLP for 
monitoring the process of fluency maintenance. Less stable fluency or a relapse could 
quickly be detected and result in taking a step back in the treatment process. 
In addition to the focus on the unique therapy aspects, the moderator asked about 
similarities between the RESTART-DCM treatment and the LP. Seven similarities were 
mentioned (see also Table 7.2): 
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1) Both treatments start with one hour weekly therapy sessions;
2) Parents are trained by the SLP to practice with their child at home;
3) Parents practice with their child 15 minutes each day;
4) Overall, the intensity of time investment for parents is the same (although according 
to the group RESTART-DCM treatment requires a greater time investment of parents at 
the early stage of therapy, while the LP takes a longer follow-up);
5) Both treatments stress the importance of a pleasant interaction between child and 
parents. Within RESTART-DCM treatment it is stressed that a child should feel “heard 
and seen”, especially during Parent-Child Interaction time, while the LP stresses the 
importance of the child’s enjoyment when practicing fluent speech with the parent;
6) Both therapies aim to increase fluent speech;
7) Both treatment regimens require the SLP to constantly refine the treatment in order to 
enhance the child’s fluency. 
4. Learning outcomes and increased professionalism as a result of participating in 
the RESTART-trial
The majority of participants mentioned that, due to their participation in the RESTART-trial, 
they now begin their clinical contact with a comprehensive assessment of the child’s speech 
and language, whereas beforehand they felt the urgency to start treatment as soon as 
possible (often because of parents’ concerns and their request for therapy). The extensive 
assessment period enables the therapist to monitor the child’s fluency over a few weeks. 
As already mentioned in the Introduction, in quite a few cases fluency spontaneously 
increased during the assessment period, thereby reducing the urgency to start treatment 
immediately (see the flow chart in[213]). Additionally, language assessment and video 
recordings of the parent-child interaction provide valuable diagnostic information which is 
helpful for therapists in their treatment decisions.
Yes, I now easily start with a series of tests. During the first meeting I ask, “What do you 
want to know before leaving here today?” Because I think, maybe they already have an 
urgent question, and if so, I want to answer it. But I’m now more relaxed and patient 
about the rest of the process. (resp 9)
About three contact moments, just to see if…(co-interviewer)
Yes. And also to decide which method I will use. I think it is important to invest time in 
figuring that out now. (resp 9)
Two other learning outcomes of participating in the RESTART-trial were that (1) participants 
felt that working with the RESTART-DCM treatment manual that was designed for the trial 
had increased their expertise with regard to this treatment, and (2) participants were able 
to learn through interaction with each other during the regular meetings. The increased 
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expertise with RESTART-DCM treatment has already been addressed above (see theme 
2. Changing beliefs about the potential of the treatments). In addition, all participants 
recommended that, in order to provide high quality RESTART-DCM treatment, a 2-3 day 
course should be provided based on the RESTART-DCM manual (as is at present the case 
for the LP). Participants assumed this would be helpful not only for SLPs who start to treat 
preschool children who stutter, but also for SLPs who already work according a DCM 
approach. With regard to the latter learning outcome, the following two quotes clarify how 
the regular meetings provided both a safe environment to exchange experiences and the 
emergence of a shared basis for discussion: 
And discussing cases regularly on the basis of the treatment manual. That is, that you 
also have this shared basis from which you discuss cases. That also provided a real 
added value for me. (resp 2)
(...) And what I personally think is great is that in our discussion meetings, that openness 
and safe feeling of exchanging experiences with colleagues – that this was possible and 
that the discussions were really useful - at least in my opinion. And that’s really great. 
(resp 11) 
DISCUSSION
This article reports the results of a focus group study that explored the attitudes, beliefs, 
and experiences of therapists participating in a RCT of stuttering therapy in preschool 
children who stutter. The results showed unequivocally that changes in attitudes and beliefs 
on RESTART-DCM treatment as well as on the LP had occurred due to their experiences 
in the trial. In particular, the potential that each treatment offered had become clearer 
over the course of the trial. This was mainly due to treating children as dictated by the 
randomization of treatments (whereby SLPs had to abandon their respective preferred 
treatment program), working intensively with both treatment manuals and meeting 
regularly to discuss and reflect on the interventions. The RESTART-DCM treatment manual 
which was developed at the start of the trial also contributed to enhanced insight into 
the opportunities of this treatment approach. Whereas prior to the trial nearly all SLPs 
had a preference for one of the treatments, in the final phase of the trial this preference 
no longer existed. Instead, all SLPs stated that their choice would now be determined by 
child-specific factors and the preference of the parents. A prevalent learning outcome for 
most participants in the RESTART-trial was the benefit of the comprehensive pre-therapy 
assessment. Not only did this result in a firm basis for therapy decisions, it also showed the 
relatively high percentage of children whose stuttering frequency decreased during this 
period and thus did not require immediate treatment. As a result of their participation in the 
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trial, participants shared the feeling that they were able to provide a higher quality of care 
because they were more flexible and more client-centered when considering treatment.
For example, participants in the focus group mentioned several child-related factors that 
they perceived to be important when considering a treatment. These factors included age, 
stuttering severity, capacities and temperament, speech- and language problems, and the 
child’s speech attitude. The factors age and stuttering severity were included in the analyses 
of our trial data but they did not predict recovery with one of either treatment. However, 
this might also be due to a lack of statistical power to prove significance for subgroup 
analysis (see [213]). In the past decade several researchers have tried to unravel the 
complex relationship between stuttering and temperament (e.g., [100,101,238]), speech 
attitude [95,96] and/or speech- and language difficulties [31,32]. However, if and how 
these factors precisely interact, as well as their potential influence on treatment outcome, 
is still unclear. Future studies could investigate the impact of the factors perceived to be 
relevant for treatment outcome by the participants on long-term outcomes of the LP and 
RESTART-DCM treatment. 
Three other findings related to the LP deserve attention. Firstly, several SLPs noticed that 
parents of children in the LP spontaneously began to praise their children outside the 
context of practicing fluent speech, in situations where a child showed other positive 
behavior (for instance, for putting away their toys). This observation might indicate a more 
general change in parent-child interaction during the course of the LP treatment. If and 
how this influences the child’s fluency is beyond the scope of this study; however, it has 
been discussed in the literature that it is not yet known which components of the LP lead 
to successful therapy outcomes [207,209]. Treatment factors underlying both the RESTART-
DCM treatment and the LP, such as an increase in self-efficacy because the child feels better 
“seen and heard” by the parent, might partly account for positive treatment outcomes. A 
second finding related specifically to the LP that was brought up by the focus group was 
uncertainty as to what action to take if progress within the LP slows down or ceases and 
the child is not yet speaking fluently. This difficulty is also acknowledged by the Lidcombe 
group and was put forward to argue the need for more evidence on the mechanisms of the 
LP by Hayhow [207]. Lastly, the SLPs noted the significance of stage 2 of the LP in reaching 
fluency and preventing relapse to occur. In contrast, an explorative study by Rousseau et al. 
[231] into the experiences of Australian SLPs with the LP revealed that about 30% of SLPs 
did not deliver therapy in stage 2 as it is intended to. 
Interestingly, the shift from “therapeutic-centered care” (What suits me as a therapist?) 
to “client-centered care” (What suits the client?) shows the transition from the primarily 
perception-based practice which existed among Dutch SLPs to a more evidence-
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based approach. Through participation in the trial, SLPs learned to look beyond their 
preconceptions and became willing to incorporate trial outcomes into their current practice. 
Since the participants consisted of pioneers within the field, this attitude shift can be of 
great value in implementing the results of the RESTART-trial, for instance in their lectures, 
courses, workshops, and other interactions with students. Together with this attitude shift, 
participation in the trial generally enhanced the clinical practice of participants and led to 
surprising learning outcomes with regard to the RESTART-DCM treatment, even though it 
has been the standard treatment in the Netherlands for the last decades. The authors share 
the strong belief of the participants that a course of several days should be made available 
for every SLP who starts working with this approach to better grasp the comprehensiveness 
and potential of this treatment, and thus ensure maximum benefit from the program. An 
explorative study by O’Brian et al. [232] showed significant effects of training on treatment 
outcomes for the LP. Education, whether it is a LP training or a DCM based treatment 
course, is best be followed by regular meetings to discuss specific issues related to 
treatment. If meetings are guided by a researcher with clinical experience, this type of 
training could lead not only to creating a degree of uniformity of clinical practice and 
enhancing professionalism in the field, but also to bridging the gap between research and 
practice by allowing opportunities for SLPs to extend their role to that of clinician-scientist.
At a more general level, the results of this focus group study demonstrate that qualitative 
research within the field of speech-language pathology can enhance the value of the more 
common quantitatively-orientated research. Where results of quantitative research provide 
insight into the what and where questions, reflection by SLPs on their current practice 
provides insight into the why and how questions such as “Why do therapists work in the 
way they do?’ and ‘How do therapists perceive different components of treatments?”. 
Thus, it reveals (sub)conscious ideas underlying the professional activities of SLPs. Besides, 
a qualitative study can make the learning outcomes of participation in a clinical trial visible. 
Since there are few clinical trials in the field of speech- and language pathology, insight 
into these experiences are important for the interpretation of study results and the setting 
up of future trials.
The limitations of this study need to be considered. Firstly, the results presented in this 
study are limited to the attitudes of SLPs who participated in the RESTART-study. Since they 
had been actively working with both treatment manuals during the trial period, they were 
a source of rich information concerning both treatments and their comparison. However, 
it would be valuable to investigate if SLPs outside the RESTART-trial (or even outside the 
Netherlands) share similar attitudes on both treatments to the participants in our study. 
Comparing such attitudes would give insight into how far the evidence-based climate in 
the field of speech-language pathology (and stuttering therapy in particular) is currently 
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established. Another possible limitation of the study is the fact that there was a single 
meeting for the focus group discussion. An additional meeting, or in depth interviews with 
all participants, might have led to more detailed insight into attitudes of participants on the 
discussed topics. However, we feel confident that there was sufficient time for discussion 
as well as an open atmosphere in which SLPs could freely discuss their attitudes and 
beliefs about the two treatments. This was due to the familiarity of the setting and to the 
moderator and assistant interviewers being conscious of the importance of encouraging 
participants to express both positive and negative views.
In conclusion, this study showed evidence of the evolution in attitudes and beliefs of Dutch 
SLPs with regard to two widely applied therapy programs for young children who stutter: 
RESTART-DCM treatment and the LP. It showed specifically that the SLPs are open to an 
evidence-based approach in the field of speech and language therapy. This work increases 
our understanding of how attitudes and beliefs of therapists play a role in the uptake and 
utilization of therapies and demonstrates the benefit of qualitative research. The results 
and recommendations should prove of value both in implementing the RESTART-trial 
results and in training of SLPs.
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INTRODUCTION 
Prior to the start of this thesis, the body of evidence to support clinical decision making 
by speech-language pathologists (SLPs) was limited. Rigorous clinical studies were scarce 
and little attention was given to evidence based practice (EBP) in speech-language 
pathology. Accordingly, decision making by SLPs was primarily opinion- and experience-
based. The field of developmental stuttering was no exception. In the past decade, the 
health care system has been changed drastically. Rising medical costs have induced an 
increasing emphasis on value for money in reimbursement decisions and, consequently, 
on the empirical validation of treatments. Reimbursement of speech-language treatment 
has become under pressure. The Dutch government introduced a plan to cut down 
reimbursement from the year 2015, but to date these plans have not been implemented. 
Meanwhile, EBP has gradually emerged within the field of speech-language pathology, 
as for instance reflected by the number of publications on this topic. A PubMed search 
revealed that, of a total of 74 scientific publications on EBP and communication disorders, 
20 have been published before and 54 since the year 2007.1 Results of the first phase III 
randomized trial into stuttering treatment in children have been published in 2005 [6], and 
in 2014 a guideline for the treatment of developmental stuttering was published [65]. It was 
the first mono-disciplinary guideline for speech and language disorders in the Netherlands, 
however, most of its recommendations were still based on limited evidence.
This thesis addressed two main gaps in the evidence base for stuttering treatment. First, 
outcome studies have traditionally focused on stuttering symptoms. Broad, patient 
reported, outcome measures like quality of life have not often been applied, while such 
instruments provide essential information on the impact of the disorder on daily living; 
information that is increasingly demanded by policy makers. Second, while it is generally 
agreed that developmental stuttering should be treated in the preschool years [11,184], 
little is known about the effectiveness of available treatments for young children who stutter. 
A systematic review and meta-analysis by Nye et al. [66] concluded that, in the limited data 
available, the Lidcombe Program offers the best empirically supported intervention, and 
that there is insufficient data using high research standards to support the effectiveness of 
other treatment approaches. The main objective of this thesis was to fill these two gaps by 
studying the impact of stuttering and the effectiveness and cost-effectiveness of treatment 
in preschool children. 
1 Search string: evidence-based practice [Title/Abstract] AND (speech language [Title/Abstract] OR stuttering 
[Title/Abstract]). 
146 | Chapter 8
This chapter discusses the main findings of this thesis and the relevance for the evidence 
base underlying stuttering treatment decisions. Furthermore, it describes methodological 
issues and implications for clinical practice and policy making. The chapter concludes with 
recommendations for future research.
MAIN FINDINGS
In the study presented in chapter 2 we found that stuttering did not affect the health-
related quality of life (HRQOL) of children in the preschool years. However, in our study into 
the HRQOL of adults who stutter (chapter 3) we found that severe persistent stuttering was 
associated with a reduced HRQOL. The impact of mild and moderate stuttering appeared 
to be limited. Coping style appeared to be related to HRQOL in almost equal amounts as 
stuttering severity. One of the instruments applied in this study was the Dutch OASES for 
adults (OASES-A-D), which is a questionnaire to comprehensively measure the impact of 
stuttering on a person’s life. The psychometric properties of the OASES-A-D were assessed 
in a separate study, of which the results are presented in chapter 4. The OASES-A-D was 
found to be a reliable and valid tool to assess the impact of the stuttering disorder on daily 
living (chapter 4). 
The current standard treatment for preschool children who stutter in the Netherlands is 
treatment based on the Demands and Capacities model (DCM), hereafter referred to as 
RESTART-DCM treatment. In the RESTART-trial, we showed that the Lidcombe Program 
(LP) is an effective and cost-effective alternative to RESTART-DCM treatment (chapter 5 
and 6). The LP decreased stuttering frequency more quickly during the first three months 
of treatment. At 18 months, clinical outcomes were comparable, though most outcome 
measures were slightly in favor of the LP. In both treatment groups, stuttering frequency 
hardly further diminished after three months, while about 30% of children was still on 
treatment at 18 months. Costs for one additional child who stopped stuttering with the 
LP as well as extra costs per QALY, were favorable for the LP compared to RESTART-DCM 
treatment. Participating in a randomized trial appeared to affect the process of individual 
clinical decision making, as discussed in chapter 7. 
In the next part I will elaborate on these findings by discussing three themes that emerged 
from this thesis. These themes addressed the following topics: (1) when to initiate treatment; 
(2) which treatment to choose; (3) how to improve the therapy process. 
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STRENGTHENING THE EVIDENCE BASE FOR STUTTERING TREATMENT
Early intervention for developmental stuttering 
It is current standard practice to treat children who stutter in the preschool years [11,184]. 
Arguments for early intervention are primarily based on studies showing that the chance 
of recovery decreases with time since stuttering onset [34,44]. Our results support the 
need for early intervention, as persistent severe stuttering was associated with a significant 
impact on HRQOL. Treating children in the preschool years reduces the likelihood that 
stuttering becomes persistent and has a negatively impact on daily living. 
Despite the apparent need for early intervention, instant treatment for every child that 
stutters who presents to the clinic is usually not required. A relatively large number of 
children recover spontaneously, and delaying treatment for one year is not associated 
with a worse treatment outcome [239,240]. Besides, the results presented in chapter 2 
suggest that the well-being of children is hardly affected at preschool age. This suggests 
that treatment may well be preceded by a period in which the child’s stuttering is solely 
monitored. Treatment would then only be required if natural recovery failed to occur. 
Monitoring a stuttering child in the first year after onset is also recommended in the current 
guideline [65]. Obviously, high parental concerns or a clear burden on the child in the first 
year after onset could be reasons to start treatment earlier.
Findings presented in this thesis suggest that Dutch SLPs are generally inclined to start 
treatment earlier than the proposed waiting time of one year. The slow inclusion of children 
in the RESTART-study was for a great part related to a relatively high percentage of children 
whose fluency increased spontaneously during the comprehensive assessment phase at 
baseline, thereby reducing the urgency to start treatment (chapter 5). The focus group 
discussion that was held in the context of the RESTART-trial (chapter 7) confirmed that 
most SLPs were used to start treatment as soon as possible before participating in the trial, 
often because of parents’ concerns and their request for therapy. In the final phase of the 
trial, most participating SLPs had integrated the comprehensive assessment of the child’s 
speech and language in their routine practice. This enabled them to make more informed 
decisions on the start and choice of treatment. 
Selecting a relevant treatment
Currently, most Dutch children are treated according to a DCM based approach. This thesis 
showed that the LP is a good alternative to DCM based treatment. Children in the LP group 
even improved slightly more in fluency as well as on most secondary outcomes, although 
the differences did not reach statistical significance (chapter 5). Mean total costs per child 
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were only marginally higher for the LP group (chapter 6). The mean difference of €168 may 
diminish in the long term, as slightly more children in the RESTART-DCM group were on 
treatment at 18 months. Although our results do not conclusively prove that the LP and 
RESTART-DCM treatment are equivalent options, there is sufficient evidence to support the 
implementation of the LP in current Dutch practice. If the LP would be available on a large 
scale, there will be freedom of choice to decide on what works best for an individual child 
and the family, which in turn creates opportunities to tailor therapy to individual needs. 
 Since the results do not indicate a clear preference for the LP or RESTART-DCM treatment, 
we concluded that shared decision making by SLP and parent is recommended. The 
results of the focus group meeting showed that, in the final phase of the trial, participating 
SLPs gave a great weight to child-specific factors and the preference of the parents in 
selecting a treatment (chapter 7). Factors that may be important for parents are related to 
type of treatment, parent’s abilities, duration and costs. The result that the LP decreased 
stuttering more rapidly during the first three months might be an argument for parents to 
prefer the LP. We incorporated the child-specific factors age, stuttering severity, and time 
since onset in our analyses in chapter 5, but none of them were related to differences 
in treatment outcome with the LP or RESTART-DCM treatment. Inspection of the data, 
however, showed a possible effect of severity, with a higher percentage of children who 
initially stuttered severe classified as non-stuttering at 18 months in the RESTART-DCM 
group. The lack of statistical significance for this analysis might be due to the small groups 
resulting of splitting up severity groups. Thus, our results so far do not enable us to provide 
recommendations on whether particular child-specific factors are relevant with regard to 
decisions on selecting the LP or RESTART-DCM treatment. 
In sum, our findings do not favor either the LP or RESTART-DCM treatment for preschool 
children who stutter and support a shared decision making by parents and clinician in the 
process of selecting a treatment.
Improving the therapy process
The RESTART-trial revealed two other findings relevant for future improvement of stuttering 
treatment in preschool children. 
The first result is related to the professional standard of DCM based treatment. The focus 
group meeting revealed that, before the RESTART-trial, and accordingly before SLPs 
started working with the RESTART-DCM manual, there was a perceived lack of guidance 
to take decisions on which components of the comprehensive framework to choose for 
an individual child. The RESTART-DCM treatment manual appeared highly instrumental in 
providing structure to the treatment. Working with this manual led to an increased insight 
into the comprehensiveness and potential of this treatment, and accordingly to a higher 
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level of expertise. Of note is that the group of participating SLPs in the RESTART-trial 
consisted of clinicians who had many years of clinical experience with DCM based treatment. 
This led us to conclude that, although DCM based treatment is the current Dutch standard 
for treating preschool children who stutter, there is considerable potential to increase the 
professional level of SLPs outside the RESTART-trial working with this approach.
The second finding refers to the data on stuttering frequency presented in chapter 5, which 
suggests that cost-effectiveness of treatment might be improved by reducing treatment 
duration and/or intensity. The largest speech improvement was obtained in the first three 
months after treatment onset. There was only a very gradual decrease in stuttering frequency 
in the following 15 months, while about 30% of children was still on treatment at 18 months. 
The merits of extending treatment beyond three months are doubtful, especially if one 
considers that the impact of mild and moderate stuttering on quality of life is negligible. 
In Dutch daily practice, the reimbursed number of stuttering treatment sessions is not 
restricted by health care policy. Criteria to terminate treatment are generally related to 
the objective of reaching fluent speech. For RESTART-DCM treatment, active monitoring 
instead of weekly treatment sessions during the very gradual improvement phase may be 
sufficient to prevent relapse and effectuate the gradual normalization of speech fluency. 
Regarding the LP, maintenance treatment is an important aspect of behavioral treatment, in 
order to reduce the risks of a relapse. However, there may be potential to reduce the length 
or intensity of the maintenance phase. A study by Rousseau et al. [231] showed that about 
30% of children treated with the LP in Australia did not participate in Stage 2 (maintenance 
phase) at all. 
Relevant in this regard is the topic of how to define normally fluent speech that is usually 
strived for. This is an ongoing topic of debate in literature [241-243]. The mean %SS in 
both treatment groups in our study had already dropped to about 3% SS after three 
months of treatment, which has been suggested to be the upper limit for normally fluent 
speech. Non-stuttering at 18 months was defined as less or equal than 1.5% SS, based on 
a recent study by Clark et al. [191] showing a mean frequency of 1.5% SS in CWNS. The LP 
manual that was applied in our study [48] specifies a slightly stricter goal of treatment: no 
stuttering, defined as a frequency less or equal than 1% SS, which must be maintained for a 
long time. As a result of this discrepancy, over 20% of children in the LP group classified as 
not stuttering anymore was still on treatment at 18 months post-treatment onset. Although 
criteria to withdraw and terminate RESTART-DCM treatment are less strictly defined, 
an approximately similar percentage of children classified in our study as not stuttering 
was still on treatment at 18 months. So, explicit or implicit criteria on fluency applied in 
stuttering treatment might be too stringent in light of the study by Clark and colleagues. 
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Considering also the possibility that recovery toward fluency -in whatever way defined- 
will not stop if therapy intensity is reduced (it may just take maturation time for the very 
mild stuttering to completely disappear), reconsidering the criteria to terminate treatment 
seems warranted. 
METHODOLOGICAL CONSIDERATIONS 
Methodological considerations related to the RESTART-trial 
Designing and conducting an RCT with a piggyback economic evaluation brings along 
several challenges and, accordingly, choices to be made. 
One challenge we faced was related to defining and measuring stuttering, which is, as said 
above, an ongoing topic of debate in literature [241-244]. Our primary outcome measure 
was based on the calculation of the mean stuttering frequency in daily conversational 
samples by expert raters. This measure does not take into account non-observable stuttering 
behaviors like facial movements, nor the duration of the stuttering events. Nevertheless, 
since it is known that stuttering in young children mainly constitutes of observable 
disruptions in the flow of speech (i.e., repetitions of sounds and syllables, prolongations, 
and/or blockages), stuttering frequency is the most widely applied outcome measure in 
research into childhood stuttering. Another choice regarding the primary outcome was 
the cut-off score. We chose a cut-off score of 1.5% SS [191], but, as said above, there is 
a grey area between about 1% and 3% SS. Applying a cut-off score of ≤ 1% SS or ≤ 2% 
SS did, however, not affect our results (chapter 5). This strengthens our finding that both 
treatments are comparably effective after 18 months of therapy. 
In designing a trial with a piggy back economic evaluation, the concepts of internal and 
external validity comes into play. Whereas an RCT generally aims for a high internal 
validity in order to establish treatment efficacy (i.e., the extent to which an intervention 
is beneficial under ideal conditions), a cost-effectiveness study desires a high external 
validity. Outcomes obtained under conditions close to daily practice have the potential to 
assist clinicians, clients and policy makers in making informed decisions that will improve 
health care at both the individual and the population level. On the efficacy-effectiveness 
continuum, our study-design was more toward the effectiveness-end. Sufficient internal 
validity was obtained by, among others, the process of randomization, the use of the 
RESTART-DCM manual, and regular contact with participating SLPs to enhance treatment 
fidelity. We achieved high external validity by, among others, sampling procedures to 
enroll participants that were representative of the clinical population, and SLPs offering 
the treatment as they would do in daily practice. Despite these achievements of external 
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validity, the effect of participation in a trial for SLPs and parents on the generalizability of 
our outcomes cannot be totally ruled out. For instance, treatment adherence rates might 
have been higher than in daily practice. In addition, participating SLPs probably differs 
from other SLPs in some respect, e.g., with regard to their level of experience and their 
attitude toward letting go of preferences for either treatment option. Furthermore, chapter 
7 showed that SLPs became more proficient in clinical decision making and delivering 
treatment during the trial. It remains unclear whether this might have influenced the results; 
possibly the obtained percentages of children who did not stutter anymore at 18 months 
in our study are slightly higher than in daily practice.
Methodological considerations related to quantifying the impact of stuttering 
on daily living
Generic preference-based HRQOL instruments can be used to generate QALY estimates 
and thus to compare the impact of stuttering to that of other conditions on the same scale. 
However, the use of these instruments requires addressing several issues, most of which are 
related to the concept of validity. In chapter 2 and 3 we already addressed some of these 
issues, like the differences in results obtained by different HRQOL measures. This section 
will discuss three other, more generic, validity issues. 
A first issue in the context of validity of HRQOL instruments is that these instruments need 
to be sensitive and specific enough to pick up small differences that are of importance to 
people living with the condition [245], in this case stuttering. It is questionable if generic 
HRQOL measures incorporate relevant domains that sufficiently capture the social and 
psychological well-being effects associated with stuttering. The impact of stuttering may 
be best assessed by condition-specific HRQOL measures, yet this kind of instruments do 
not exist. The OASES-A-D incorporates one section on quality of life and, due to the broad 
range of questions, provides a comprehensive assessment of the impact of stuttering on a 
person’s life. This instrument is therefore relevant for use in clinical practice, but it cannot 
be used to capture the benefits of stuttering interventions in terms of QALYs. 
A second validity issue relates to the measurement of HRQOL in children, which is generally 
acknowledged to be complex. Several problems have been raised in the literature. Briefly 
discussed, they relate to (1) a lack of consensus on the conceptual definition of HRQOL as it 
relates to children [246]; (2) the proxy issue [247]; and (3) the suitability of HRQOL measures 
adapted from instruments initially developed for adult populations [248,249]. With regard 
to the latter, the health state descriptions of the HUI3, applied in the study in chapter 2, 
may not fully reflect the health dimensions applicable to young children [245]. 
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Thus, to adequately measure the effect of stuttering (treatment) on HRQOL by preference-
based measures, we are in need of an instrument that includes relevant domains, can 
detect a small change in health state, and can be applied in young children. At present, an 
instrument possessing all these characteristics seems not to exist. Since the HUI3 includes 
domains on speech and on psycho-social aspects, and since this instrument showed some 
variability in our study, the HUI3 might be the current best available alternative instrument 
in this regard [151,245].
Nevertheless -and this is the third issue related to validity- it is open to discussion whether 
preference-based generic HRQOL measures could be capable of determining the impact 
(or value) of stuttering at all. Since people who stutter can face many hurdles in verbal 
communication throughout the day, stuttering may well be a “high attention grabber” 
for an individual who stutters. As proposed by Paul Dolan, adaptation - the process of 
adjustment to new or changed circumstances - to a condition that potentially has such a 
high impact on the frequency, intensity and duration of one’s thoughts and feelings is rather 
difficult [148,250]. Adaptation is probably further hampered by the variable character of 
the stuttering severity. This is probably quite hard to estimate for the general public, whose 
preferences are used to express the relative desirability -value- of different health states in 
generic preference-based HRQOL measures as the HUI3. As a result, the general public 
might overestimate the HRQOL of people who stutter. However, the potential influence of 
stigma on preference-based generic HRQOL values might work out the other way around. 
That is, public stigma related to stuttering (e.g., in the form of negative stereotypes, 
prejudice, and discrimination [251,252]) might degrade HRQOL values for stuttering given 
by the general public. 
An appealing alternative in this regard might be to use ‘‘patient preferences”. However, it 
has been argued that preference-based valuations obtained in patients suffer from the same 
problem as those obtained in the general public: the values elicited reflect imaginations 
about the impact of a health state when people are focusing attention on the impact 
[253]. Thus, they do not reflect the (future) value while experiencing a particular health 
state. Dolan [253] argues that these values are therefore not useful in establishing “how 
severe different conditions are when they drift in and out of attention in the day-to-day 
experiences of life” ([253], p.2). Dolan claims that we should seek for more direct measures 
of the value associated with different health states, like directly measuring happiness 
[250,253]. It is conceivable that a high attention-seeking condition like stuttering will have 
a greater impact on happiness than, for instance, suffering from some problems walking 
about. This new avenue might therefore be of great relevance to the field of stuttering. 
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IMPLICATIONS
Clinical implications
At present, most Dutch SLPs are trained and experienced in DCM based treatment, which 
forms a part of their regular education. As discussed above, there is sufficient evidence to 
support the uptake and utilization of the LP in current Dutch practice. In particular, SLPs 
who currently only provide DCM based treatment should be encouraged also to become 
a LP certified clinician by following the Lidcombe Program training. The LP should also 
receive considerable attention in regular educational programs. 
With regard to DCM based treatment, SLPs should be encouraged to apply the RESTART-
DCM manual. This is expected to lead to more uniformity and transparency in the goals, 
content and principles of the treatment. This, in turn, can facilitate communication and 
negotiations with other players in the field, like other health care providers and decision 
makers. Developing a course based on the RESTART-DCM manual for SLPs who starts 
working with this treatment is highly recommended. 
This thesis brought about several aspects of clinical decision making in stuttering that must 
also be faced by the professional community in the field of speech-language pathology. 
First, EBP prescribes incorporation of preferences and values of patients in treatment 
decisions. Based on our result we strongly propose shared decision making by SLP and 
parents in the process of selecting a relevant treatment for an individual child. This is in line 
with the recently published Dutch guideline on developmental stuttering [65]. Second, in 
light of arguments of cost-effectiveness, criteria for initiation and termination of treatment 
deserve more attention of experts in the field of stuttering. These aspects have not 
yet gained much attention from clinicians. In order to address them, it is vital that SLPs 
acknowledge the relevance of research in this area. 
Hopefully this thesis has not only contributed to a growing evidence base, but also 
toward helping SLPs to develop an evidence-based mind-set. In this regard, it is highly 
recommended that SLPs who participated in the RESTART-trial will be involved in the 
implementation of our study results and in the initiation of further research. Not only does 
this group of SLPs consist of “early adopters” [233] who can inspire change among the 
majority of SLPs, chapter 7 also revealed that they had made a transition from a primarily 
opinion-based practice to a more evidence-based approach as a result of their participation 
in the trial. As such, they prove to be a valuable example in EBP for colleagues. If SLPs can 
achieve not only to provide excellent care but also to improve the efficiency of care, they 
will have a competitive position in negotiations with insurance companies and health care 
policy makers.
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With regard to treatment for adults who stutter, our results suggest that assessment of 
stuttering in adult clients should explicitly address potential quality of life impairments 
as well as coping style as one of its determinants. The importance of a multidimensional 
approach addressing quality of life has already been acknowledged by the guideline 
[65]. Although further research on test-retest reliability and potential improvements for 
decreasing the length of the OASES-A-D would be useful, we consider the OASES-A-D a 
valuable tool for comprehensively assessing the impact of the stuttering disorder in clinical 
practice. The relevance of addressing coping style, which was equally related to HRQOL as 
stuttering severity, should be more clearly articulated in the guideline. Treatment aimed at 
decreasing stuttering severity and increasing adequately coping strategies might possibly 
result in the best chances for enhancement of a person’s quality of life. 
Implications for policy makers
Given the small differences in effects and costs, we propose that the LP and RESTART-
DCM treatment both remain in the basic health insurance package. Supporting the 
implementation of the LP and training SLPs in the RESTART-DCM method is associated 
with additional costs, but could eventually lead to better quality of care and potential 
reductions in health care expenditures, since SLPs mastering both type of treatments are 
more flexible in selecting the appropriate treatment and adjusting the treatment according 
to individual needs. 
Cost-effectiveness alone is never sufficient for rational decision making on reimbursement of 
treatments. In particular, the burden of a disease is known to interact with cost-effectiveness 
considerations. The higher the burden of disease, the more willing society is to accept a 
poor cost-effectiveness. This can be shown by the example of Viagra, which is known to 
be highly cost-effective but is not collectively reimbursed [254,255]. Lung-transplantation, 
on the other hand, is known for its unfavorable cost-effectiveness, yet the reimbursement 
is no matter of debate [256]. Our studies showed a high HRQOL, and thus a low burden 
of disease, in children who stutter in the preschool years, but a higher burden of disease 
for adults with persistent stuttering. Persistent stuttering has also shown to be related to 
substantial health care costs [212], while chapter 6 of this thesis showed that the absolute 
costs of stuttering treatment in the preschool years were relatively low (about €3000 in 18 
months). Therefore, we strongly recommend full reimbursement of stuttering treatment in 
the preschool years. In case parents should pay treatment for their stuttering preschooler 
by themselves, they possibly will wait too long to seek treatment, thereby increasing the 
chance that stuttering will be more difficult to treat. On the other hand, because of the 
high chance of spontaneous recovery in the early years [12,34], treating many children 
that would recover spontaneously anyway is neither regarded a cost-effective strategy. 
Encouraging SLPs to follow the guideline by Pertijs et al. [65] in the process of clinical 
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decision making regarding treatment onset could be a cost-effective way to promote 
effective and efficient healthcare [257].
The relatively high disease burden in terms of HRQOL associated with severe stuttering 
in adulthood yields also an argument in favor of reimbursing (effective) treatments for this 
population. Disease burden associated with mild and moderate stuttering appeared to be 
low, however a limitation of our study is that we only applied subjective stuttering severity 
measures. Furthermore, other criteria that were outside the scope of this thesis (e.g., 
treatment effectiveness and cost-effectiveness) are of course also relevant in reimbursement 
decisions on treatment for adults who stutter.
RECOMMENDATIONS FOR FUTURE RESEARCH
Besides providing valuable new insights into the impact and treatment of stuttering, this 
thesis offers several avenues for future research. 
First, the very slight differences in outcomes between the LP and RESTART-DCM treatment 
suggest to investigate the underlying factors that contribute to a positive treatment 
outcome. Further research could explore if prognostic indicators of spontaneous recovery, 
like a shorter time since onset or recovery of stuttering in the family, or aspects related to 
the child’s speech-language profile, can also predict treatment outcome– regardless from 
the provided therapy. Exploring treatment agents, including common factors, underlying 
the LP and RESTART-DCM treatment is another interesting research area in this regard. 
Especially for those children who are likely to recover spontaneously, common factors may 
be enough to accelerate the process of recovery. Since there is still much to be learned on 
the nature of the stuttering disorder and the role of treatment in recovery, this kind of data 
could be of great value.
Second, further research should address the efficiency of treatment by determining whether 
treatment duration or intensity can be reduced, without reducing treatment effectiveness. 
This avenue of future research could result in a relatively large reduction of treatment costs. 
Third, the need for early intervention could be justified by research on the long term effects 
of treatment in the preschool years. Besides following the children that participated in 
the RESTART-study, which is planned to be initiated, a model-based study incorporating 
data from the RESTART-trial and HRQOL data of adults who stutter could quantify the 
gains of early intervention in terms of prevented HRQOL losses associated with persistent 
stuttering. 
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CONCLUDING REMARKS
The overarching goal of every discipline in health care is maximizing value for patients. 
How to define value is yet a topic of continual debate. Ask a patient, a health care provider, 
a policy maker and a health economic researcher, and you will probably get four different 
answers. This thesis aimed to bridge the gap between different stakeholders in the field 
of developmental stuttering by strengthening the evidence base and addressing various 
aspects of the “value” of stuttering and its treatment. There are still steps to be taken 
in order to improve the care of people who stutter. This is only possible through active 
collaboration between different stakeholders in the field. Clinicians, researchers, policy 
makers, people who stutter and their families can help this process along- and all will 
benefit from doing so.
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SUMMARY
Stuttering is a developmental disorder characterized by an abnormally high frequency of 
disruptions in the flow of speech. Stuttering onset is most likely in children between three 
and five years of age. About 5 to 11% of all children stutter at some time in their life. Most 
children outgrow the disorder of stuttering before the age of 10 years. Although several 
factors related to a higher chance for recovery have been identified in the past decennia, 
it cannot be predicted whether a child will recover naturally. The chance for complete 
recovery diminishes as children grow older, and persistent stuttering is assumed to 
negatively impact on a person’s daily life. Therefore, stuttering is generally recommended 
to start in the preschool years (before the age of six years). 
This thesis is devoted to studying the impact of developmental stuttering in childhood and 
adulthood, and the outcomes of treatment in the preschool years. Chapter 1 introduces 
and motivates this thesis. It describes that the introduction of evidence based practice (EBP) 
in the paramedical field led in the nineties to a growing awareness among speech- and 
language pathologists (SLPs) to incorporate scientific evidence in their clinical decisions. 
However, a decade ago high quality evidence to support treatment decisions was still scarce. 
Policy changes in healthcare and overall increasing health care expenditures exposed the 
urgency of research on effects as well as on costs of alternative treatment strategies. The 
field of developmental stuttering was no exception with respect to the poor evidence base 
underlying clinical decision making, as explained in chapter 1. It is substantiated that there 
is a need for data on the disease burden associated with stuttering, as well as high standard 
research into the effectiveness and cost-effectiveness of treatment in the preschool years.
Chapter 2 to 4 of this thesis focus on the impact of stuttering on daily living. Chapter 2 
explores the burden of stuttering in terms of health-related quality of life (HRQOL) among 
preschool children. Parents of children participating in the RESTART-study, a randomized 
controlled trial into stuttering treatment in preschoolers, filled in several questionnaires on 
the HRQOL of their children. Data collected before the start of treatment were compared 
to HRQOL data of a reference population of Dutch children who did not stutter. Results 
indicate that the HRQOL of preschool stuttering children is comparable to that of non-
stuttering children. Furthermore, stuttering severity and time since onset of stuttering were 
not related to HRQOL scores. It was concluded that, generally speaking, the HRQOL of 
preschool children who stutter is not diminished. However, only a small number of children 
with severe stuttering participated in this study. Therefore, we recommend future research 
including a larger cohort of children with severe stuttering. In a future study, it would also 
be relevant to study the course of HRQOL over time and incorporate additional parameters 
such as characteristics of the child and his environment.
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Chapter 3 shows that, if stuttering persists into adulthood, the impact on HRQOL becomes 
more prominent. In the study presented in this chapter, 91 adults who stutter participated. 
They were partly recruited informally, and partly from stuttering and/or speech- and 
language therapy centers throughout the Netherlands. By a comprehensive approach their 
stuttering severity, functioning, HRQOL and coping style was investigated. Particularly 
severe stuttering was found to be related to a lower HRQOL. Not only the speech domain 
of one of the HRQOL instruments (HUI3) showed lower values for higher stuttering severity, 
but also the emotional and social domains. On two instruments (EQ-VAS and OASES-A-D), 
the scores of adults in therapy indicate a significant higher impact on daily living than the 
scores of adults not in therapy. Results show that coping style was equally strongly related 
to HRQOL as was stuttering severity. In particular, higher scores on the emotion-oriented 
subscale of the CISS coping instrument (reflecting a more negative way of dealing with 
emotions) were correlated with lower HRQOL values.
The studies described in chapter 2 and 3 applied generic HRQOL questionnaires. That is, 
they measured HRQOL in terms that are relevant to everyone. Generic instruments can 
therefore be applied in all kind of populations. Disease specific instruments, on the other 
hand, include only domains that are deemed to be relevant to people with the disorder 
under study. Preferably, a combination of generic and disease specific instruments is applied 
in the assessment of HRQOL. However, no Dutch validated stuttering specific HRQOL 
instrument was available at the time we conducted our studies. A few years before starting 
our study, the English OASES for adults was developed and psychometrical validated. The 
OASES is a broad instrument, including a section on the measurement of quality of life. It 
provides information on the experience of the stuttering disorder from the perspective of 
the adult who stutter himself. Chapter 4 described the translation of the OASES into Dutch 
and the examination of the psychometric properties of this instrument. The Dutch OASES 
for Adults (OASES-A-D) was found to be a reliable and valid instrument for providing a 
comprehensive assessment of how stuttering affects the lives of individuals who stutter. 
All sections of the OASES-A-D were able to differentiate between groups of participants 
with different levels of stuttering severity. We concluded that the OASES-A-D could be 
valuable in clinical practice to assess the impact of stuttering on daily living, although 
further research on the test-retest reliability and potential improvements for decreasing the 
length of the instrument is recommended.
Chapter 5 to 7 of this thesis were devoted to the RESTART trial (Rotterdam Evaluation study 
of Stuttering Therapy in preschool children- A Randomized Trial). In this 18-month trial, 199 
preschool children who stuttered for at least six months were randomized to the Lidcombe 
Program (LP) or treatment based on the Demands and Capacities Model (RESTART-DCM 
based treatment). The latter has been the Dutch standard treatment for preschool children 
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who stutter since the eighties. It is an indirect approach, in the sense that treatment focuses 
on manipulating child related and environmental factors assumed to influence the child’s 
speech fluency. In contrast, the LP is a direct approach that targets the child’s speech 
fluency directly by means of behavioural modification (i.e., treatment based on operant 
conditioning). The interventions were offered by 24 SLPs in private practices throughout 
the Netherlands. Health outcomes and costs were evaluated at baseline and 3, 6, 12, and 
18 months after the start of treatment. 
Chapter 5 describes the results of the comparative effectiveness of the LP and RESTART-
DCM treatment. The primary outcome measure was the percentage of children who did 
not stutter at 18 months. Secondary outcome measures included stuttering frequency, 
stuttering severity ratings by the parents, therapist, and child, HRQOL, emotional and 
behavioral problems, and speech attitude. Treatment by the LP decreased stuttering 
more quickly than RESTART-DCM treatment during the first three months of treatment. 
At 18 months, however, clinical outcomes for both treatments were comparable. Slightly 
more children in the LP group were defined as non-stuttering compared to the RESTART-
DCM group (76.5 and 71.4%, respectively) but this was a non-significant difference. We 
concluded that both treatments are roughly equal in treating developmental stuttering in 
ways that surpasses expectations of natural recovery. An interesting finding was that, for 
both treatment groups, the largest speech improvement was obtained in the first three 
months after treatment onset and that there was only a very gradual decrease in stuttering 
frequency in the following 15 months, while about 30% of children was still on treatment 
at 18 months.
Chapter 6 reports on the results of an economic evaluation that was conducted alongside 
the RESTART-trial. The total 18-month costs were related to the number needed to treat 
(NNT; the number of children who need to be treated with the LP in order to have one extra 
child defined as non-stuttering at 18 months post-treatment onset, compared to RESTART-
DCM treatment), and to quality adjusted life years (QALYs) based on the measurement of 
HRQOL. Since HRQOL values were high at baseline, only slight gains in quality of life were 
established during the follow-up. At 18 months, health outcomes were slightly better in 
the LP group, but differences were statistically and/or clinically not significant. Total costs 
were somewhat higher for the LP group. The difference in costs could possibly diminish in 
the long term, as slightly more children in the RESTART-DCM group were on treatment at 
18 months. Based on the NNT of 20 and the difference in total costs of €168, the estimate 
of the incremental costs per NNT was €3360. Thus, an extra investment of €3360 would 
result in one more child classified as non-stuttering with the LP compared to RESTART-
DCM treatment. The costs to obtain extra improvement in HRQOL by the LP compared to 
RESTART-DCM treatment were €10413 per extra V-QALY and €18617 per extra U-QALY, 
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which indicates good cost-effectiveness of the LP. Based on the results presented in chapter 
5 and 6, it is concluded that LP is a good alternative to RESTART-DCM treatment in Dutch 
primary care.
Decisions on treatment selection and implementation of study results are known to 
be influenced by ideas, perceptions and experiences of clinicians. Chapter 7 therefore 
describes the results of a focus group meeting, in which participating SLPs discussed their 
attitudes and beliefs with regard to the LP and RESTART-DCM treatment, and how these 
might have changed as a result of participating in the RESTART-trial. The results show 
that, in the final stage of the trial, participating SLPs found themselves to be more flexible 
and more client-centered when considering treatment. The potential that each treatment 
offered had become clearer over the course of the trial. Whereas prior to the trial nearly 
all SLPs had a preference for one of the treatments, in the final phase of the trial this 
preference had diminished. Instead, all SLPs stated that their treatment selection would 
now be determined by child-specific factors and the preference of the parents. 
Chapter 8 discusses three themes that emerged from this thesis, related to (1) early 
intervention; (2) selecting a treatment, and (3) improving the therapy process. First, as 
persistent severe stuttering in adulthood was associated with a significant impact on 
HRQOL, this supports the need for early intervention. The HRQOL of preschool children who 
stuttered was found to be hardly affected, indicating that treatment may well be preceded 
by a period in which the child’s stuttering is solely monitored, as also recommended in the 
current guideline on stuttering. Second, our findings do not favor either the LP or RESTART-
DCM treatment for preschool children who stutter and support a shared decision making 
by parents and clinician in the process of selecting a treatment. Third, the therapy process 
can be improved by encouraging the use of the RESTART-DCM manual by SLPs who want 
to treat a child according to a DCM method, as well as by reconsidering the merits of 
treatment beyond three months. Methodological issues related to the RESTART-trial and 
to quantifying the impact of stuttering on daily living are also discussed in chapter 8. In 
particular, validity issues regarding the use of HRQOL measures to assess the impact of 
stuttering are considered. The chapter concludes with implications for clinicians and policy 
makers, and recommendations for future research. There is sufficient evidence to support 
the uptake and utilization of the LP in current Dutch practice. Given the small differences in 
effects and costs, we propose that the LP and RESTART-DCM treatment both remain in the 
basic health insurance package. Future research should investigate the underlying factors 
that contribute to a positive treatment outcome, whether treatment duration or intensity 
can be reduced without reducing treatment effectiveness, and the long term effects of 
treatment in the preschool years.
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SAMENVATTING
Stotteren is een ontwikkelingsstoornis die gekenmerkt wordt door onderbrekingen in 
de vloeiendheid van de spraak. Stotteren ontstaat meestal tussen het derde en vijfde 
levensjaar. Ongeveer 5 tot 11% van alle jonge kinderen stottert een bepaalde periode. De 
meeste kinderen groeien er overheen voor de leeftijd van 10 jaar. Ondanks dat er factoren 
bekend zijn die de kans op herstel van stotteren vergroten, is het niet te voorspellen of 
een kind over het stotteren heen zal groeien. De kans op volledig herstel neemt af met de 
leeftijd. Blijvend stotteren wordt in verband gebracht met negatieve gevolgen voor het 
dagelijks leven. Het wordt daarom aangeraden om behandeling voor stotteren te starten 
in de voorschoolse leeftijd, dat wil zeggen voor de leeftijd van zes jaar.
Dit proefschrift richt zich op het onderzoeken van de impact van ontwikkelingsstotteren 
op de voorschoolse en volwassen leeftijd en op de uitkomsten van behandeling in de 
voorschoolse leeftijd. Hoofdstuk 1 is een inleidend hoofdstuk, waarin de motivatie voor het 
onderzoek uiteen wordt gezet. De introductie van evidence based practice (EBP: op bewijs 
gebaseerd handelen door een therapeut) in de paramedische sector in de jaren negentig 
leidde tot een vergroot bewustzijn onder logopedisten om wetenschappelijk bewijs te 
integreren in het klinisch handelen. Desondanks was er begin deze eeuw nauwelijks 
bewijs van hoog wetenschappelijk niveau voorhanden. Veranderingen in het beleid en 
stijgende kosten van de gezondheidszorg leidden verder tot een toenemende vraag naar 
op bewijs gebaseerde zorgverlening. In hoofdstuk 1 wordt uitgelegd waarom er enerzijds 
meer gegevens nodig zijn over de invloed die stotteren heeft op het dagelijks leven en 
anderzijds meer gedegen onderzoek nodig is naar de effectiviteit en kosteneffectiviteit van 
behandeling in de voorschoolse leeftijd.
De hoofdstukken 2, 3 en 4 hebben betrekking op de impact van stotteren op het 
dagelijks leven van personen die stotteren. Hoofdstuk 2 verkent de impact van stotteren 
op kinderen in de voorschoolse leeftijd in termen van gezondheidsgerelateerde kwaliteit 
van leven (KVL). Ouders van 199 kinderen die deelnamen aan de RESTART-studie -een 
gerandomiseerde gecontroleerde studie waarin de behandeling van stotteren bij jonge 
kinderen is geëvalueerd- vulden verschillende vragenlijsten in over de KVL van hun 
kinderen. De gegevens die voorafgaand aan de behandeling werden verzameld, werden 
vergeleken met KVL gegevens van een groep niet stotterende Nederlandse kinderen (een 
zogenoemde vergelijkende populatie). De resultaten wijzen erop dat de KVL van kinderen 
die stotteren in de voorschoolse leeftijd vergelijkbaar is met die van kinderen die niet 
stotteren. Stotterernst en duur van het stotteren waren niet gerelateerd aan KVL scores. De 
conclusie van het hoofdstuk luidt dat over het algemeen de KVL van kinderen die stotteren 
niet aangedaan is. Een beperking van onze studie is dat slechts een klein aantal kinderen 
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met ernstig stotteren deelnamen. We adviseren daarom in vervolgonderzoek een groter 
cohort kinderen met ernstig stotteren op te nemen. Daarnaast is het relevant om te kijken 
naar het verloop van KVL in de tijd en om aanvullende parameters, zoals kenmerken van 
het kind of de omgeving, mee te nemen in vervolganalyses. 
Hoofdstuk 3 laat zien dat, in geval van blijvend stotteren in de volwassen leeftijd, de impact 
op KVL groter wordt. Er namen 91 volwassenen deel aan de studie die in hoofdstuk 3 
beschreven wordt. Zij werden voor een deel via ons eigen netwerk geworven en voor een 
deel via stottercentra en logopediepraktijken verspreid over Nederland. Door middel van 
een uitgebreide onderzoeksaanpak werd hun stotterernst, functioneren, KVL en copingstijl 
geëvalueerd. Ernstig stotteren bleek samen te hangen met lagere KVL scores. Een hogere 
stotterernst was niet alleen gerelateerd aan een lagere score op het spraakdomein van een 
van de KVL-instrumenten (HUI3), maar ook aan een lagere score op emotionele en sociale 
domeinen. Copingstijl hing even sterk samen met KVL als stotterernst. In het bijzonder was 
een hogere score op de emotie-gerichte subschaal van het CISS copinginstrument (wat 
een negatievere manier van omgaan met emoties weergeeft) gerelateerd aan een lagere 
KVL waarde.
In de studies beschreven in hoofdstuk 2 en 3 zijn generieke KVL vragenlijsten gebruikt. 
Dat wil zeggen dat ze KVL meten in termen die voor iedereen relevant zijn, dus ongeacht 
de aan- of afwezigheid van ziekten. Generieke KVL instrumenten kunnen daarom in 
diverse populaties gebruikt worden. Ziektespecifieke instrumenten daarentegen bevatten 
domeinen die relevant worden geacht voor mensen die een specifieke aandoening 
hebben. Het heeft de voorkeur om in KVL onderzoek zowel een generiek als ziektespecifiek 
instrument te gebruiken. Ten tijden van ons onderzoek was er echter geen stotterspecifiek 
KVL instrument voorhanden. Een aantal jaar daarvoor was de Engelse OASES voor 
volwassenen ontwikkeld en psychometrisch gevalideerd. Ondanks dat de OASES geen 
KVL instrument is, bevat het wel een onderdeel dat de invloed van stotteren op KVL 
meet. Het instrument geeft de ervaring met betrekking tot het stotteren weer vanuit het 
perspectief van de volwassene die stottert. Hoofdstuk 4 beschrijft het proces van het 
vertalen van de OASES naar het Nederlands en het onderzoek naar de psychometrische 
eigenschappen van het instrument. We concluderen dat de Nederlandse OASES voor 
volwassenen (OASES-A-D) een betrouwbaar en valide instrument is dat van waarde kan zijn 
in de klinische praktijk om de invloed van stotteren op het dagelijks leven te onderzoeken. 
Alle onderdelen van de OASES-A-D waren in staat om groepen deelnemers met een 
verschillend niveau van stotterernst van elkaar te onderscheiden. Verder onderzoek 
naar de test-hertestbetrouwbaarheid en mogelijke reductie van het aantal vragen wordt 
geadviseerd.
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De hoofdstukken 5, 6 en 7 van dit proefschrift zijn gewijd aan de RESTART-studie (Rotterdam 
Evaluation study of Stuttering Therapy in preschool children- A Randomized Trial). In deze 
18 maanden durende studie werden 199 kinderen in de leeftijd van 3 tot 6 jaar die minstens 
zes maanden stotterden op basis van loting toegewezen aan het Lidcombe Programma 
(LP) of behandeling gebaseerd op het Verwachtingen en Mogelijkheden model (RESTART-
DCM behandeling). Behandeling volgens de DCM methode is sinds de jaren tachtig 
de Nederlandse standaard behandeling voor jonge kinderen die stotteren. RESTART-
DCM behandeling is een indirecte benadering, wat wil zeggen dat behandeling gericht 
is op het werken aan kind- en omgevingsgerelateerde factoren waarvan verondersteld 
wordt dat ze de spraakvloeiendheid van het kind beïnvloeden. Het LP, de Australische 
standaardbehandeling, werd in 2000 geïntroduceerd in Nederland. Deze directe benadering 
maakt gebruik van operante gedragstherapeutische principes om de vloeiendheid van 
het spreken van het kind te beïnvloeden. In totaal deden 24 logopedisten mee aan de 
RESTART-studie, werkzaam in vrijgevestigde logopedische (stotter)centra verspreid over 
Nederland. Gezondheidsuitkomsten en kosten werden geëvalueerd voorafgaand en 3, 6, 
12 en 18 maanden na aanvang van de behandeling. 
Hoofdstuk 5 beschrijft de studie naar de vergelijkende effectiviteit van het LP en RESTART-
DCM behandeling. De primaire uitkomstmaat was het percentage kinderen dat na 18 
maanden niet meer stotterde. Secundaire uitkomstmaten, gemeten op de verschillende 
meetmomenten, waren de stotterfrequentie, het oordeel over de stotterernst gegeven 
door de ouders, therapeut en het kind zelf, KVL, emotionele en gedragsproblemen en 
de spreekattitude van het kind. Afgezien van een grotere verbetering van het spreken in 
de eerste drie maanden na behandeling met het LP waren de resultaten op de diverse 
uitkomstmaten voor beide behandelingen na 18 maanden gelijk. In de LP behandelgroep 
werden iets meer kinderen na 18 maanden geclassificeerd als niet stotterend in vergelijking 
met de RESTART-DCM groep (respectievelijk 76.5 en 71.4%), maar dit verschil was niet 
significant. We concluderen dat beide methoden effectief zijn in het behandelen van 
jonge kinderen die stotteren. Een opvallende uitkomst was dat in beide behandelgroepen 
de grootste verbetering in het spreken in de eerste drie maanden plaatsvond. De 
stotterfrequentie daalde hierna nog licht, terwijl op het meetmoment na 18 maanden 
ongeveer 30% van de kinderen nog in behandeling was.
Hoofdstuk 6 presenteert de resultaten van een economische evaluatie van het LP versus 
RESTART-DCM behandeling. De totale kosten in 18 maanden werden gerelateerd aan de 
volgende gezondheidsuitkomsten: ‘Number needed to treat’ (NNT: Het aantal kinderen 
dat gemiddeld genomen met het LP behandeld moet worden om één kind extra van 
het stotteren af te helpen, vergeleken met wanneer deze kinderen behandeld worden 
volgens de RESTART-DCM methode) en voor kwaliteit van leven gecorrigeerde levensjaren 
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(QALY’s), gebaseerd op KVL scores. Omdat de KVL scores hoog waren aan het begin van 
de studie, werd slechts een kleine KVL winst behaald in de 18 maanden van de studie. 
Na 18 maanden waren de gezondheidsuitkomsten iets beter voor de LP groep, maar de 
verschillen waren statistisch en/of klinisch niet betekenisvol. De totale kosten waren iets 
hoger voor de LP groep. Aangezien er na 18 maanden een iets hoger percentage kinderen 
in de RESTART-DCM groep nog in behandeling was, zal het verschil in kosten op termijn 
mogelijk afnemen. Op basis van de NNT van 20 en het verschil in kosten van €168 worden 
de extra kosten per NNT geschat op €3360. Dit wil zeggen dat een extra investering van 
€3360 zal resulteren in één extra kind dat geclassificeerd word als ‘niet stotterend’ na 
behandeling met het LP in vergelijking tot RESTART-DCM behandeling. De extra kosten 
om extra verbetering in KVL te bewerkstelligen met het LP in vergelijking met de RESTART-
DCM behandeling waren €10413 per extra V-QALY en €18617 per extra U-QALY. Deze 
ratio’s impliceren een goede kosten-effectiviteit van het LP. Op basis van de uitkomsten die 
in hoofdstuk 5 en 6 gepresenteerd zijn, concluderen we dat het LP een goed alternatief is 
voor behandeling volgens de RESTART-DCM methode in de Nederlandse eerstelijnszorg.
Het is bekend dat beslissingen betreffende behandelkeuzes en implementatie van 
studieresultaten beïnvloed worden door ideeën, percepties en ervaringen van therapeuten. 
Daarom is een focus groep bijeenkomst gehouden met logopedisten die aan de RESTART-
studie deelnamen. De resultaten hiervan zijn beschreven in hoofdstuk 7. De houdingen en 
overtuigingen van therapeuten ten opzichte van het LP en RESTART-DCM behandeling 
werden geëvalueerd, evenals hoe deze mogelijk veranderd zijn door deelname aan de 
RESTART-studie. In de eindfase van de studie bleken deelnemende therapeuten flexibeler 
en meer cliënt-gericht in hun keuzes voor een behandeling. Dit hing samen met de 
bevinding dat de mogelijkheden van beide behandelingen duidelijker waren geworden 
tijdens het onderzoek. Daar waar, voorafgaand aan het onderzoek, bijna alle logopedisten 
een voorkeur hadden voor een van beide behandelmethoden, was deze voorkeur in de 
eindfase van het onderzoek zo goed als verdwenen. Alle logopedisten gaven aan dat 
hun behandelkeuze vooral bepaald werd door kindgerelateerde factoren en door een 
eventuele voorkeur van ouders.
Hoofdstuk 8 bediscussieert drie thema’s die voortkomen uit dit proefschrift en die 
betrekking hebben op (1) vroegtijdige interventie, (2) behandelkeuze en (3) verbetering 
van het therapieproces. Ten eerste onderschrijft de bevinding dat blijvend ernstig stotteren 
op de volwassen leeftijd samenhangt met een grotere impact op KVL de noodzaak van 
vroege interventie. Aangezien de KVL van kinderen in de voorschoolse leeftijd die stotteren 
nauwelijks verlaagd bleek, kan behandeling voorafgegaan worden door een periode 
waarin het stotteren van het kind gemonitord wordt, zoals ook in de huidige richtlijn 
voor stotteren wordt geadviseerd. Ten tweede is er op basis van onze resultaten geen 
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duidelijke voorkeur uit te spreken voor een van beide behandelingen (LP of RESTART-
DCM behandeling). Een aanpak waarbij de logopedist samen met de ouders een keuze 
voor een behandeling maakt is aan te raden. Ten derde adviseren we het gebruik van de 
RESTART-DCM werkwijze door logopedisten die een kind volgens de DCM methode willen 
behandelen, te stimuleren en daarnaast de winst die behandeling na drie maanden met 
zich meebrengt in heroverweging te nemen. Hoofdstuk 8 bespreekt ook methodologische 
uitdagingen die samenhingen met de RESTART-studie en met het meten van de impact van 
stotteren op het dagelijks leven. In het bijzonder komt de validiteit van KVL instrumenten 
aan bod. Het hoofdstuk besluit met implicaties voor logopedisten en beleidsmakers en 
aanbevelingen voor verder onderzoek. Er is voldoende bewijs om de implementatie van 
het LP in de dagelijkse praktijk in Nederland aan te moedigen. Vanwege het kleine verschil 
in effecten en kosten tussen het LP en de RESTART-DCM behandeling, adviseren we om 
beide behandelingen in het verzekerde pakket te behouden. Toekomstig onderzoek moet 
uitwijzen of specifieke factoren bijdragen aan een positieve behandeluitkomst, of de 
behandelduur en/of –intensiteit verkort kan worden zonder de effectiviteit aan te tasten, 
en wat de lange termijn effecten zijn van behandeling in de voorschoolse leeftijd.
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LIST OF ABBREVIATIONS
ANOVA  Analysis of Variance
AWS  Adults Who Stutter
AWNS  Adults Who do Not Stutter
CA scale  Clinical Assessment scale
CBCL  Child Behaviour Checklist
CEA  Cost-Effectiveness Analysis
CHQ-PF28 Child Health Questionnaire-Parent Form 28 items
CI   Confidence Interval
CISS  Coping Inventory for Stressful Situations
CISS-A  CISS Avoidance-oriented coping style
CISS-E  CISS Emotion-oriented coping style
CISS-T  CISS Task-oriented coping style
CUA  Cost-Utility Analysis
CWS  Children Who Stutter
DCM  Demands and Capacities Model
EBP  Evidence Based Practice
Erasmus MC  Erasmus Medical Center
ES   Effect Size
EQ-5D   EuroQol five-Dimensional 
EQ-VAS  EuroQol Visual Analogue Scale
HRQOL  Health-Related Quality of Life
HUI3  Health Utility Index mark 3
ICER  Incremental Cost-Effectiveness Ratio
ICUR  Incremental Cost-Utility Ratio
ITQOL-97 Infant and Toddler Quality of Life Questionnaire 97 items
KiddyCAT Communication Attitude Test- preschool child version
LP   Lidcombe Program for early stuttering intervention
NNT  Number Needed to Treat
NT group adults who stutter who were Not in Therapy
OASES  Overall Assessment of the Speaker’s Experience of Stuttering
OASES-A-D Dutch version of the OASES for Adults
OR   Odds Ratio
QALY  Quality-Adjusted Life Year
QOL  Quality of Life
RCT  Randomized Controlled Trial
Resp  Respondent
RESTART the Rotterdam Evaluation study of Stuttering Therapy in preschool 
   children- A Randomized Trial
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S24  Scale of of communication attitudes with 24 items
SA1  Sensitivity Analysis 1
SA-scale  Self-Assessment scale of speech
SD   Standard Deviation
SE   Standard Error
SF-36  medical outcomes study Short Form 36-Item health survey
SG   Standard Gamble
SLP  Speech-Language Pathologist
SPSS  Statistical Package of Social Sciences
SS   Syllables Stuttered
SSI-3  Stuttering Severity Instrument-3
T group  adults who stutter who were in Therapy
TSO  Time Since Onset
TTO  Time Trade-Off
U-QALYs Quality-Adjusted Life Years based on measurement by the HUI3
V-QALYs  Quality-Adjusted Life Years based on measurement by the EQ-VAS
WTP  Willingness To Pay
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DANKWOORD
Het is een heerlijk gevoel om na jaren dankwoorden gelezen te hebben nu eindelijk mijn 
eigen dankwoord te mogen schrijven. Ik wil heel graag iedereen bedanken die direct of 
indirect heeft bijgedragen aan de totstandkoming van dit proefschrift. 
Allereerst mijn promotoren; oorspronkelijk Frans Rutten, daarna Carin Uyl-de Groot vanuit 
het iBMG, en Rob Baatenburg de Jong vanuit KNO. Bedankt voor de kans die ik kreeg om 
me te verdiepen in een onderwerp op het grensvlak van twee interessante vakgebieden. 
Carin, jij was altijd bereid mee te denken en hielp me de grote lijnen te blijven zien. Rob, 
in de afgelopen jaren hebben we de diverse uitkomstmaten en uitkomsten van studies 
bediscussieerd, meestal tijdens of na afloop van een van mijn presentaties. Jouw kritische 
vragen zetten me altijd weer aan het denken.
Elly en Marie-Christine, met jullie heb ik de bulk van het werk gedaan en alle hobbels die 
we onderweg tegenkwamen, genomen. Dank voor jullie begeleiding. MC, jouw ideeën 
liggen aan de basis van dit proefschrift. Ik bewonder jouw kennis van het vakgebied Sto-
tteren en de bevlogenheid en gedrevenheid waarmee je je vak uitoefent. Dit heeft mij 
vaak gestimuleerd om nog een stapje verder te zetten. Elly, van jou heb ik veel over het 
vak gezondheidseconomie geleerd, zodat begrippen als HTA, QALYs en ICERs al snel heel 
gewoon voor me werden. Een rekensommetje laat zien dat wij samen in totaal ongeveer 
3 jaar en 8 maanden zwanger zijn geweest gedurende mijn promotietraject. Met daarbij 
opgeteld ongeveer 15 maanden bevallingsverlof en nog eens tweeënhalf jaar verder ont-
zwangeren vind ik dat we een knappe prestatie hebben geleverd. Jouw ‘niet snel uit het 
veld geslagen’ instelling en daarbij horende pragmatische aanpak brachten de rode draad 
weer helder naar voren wanneer ik dreigde te verzanden in details.
De leden van de promotiecommissie wil ik bedanken voor het lezen en beoordelen van 
mijn proefschrift en het opponeren bij de verdediging.
Bij het schrijven van alle artikelen voor dit proefschrift heb ik de prettige samenwerking 
met en de waardevolle input van anderen mogen ervaren. Toni, in Nijmegen heb jij me 
enthousiast gemaakt voor onderzoek binnen de spraak-taalpathologie. Ik ben blij dat je, 
ondanks dat je met emiraat bent, hebt mee willen werken in het lange traject dat tot een 
mooie publicatie van ons hoofdartikel heeft geleid. Scott, thank you very much for your 
contribution to Chapter 4. It was a genuine pleasure working with you. Matthijs, het artikel 
van hoofdstuk 4 was verreweg de snelste publicatie uit dit boekje. Jouw kennis en kunde 
hebben daar zeker aan bijgedragen! Sam, dank voor de prettige samenwerking en jouw 
waardevolle inbreng voor hoofdstuk 7; een geslaagd uitstapje naar het kwalitatieve onder-
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zoek. Clazien, naar jouw gaat mijn speciale dank uit. Je bent coauteur van drie artikelen in 
dit proefschrift en hebt me met raad en daad bijgestaan tijdens het RESTART-project. Zo 
heb je bijvoorbeeld de inclusie van me overgenomen in de periode dat ik met verlof was. 
Veel dank daarvoor. 
Het uitvoeren van een gerandomiseerd onderzoek is een hele klus. De medewerking van 
alle RESTART-logopedisten/stottertherapeuten was onmisbaar. Alies, Anne, Anneke, Bren-
da, Brunette, Caroline, Corrie, Durdana, Eeuwkje, Ellen, Esther, Fine, Hannie, Irma, Jean-
ette, Karin, Liesbeth, Lisette, Mark, Mary, Meina en Patricia: Jullie enthousiasme en inzet 
heeft ertoe geleid dat we, met een verlenging van anderhalf jaar, het toch voor elkaar 
hebben gekregen om bijna 200 kinderen te includeren. Ik kijk terug op vele momenten 
van prettig contact, bijvoorbeeld tijdens alle vrijdagmiddagen Intervisie, waarvoor jullie je 
praktijk moesten sluiten en naar Utrecht afreisden om onder het genot van wat lekkers uit 
een van de windstreken en met veel inzet (en Durdana als enthousiaste voorzitter) allerlei 
aan het onderzoek gerelateerde onderwerpen te bespreken. Met als een van laatste bi-
jeenkomsten de focus groep meeting waar hoofdstuk 7 uit dit proefschrift op gebaseerd 
is. Als voorlopers in het veld zijn jullie een voorbeeld voor andere logopedisten. Chapeau 
voor jullie allen! 
Judith, Maaike, Marjon, Robine, Sandra, Veronica, Wendy en Yoranique; dank jullie wel 
voor het scoren van de ruim 2700 audiosamples!! 
Mijn bijzondere dank gaat uit naar alle kinderen en hun ouders die deelgenomen hebben 
aan de RESTART-studie. Dank voor jullie deelname aan het onderzoek, het maken van alle 
audio-opnamen thuis, het invullen van de vragenlijstboekjes en het soms speciaal naar de 
praktijk komen voor een meting.
Oud-collega’s, ook al ben ik alweer even weg bij het iBMG, dankzij jullie was het altijd 
prettig om weer een dagje op de uni te zijn om aan m’n proefschrift te werken. Steef, 
verreweg de meeste jaren heb ik een kamer met jou gedeeld. Dank voor alle gesprekken 
tussen het werken door en je bereidheid om je werk te onderbreken voor weer eens een 
vraag over Excel, ftp-servers of wat voor computer gerelateerd onderwerp dan ook. Het 
‘vrijdag kroket-clubje’ is inmiddels niet meer, maar gezellig dat we het contact in de vorm 
van iets meer culinaire etentjes weten te houden, Annemieke, Claudine, Liesbet, Renske, 
Saskia en Sophie!
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Lieve vrienden, bedankt voor jullie interesse in mijn promotie en vooral voor alle gezel-
ligheid en fijne gesprekken in de afgelopen jaren tijdens etentjes, (strand)wandelingen, 
dagjes speeltuin, avondjes Delft, en andere momenten die ik met jullie gedeeld heb. Car 
en Nens, super leuk om vandaag twee spraak-taalpathologen en vriendinnen naast me te 
hebben staan als paranimf!
Familie en schoonfamilie; dank voor jullie interesse en steun! Jenny, jouw kritische blik op 
m’n Engelse stukken hebben het niveau van een aantal hoofdstukken in dit proefschrift 
verhoogd, waarvoor veel dank! Pap en mam, jullie hebben me altijd gesteund. De laatste 
jaren met vele oppasdagen zodat ik ongestoord mijn proefschrift af kon ronden. Dank jullie 
wel voor alles!
Tot slot, het onmisbare thuisfront. Ben, het schrijven van dit proefschrift was soms een 
zware opgave. Dankjewel voor jouw altijd aanwezige steun en het kritisch maar geduldig 
meedenken in alle processen die hierbij kwamen kijken. Lieve Rosa en Sepp, mijn zonnet-
jes in huis, dank dat jullie er zijn!
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